Twist Bioscience Corp 10-K for FY2026
Twist Bioscience Corp (TWST)
10-K
2026-11-16
For: 2026-09-30
View Original
Added on
November 17, 2026
About this 10-K
Twist Bioscience Corp filed this 10-K on November 16, 2026, covering the fiscal year ended September 30, 2026 (FY2026).
Twist Bioscience reported revenue up 22% to $459.4 million for fiscal 2026 from $376.6 million, while net loss widened to $130.2 million from $77.7 million. AI summary
Headline figures
Fiscal year ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $459.43M
- up 22.0% from $376.57M a year earlier
- Net loss
- $130.2M
- compared with a net loss of $77.67M a year earlier
- Diluted EPS
- -$2.08
- compared with -$1.30 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
| ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the fiscal year ended September 30 , 2026
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from to
Commission File Number: 001-38720

(Exact Name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||
(Address of principal executive offices and zip code)
(800 ) 719-0671
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Securities Registered Pursuant to Section 12(g) of the Act: None
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
| ☒ | Accelerated filer | ☐ | ||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ||||||||||||
| Emerging growth company | ||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒
As of March 31, 2026, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of shares of common stock held by non-affiliates of the registrant was approximately $2.91 billion based upon the closing sale price on the Nasdaq Global Select Market reported for such date.
The number of shares of the Registrant’s common stock outstanding as of November 11, 2026, was 68,178,692 .
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant’s definitive proxy statement to be filed in connection with its 2027 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.
TWIST BIOSCIENCE CORPORATION
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
| Page | ||||||||
Forward-looking statements
This Annual Report on Form 10-K for the fiscal year ended September 30, 2026 (this "Form 10-K"), contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements relate to, among other matters, plans for product development and licensing to third parties, expectations regarding market penetration, anticipated customer conversions to our products, plans to expand in the international markets, and identification and development of potential antibody candidates. Forward-looking statements are also identified by the words “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” and variations of such words and similar expressions. You should not rely upon forward-looking statements as predictions of future events. Such statements are based on management’s expectations as of the date of this filing and involve many risks and uncertainties that could cause our actual results, events or circumstances to differ materially from those expressed or implied in our forward-looking statements. Forward-looking statements contained in this Form 10-K include, but are not limited to, statements about:
•our ability to increase our revenue and our revenue growth rate;
•our ability to effectively manage our growth and maintain and improve operational efficiency, cost control, and gross margin as we scale;
•our estimates of the size of our market opportunities;
•our ability to increase DNA production, reduce turnaround times and drive cost reductions for our customers;
•our ability to accurately estimate capital requirements and our needs for additional financing;
•our ability to successfully enter new markets and manage our international expansion;
•our ability to comply with evolving international regulatory requirements, including those in the European Union and other key markets;
•our ability to develop and commercialize additional products in the therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners revenue industries;
•our ability to leverage our investment in our manufacturing infrastructure;
•our ability to protect our intellectual property, including our proprietary DNA synthesis platform;
•costs associated with defending intellectual property infringement and other claims;
•the effects of increased competition in our business;
•our ability to keep pace with rapid changes in technology and evolving competitive dynamics;
•our ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions;
•our ability to successfully identify, evaluate and manage any future acquisitions of businesses, solutions or technologies;
•the success of our marketing efforts;
•a significant disruption in, or breach in security of our information technology systems and resultant interruptions in service and any related impact on our reputation;
•our ability to attract and retain qualified employees and key personnel;
•the effects of natural or man-made catastrophic events or public health emergencies;
1
•the effectiveness of our internal controls;
•changes in government regulation affecting our business;
•uncertainty as to economic and market conditions and the impact of adverse economic conditions; and
•other risk factors included under the section titled “Risk Factors"
Readers are urged to carefully review and consider all of the information in this Form 10-K and in other documents we file from time to time with the Securities and Exchange Commission (the "SEC"). We undertake no obligation to update any forward-looking statements made in this Form 10-K to reflect events or circumstances after the date of this filing or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.
When we use the terms “Twist,” “Twist Bioscience,” the “Company,” “we,” “us” or “our” in this report, we are referring to Twist Bioscience Corporation and its consolidated subsidiaries unless the context requires otherwise. Sequence space and the Twist logo are trademarks of Twist Bioscience Corporation. All other company and product names may be trademarks of the respective companies with which they are associated.
* * * * *
2
PART I
Item 1.Business
Twist Bioscience Corporation provides customizable solutions across the biological continuum, helping customers read, write and innovate in biology. Across diagnostics, therapeutics, industrial, agriculture and research markets, our customers use our products and services to develop ways to improve human health and the sustainability of the planet. Our goal is to enable them to do this work with confidence, without having to compromise on quality, speed, scale or cost. We believe that the faster our customers succeed, the better for all of us.
At the core of our business is a proprietary platform that allows us to manufacture synthetic DNA by “writing” DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing the amount of chemicals by 99.8% compared to plate-based synthesis. We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation and manufacturing throughput at a lower cost relative to legacy methods. Because our platform writes millions of unique sequences in parallel, we can build products to customers' specification at scale.
Building from this platform, we serve customers through two product groups. Through DNA Synthesis and Protein Solutions, we offer end-to-end solutions for therapeutic drug discovery including DNA synthesis, protein expression, antibody characterization and biologics discovery solutions. Through NGS Applications, we provide tools used between the sample and the sequencer including target enrichment panels and library preparation kits. Both product lines start with DNA written on our silicon platform. Our products and services are designed to enable customers to run more experiments and iterations with the same resources, giving them more opportunities for success. We sell our products and services to a global customer base of approximately 4,100 customers across a broad range of industries.
We believe our products and services enable a broad range of customers including applications that may ultimately improve health and the sustainability of the planet across multiple industries, including:
•therapeutics, to discover new biologic drugs that treat a wide range of diseases;
•diagnostics, to detect and monitor disease and guide treatment decisions, including in cancer and inherited and rare disease;
•industry and applied markets, including enzyme engineering and the cost-effective and sustainable production of new and existing specialty chemicals and materials, such as spider silk, nylon, rubber, fragrances, food flavors and food additives;
•agriculture, for more effective and sustainable crop production; and
•academic research and government, for a broad range of education and discovery applications.
Background
We generate revenue from our two product groups: DNA Synthesis and Protein Solutions and NGS Applications. Beginning in fiscal 2026, we combined our synthetic biology products and biopharma services for antibody discovery into DNA Synthesis and Protein Solutions, as more customers use both together, and renamed NGS tools as NGS Applications to reflect their role in sequencing workflows. In addition, we are leveraging our platform to expand our portfolio to include other products and services to address additional market opportunities.
In fiscal year 2026, we served approximately 4,100 customers and reported $459.4 million in revenue, including $162.3 million in revenue from therapeutics, $164.3 million in revenue from diagnostics, $56.6 million in revenue from academic research and government, $52.0 million in revenue from global supply partners and $24.2 million in revenue from industry and applied.
3
Our Markets
Our next-generation sequencing (NGS) applications and DNA synthesis and protein solutions product groups serve large and growing markets. Based on third-party industry reports and our internal estimates, we estimate that by 2030 our combined serviceable addressable market (SAM) across both will exceed $13 billion. We expect our SAM to continue to expand as we introduce new products.

NGS Applications
By 2030, we estimate our SAM for NGS applications will be approximately $6 billion, within a total addressable market (TAM) of more than $90 billion. Our NGS SAM includes approximately:
•$3.6 billion in oncology diagnostics. This covers liquid biopsy for therapy selection, multicancer screening (multicancer early detection and multicancer detection) and molecular residual disease (MRD), plus comprehensive genomic profiling (CGP) of tissue;
•$800 million in academic research;
•$500 million in microarray;
•$400 million in rare and inherited disease; and
•$400 million in biotech and pharma research and development.
DNA Synthesis and Protein Solutions
By 2030, we estimate our SAM for DNA synthesis and protein solutions will exceed $7 billion, within a TAM of approximately $18 billion. This SAM includes approximately:
•$2.5 billion in antibody discovery services;
•$2.0 billion in DNA synthesis;
•$1.6 billion in protein expression; and
•$1.0 billion in nucleic acid therapeutics.
As of May 2026, we estimated that $1 billion of the DNA Synthesis and Protein Solutions SAM comes from artificial intelligence ("AI")-enabled drug discovery, split evenly between antibody discovery services and protein expression. This estimate covers customers building foundational models for antibody discovery and customers using those models to discover antibodies. It assumes no single model becomes dominant for binding prediction or other characterization, so iteration continues. It also assumes the scope of preclinical development work done with these models keeps expanding. Subsequent models for AI drug discovery have estimated the market to be significantly larger.
4
Our market estimates rely on assumptions and third-party data that may prove inaccurate, and the actual size and growth of these markets may differ materially from our estimates. See “Risk Factors.”
Sources: BCC Research, DeciBio, Grand View Research and Twist internal estimates.
Our Product Groups
DNA Synthesis and Protein Solutions
Our DNA Synthesis and Protein Solutions serve life sciences researchers across a variety of healthcare applications including AI drug discovery, traditional drug discovery, enzyme engineering, gene editing and basic academic research. In addition, these products are used for chemical and materials applications including development of synthetic spider silk, nylon, rubber, fragrances, flavors and food additives; for food and agricultural applications including improving crop traits such as adding vitamins or improving drought tolerance, and engineering bacteria to deliver nitrogen at the root of plants. While synthetic DNA has been produced for more than 40 years, the complexities of biology and the production constraints inherent in legacy processes have historically limited the applications and market opportunities for DNA synthesis.
Synthetic DNA is the fundamental building block that allows researchers to engineer biology. Synthetic DNA is a foundational product enabling the entire bioeconomy. The National Security Commission on Emerging Biotechnology recognized synthetic DNA as a critical choke point in many supply chains, making broad access important for many industries. In addition to synthetic DNA, we offer RNA products, expressed proteins and characterization data that support customers through the design-build-test-learn cycle. Customers can work with us at any point in that cycle, from ordering gene fragments to run their own experiments to having us manage the full workflow of DNA synthesis, gene construction, protein expression and characterization.
We see increasingly more revenue from DNA Synthesis and Protein Solutions supporting AI drug discovery. Customers use AI to design antibodies and other proteins and generate candidate sequences computationally. Those sequences are then sent to Twist for build and test in our lab. Demand from these customers grew substantially in fiscal 2026 as we have become a protein and data partner as well as a DNA supplier.
NGS Applications
Our NGS Applications products help customers read DNA. They play an integral role in the way our customers prepare their samples to be sequenced. NGS has transformed many markets in recent years by changing the landscape of diagnosing disease and disorders and offers a path to prevent or treat disease. Some of the markets impacted by NGS include cancer diagnostics, rare disease, reproductive health, food/agriculture, consumer genomics, infectious disease research and drug discovery. As NGS technology improves and the cost of sequencing declines, new emerging markets that were once considered impractical, such as therapy selection, population-scale sequencing, liquid biopsy (analysis of tumor-derived DNA in blood or other body fluids), molecular residual disease ("MRD") workflow, as well as spatial and single cell sequencing, have become major areas of interest and investment.
Historically, a significant constraint in many NGS applications has been the high cost and long turnaround time of oligonucleotide production. Highly accurate and reproducible oligonucleotide production is required to produce high quality target enrichment data. Traditionally, the lack of options for oligonucleotide production forced researchers to choose between using less precise methods or reducing the number of samples in their study. Twist’s silicon-based platform synthesizes millions of oligonucleotides simultaneously with high uniformity and accuracy. Using highly uniform oligonucleotides ensures that the amount of oversampling needed to represent a dataset is kept to a minimum, meaning researchers can screen with confidence while reducing the down-stream sequencing costs.
The ability of the Twist DNA synthesis platform to precisely manufacture target enrichment probes at large scale has dramatically increased the types of projects that can now be addressed using NGS technologies. In addition to target enrichment, we offer innovative and application-specific library preparation with Twist-developed enzymes, buffers, beads, unique dual indexes ("UDIs"), unique molecular identifiers ("UMIs"), adapters and more. Our platform has unlocked new applications, improved data quality, and dramatically expanded the types of scientific questions that can be answered using NGS. In addition, the speed of our DNA
5
synthesis platform enables customers to quickly deploy NGS technologies to applications where the time to answer is critical.
We grow with our NGS Applications customers as they move their workflows from research and development through verification and validation, clinical studies and commercial launch. Our largest NGS Applications customers are increasingly commercial diagnostics companies whose purchases scale with market demand, including for MRD workflows.
Our Platform
We developed the Twist Bioscience DNA synthesis platform to address the limitations of throughput, scalability, and cost inherent in legacy DNA synthesis methods. Our platform stems from extensive analyses and improvements to the existing gene synthesis and assembly workflows. Our core technologies combine expertise in silicon, software, fluidics, chemistry, and motion and vision control to miniaturize thousands of parallel chemical reactions on silicon and write thousands of strands of DNA in parallel.
The same platform supports both of our product lines, which allows us to add products, applications, customers and markets on infrastructure we have already built. Over time, we have used this approach to expand from genes and oligo pools into NGS target enrichment, library preparation kits, antibody discovery, protein characterization and AI-enabled drug discovery. We believe new products that leverage the platform increase its utilization and help improve our unit economics.
Our Solutions
We have developed multiple products and solutions derived from synthetic DNA and our versatile DNA synthesis technology. Our current offering consists of two product groups, DNA Synthesis and Protein Solutions and NGS Applications, that address different needs of our customers across a variety of applications. As we have moved further up the value chain from fragments to genes to preps to proteins and beyond, the connection between our DNA synthesis products and our discovery and protein services has strengthened. More customers now use both to accelerate discovery and identify breakthrough therapeutics, and in fiscal 2026 we began reporting them together as DNA Synthesis and Protein Solutions.

6
DNA Synthesis and Protein Solutions
Synthetic Genes and Gene Fragments
Synthetic genes are manufactured strands of DNA. Customers (biotech, pharma, industrial chemical, agricultural companies as well as academic labs) order our synthetic genes to conduct a wide range of research, including product development for therapeutics, diagnostics, chemicals/materials, food/agriculture as well as a multitude of emerging applications within academic research. Virtually all research and development of this type requires trial and error, and our customers require many variations of genes to find the DNA sequence that achieves their objectives.
We offer two primary categories of synthetic genes: sequence-verified clonal genes delivered to the customer in a vehicle called a vector; and genes that customers can place in their own vector, non-clonal genes or fragments. Within these two categories, customers can order different lengths of DNA depending on their required final gene construct. Customers can order longer genes or shorter genes and can stitch genes together to create longer or shorter constructs if desired.
Currently, we manufacture genes of up to 7,000 base pairs in length, yielding sequence-verified clonal genes that our customers can immediately use for their research. We offer non-clonal genes of up to 5,000 base pairs in length, which we believe addresses the vast majority of demand for non-clonal genes. Our error rate for gene fragments is 1:7500 nucleotides.
Oligonucleotide, or Oligo Pools
Oligo pools, or high diversity collections of oligonucleotides, are utilized in many applications, including targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami (the nanoscale folding of DNA to create two- and three-dimensional shapes at the nanoscale), among others. Our oligo pools are also used for high-throughput reporter assays to study cell signaling pathways, gene regulation and the structure of cell regulatory elements. For these applications, we provide customers with oligos designed to match their required designs.
We sell a diverse, customizable set of oligo pools, ranging from a few hundred oligos to over one million, and offer oligonucleotides of up to 500 nucleotides in length, with an error rate of 1:3000 nucleotides.
Biologics Discovery, Protein Expression and Characterization Data
Modern therapeutic targets are increasing in complexity and traditional, single modality platforms are no longer sufficient on their own. We offer partners an end-to-end workflow from DNA synthesis to characterization data. Partners can start and finish at different points in this workflow, which can be through in vitro, in vivo or in silico drug discovery.
We offer a broad suite of protein and antibody characterization solutions that generate experimental data to empower therapeutic discovery, candidate optimization and development decisions. This includes in vivo, in vitro and in silico discovery solutions. Traditional antibody discovery workflows using in vivo and in vitro methods support target-to-lead identification and can also facilitate downstream development with, for example, anti-idiotype discovery. To support AI-enabled drug discovery, our capabilities span biochemical, biophysical and cell-based functional assessments, enabling customers to evaluate target binding, biological activity and developability, including properties relevant to stability and manufacturability. Binding assessments include affinity and kinetics measurements using surface plasmon resonance (SPR) and biolayer interferometry (BLI), epitope binning, binding and blocking assays, and cell-surface binding analysis by flow cytometry. Our developability portfolio of assays evaluates thermal stability, purity, aggregation, self-association, hydrophobicity and nonspecific interactions through complementary chromatography, light-scattering, fluorescence and immunoassay methods. Additional capabilities include endotoxin testing and species cross-reactivity
assessment.
We also offer standard and customized cell-based assays to evaluate signaling, internalization, immune cell activation, cytokine release, cytotoxicity, phagocytosis and proliferation. Customers can access these services individually or integrate them with our DNA synthesis, protein expression and purification capabilities in a connected workflow. By combining automated, high-throughput testing with scientific expertise and flexible
7
assay design, we enable customers to assess large panels of candidates across multiple properties, identify potential development liabilities earlier and generate datasets to train, validate and refine AI and machine learning models.
In February 2026, we entered into a co-exclusive license to Invenra Inc.’s ("Invenra") B-Body bispecific antibody discovery platform and acquired a minority equity interest in Invenra. The platform extends our discovery and data generation capabilities to bispecific antibodies.
NGS Applications
Building from our DNA synthesis platform, we have developed products to enable NGS. Our products work on multiple sequencing platforms as we are sequencer agnostic. In particular, we are focused on addressing the demand for better sample preparation products that improve sequencing workflow, increase sequencing accuracy, and reduce downstream sequencing costs. Using our silicon-based DNA synthesis platform, we are able to synthesize exact sequences of interest. In the target enrichment process, our synthetic DNA probes bind to the sequence of interest within the sample, acting like a magnet to isolate and physically extract the targeted segment of DNA.
Our customers use our NGS products in research and in the development and commercialization of their own workflows, including cancer detection through liquid biopsy and MRD as well as rare disease. In addition, customers use our NGS products for therapy selection, population genetics research and biomarker discovery, translational research, microbiology and applied markets research. Our customers are primarily diagnostic companies and hospitals, research institutions, agricultural biotechnology companies, and consumer genetics companies.
We offer a wide variety of NGS Applications for our customers including library preparation kits, human exome kits, fixed and custom panels, panels for liquid biopsy and MRD research as well as Alliance panels. Alliance panels are customer-curated content sold through Twist. In addition, we offer specific workflow solutions including a methylation detection kit for cancer, rare and inherited disease study, as well as a fast hybridization solution (FastHyb), which allows researchers to go from sample to sequencer in a single day. In addition to NGS products for DNA workflows, we offer full RNA sequencing workflows.
Synthetic Controls
Leveraging our DNA synthesis platform, we offer positive synthetic controls that provide quality control measures for a wide range of applications from assay development to routine testing of samples with both NGS and reverse transcription polymerase chain reaction (RT-PCR) assays.
Enzyme Engineering
We have a small group focused on engineering enzymes for our NGS library preparation kits as well as internal workflows. We use AI-guided design together with our own gene synthesis and protein expression to design, build and test enzyme variants, and we select variants using assays that reflect how the enzyme will perform in the final kit. Engineered enzymes are used in products including our TrueAmp and PCR-free whole genome sequencing library preparation kits and are intended to improve kit performance and give us more control over supply and cost.
Our Growth Strategy
Our objective is to be the leading provider of customizable solutions across the biological continuum worldwide, from synthetic DNA and RNA to proteins and data, and to leverage our platform to build a leadership position in other life sciences markets in which we have a competitive advantage. Our strategy is to introduce more products, applications, and solutions that benefit from our proprietary silicon platform, adding volume to infrastructure we have already built. We intend to accomplish this objective by executing on the following:
•maintain and expand our position as the provider of choice for high-quality, affordable synthetic DNA, RNA, proteins and data at scale for customers across multiple industries;
8
•expand protein production, characterization and data generation to support customers conducting traditional and AI-enabled therapeutics discovery;
•maintain and expand our position as a leading supplier of NGS sample preparation products for a wide range of applications including liquid biopsy workflows, MRD, rare disease, agricultural genomics and population genomics, and grow with our customers as their workflows move into clinical and commercial use;
•continue to introduce new products that use our existing platform and infrastructure, including products for nucleic acid therapeutics;
•improve efficiency and expand capacity through automation and continuous process improvement; and
•expand our global presence and reach through direct, digital and partner channels.
Sales and Marketing
We have built a versatile and scalable commercial platform that enables us to reach a diverse customer base that we estimate consists of over 100,000 synthetic DNA users, potential customers of our NGS Applications products and partners who may use our solutions for biologics discovery. In order to address this diverse customer base, we employ a multi-channel strategy comprised of a direct sales force targeting synthetic DNA customers, a direct sales force focusing on the NGS market and an e-commerce platform that serves both commercial channels. We employ business development and sales representatives for our antibody discovery and protein solutions as well. Our sales force is focused on customer acquisition, support, and management across industries, and is highly trained on both the technical aspects of our platform and how our products and services can be used in a wide range of industries. Our easy-to-use e-commerce platform allows customers to design, validate, and place on-demand orders of customized products online, and enables them to receive real-time customized quotes for their products and track their order status through the manufacturing and delivery process. This is a critical part of our strategy to address our large markets and diverse customer base, as well as drive commercial productivity, enhance the customer experience, and promote loyalty. Staying close to customers is central to how we compete. Our technical support team, which includes former scientists, works with our sales team to understand customer workflows and goals and to anticipate customer needs from research through commercialization.
We sell our products through a worldwide commercial organization that includes direct sales personnel, commercial consultants in Europe and Asia, an e-commerce platform, distributors and OEM partners. We report revenue from distributors and OEM partners that resell our products as global supply partners. As of September 30, 2026, we employed 321 employees and 20 dedicated commercial consultants in sales, marketing and customer support.
Research and Development
We are engaged in ongoing research and development efforts focused on enhancements to existing products and the development of new products. Currently, we are pursuing research and development projects with respect to the following:
•process development for highest quality oligos;
•engineer proprietary enzymes, using AI-guided design, to improve our DNA Synthesis and Protein Solutions and NGS Applications products and workflows;
•evaluate and implement AI applications to potentially optimize services for our customers;
•expansion of our product offerings for oligo, gene, synthetic controls, NGS library preparation and target enrichment, and DNA Libraries products;
•continuous process improvements across the business to facilitate speed, throughput, efficiency and automation;
•develop new products, including mRNA, proteins and for nucleic acid therapeutics;
9
•develop new methods and platforms for in vitro and in vivo-based antibody discovery for therapeutic, diagnostic and tool reagent use cases;
•advance high throughput bispecific antibody production, purification and analytical techniques that are both robust at small scale as well as larger scales; and,
•expand capabilities for antibody and protein production to support multiple formats and provide a wide array of characterization assays.
Research and development activities are conducted in collaboration with manufacturing activities to help expedite new products from the development phase to manufacturing and to more quickly implement new process technologies. From time to time, our research and development efforts have included participation in technology collaborations with universities and research institutions.
As of September 30, 2026, we employed 130 people in our research and development team.
Patents and Other Intellectual Property Rights
Worldwide, we own or exclusively in-license over 200 issued or allowed patents and more than 230 pending patent applications as of September 30, 2026. In addition to these owned and exclusively licensed patents and pending patent applications, we also license patents on a non-exclusive and/or territory restricted basis. Our intellectual property portfolio includes important patents and patent applications directed to DNA synthesis, NGS and antibody libraries. Our policy is to file patent applications to protect technology, inventions and add improvements that are important to our business. Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained.
Manufacturing and Facilities
The production of our products is a highly complex and precise process. We currently manufacture substantially all of our products and multiple sub-assemblies at our manufacturing facilities in South San Francisco, California and Wilsonville, Oregon. Wilsonville is our primary manufacturing site for DNA Synthesis and Protein Solutions, and South San Francisco is our primary site for NGS Applications products. We also outsource some of our sub-assemblies to third party manufacturers. All of our products originate from synthetic DNA obtained from nanostructured clusters fabricated on our proprietary silicon technology platform. Due to its on-demand nature, the gene synthesis business requires manufacturing operations to be in operation 24 hours a day, seven days a week, 365 days per year. For synthetic genes, we have built a highly scalable gene production process with what we believe is industry-leading capacity to address the growing demand of scalable, high-quality, affordable synthetic genes. As of September 30, 2026, we employed 431 people in our manufacturing and operations team.
In addition to synthetic genes, we manufacture pooled DNA including oligo pools, multiplexed gene fragments and gene pools. The pooling process has been automated through a mixture of custom proprietary and over-the-counter liquid handling equipment. We have the capacity to make many millions of high-quality oligos per day that can be used to make genes and gene fragments of various lengths, multiplexed gene fragments, gene pools, oligo pools of various sizes, DNA libraries and NGS Applications products. We intend to increase our shipments to leverage our production capacity through our e-commerce platform, and express offerings, which we believe will expand both our market opportunity and our customer base.
The manufacturing process for our NGS Applications products is designed for flexibility and efficiency. We have automated substantially all of the processing steps in the workflow using proprietary and commercially available laboratory equipment, operated by our trained manufacturing team. We have built dedicated production capabilities for our NGS products.
We design new products to use our existing DNA writers, equipment and software where possible, and we continue to automate processes. This approach has allowed us to add products and increase capacity within our existing facilities.
ISO certifications
10
We maintain a Quality Management System ("QMS") certified to International Organization for Standardization (“ISO”) 13485:2016 (Medical devices—Quality management systems—Requirements for regulatory purposes), the internationally recognized standard for quality management in the medical device industry. ISO is a global network of national standards with over 25,000 standards for nearly every aspect of technology and business and has standard bodies in 177 countries. Our certification body conducts annual surveillance audits and a full recertification audit every three years. We have maintained our ISO 13485 certification since first obtaining it in 2019, and our most recent surveillance audit was completed in August 2026. Our ISO 13485-certified QMS covers both our research use only products and our Twist Precision Dx in vitro diagnostic products at our South San Francisco and Wilsonville manufacturing facilities.
We also maintain ISO/IEC 27001:2022 certification for our information security management system, as described in Part I, Item 1C, “Cybersecurity.”
Supply Chain
We have historically purchased many of the components and raw materials used in our products from numerous suppliers worldwide. For reasons of quality assurance, sole source availability or cost effectiveness, certain components and raw materials used in the manufacture of our products are available only from one supplier. We have worked closely with our suppliers to develop contingency plans to assure continuity of supply while maintaining high quality and reliability, and in some cases, we have established long-term supply contracts with our suppliers. We qualify additional suppliers for key materials in an effort to ensure continuity of supply for our operations.
Competition
The markets in which we compete are intensely competitive and are characterized by price competition, technological change, international competition, product turnaround time and manufacturing yield problems. The competitive factors in the market for our products include:
•product quality, reliability and accuracy;
•product offerings & complexity;
•turnaround time;
•price;
•breadth of product line;
•design and introduction of new products;
•market acceptance of our products and those of our customers;
•throughput and scale; and
•technical support and service.
We face competition from a broad range of life sciences companies such as Integrated DNA Technologies, Inc. (owned by Danaher Corporation), GenScript Biotech Corporation, Agilent Technologies, Inc., Roche Holding AG, Illumina, Inc., Watchmaker Genomics, Inc., WuXi Biologics (Cayman) Inc., Specifica Inc. (owned by IQVIA Holdings Inc.), Alloy Therapeutics, Inc., FairJourney Biologics S.A/IONTAS Limited and Biointron Biological, Inc., as well as a number of smaller and emerging companies.
Corporate Responsibility
Our customers, which consist of diagnostic, therapeutic and healthcare companies, agricultural biotech companies, chemical companies, academic institutions and government entities around the world, use our products to address large societal challenges. All of our work supports our mission to provide customizable solutions across the biological continuum to improve health and sustainability.
Full results from our Corporate Responsibility efforts, including our 2025 Corporate Responsibility Report can be found here: https://www.twistbioscience.com/company/corporate-responsibility. The information on our website, including, without limitation, in the 2025 Corporate Responsibility Report, should not be deemed
11
incorporated by reference into this annual report or otherwise “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section.
Human Capital
Our employees are a key factor in our ability to serve our customers. The ability to hire and retain highly skilled professionals remains key to our success in the marketplace. To attract, develop and motivate our employees, we offer a challenging work environment, ongoing skills development initiatives, attractive career advancement, opportunities and a culture that rewards entrepreneurial initiative and exceptional execution.
Our guiding principles of grit, impact, service and trust serve as the foundation of our culture. Our guiding principles set the tone for how we work together, provide a framework for giving feedback and increase the power of our brand. Service is at the core of our business and our interactions with one another. We relentlessly focus on exceeding internal and external customer needs.
Employee Population
As of September 30, 2026, we had 1,080 employees. Of these employees, 130 were primarily engaged in research and development activities; 321 were primarily engaged in marketing, sales and customer support; 198 were primarily engaged in general and administrative activities; and 431 were primarily engaged in operations and manufacturing, dedicated to manufacturing our DNA Synthesis and Protein Solutions and NGS Applications products and solutions. None of our employees is represented by a labor union, and we consider our employee relations to be good.
Recruiting, Development and Retention
Recruiting
We believe that our employees are our most important asset. Beginning with the pre-recruitment process, we provide internship opportunities in both scientific and non-scientific fields for students interested in biotechnology and the science, technology, engineering and mathematics (STEM) careers. We engage with local communities to provide expert speakers sharing nontraditional career pathways for the biotechnology field. We partner with community colleges to build our brand as a source of high-quality candidates for every role with the goal of identifying the best possible candidate to fill open positions within the Company.
Growth and Development
We invest significant financial and support resources to develop the talent we need to remain at the cutting edge of innovation to ensure Twist Bioscience is an employer of choice. Our performance management system is aimed at supporting our culture, maintaining consistency with our guiding principles and to focusing on continuous learning and development. Our success in the market depends on employees understanding and embracing how their job contributes to the Company’s overall strategy. We encourage cross team communication as well as integrated departmental communication. We believe this broadens our employee’s skill sets and provides opportunity for growth and advancement. We invest in our next generation of leaders through leadership programs and individualized coaching for mid-level managers. In addition, we offer tuition reimbursement aimed at growth and career development.
Compensation and Benefits, Health and Wellness
We strive to provide pay, comprehensive benefits and services that help meet the varying needs of our employees. Our total rewards package includes above-market pay; fully covered healthcare benefits for employees, with family member healthcare benefits covered at 90%; onsite services; and other benefits.
Employee Health and Safety
We remain steadfast in our commitment to promote the health and safety of our employees and have implemented a robust Injury and Illness Prevention Program (IIPP). We require annual workplace safety training to reinforce workplace safety procedures that may be useful in the event of emergency situations and to assist our employees in helping to prevent workplace accidents. Our Employee Safety Committee, which is comprised of numerous cross-departmental members, meets at least quarterly to review workplace safety and adherence to safety policies. As part of our efforts, all employees and managers complete workplace harassment and sexual harassment training that includes details on how to report any violation of these policies.
12
Employee Communications and Engagement
We employ a variety of tools to facilitate open and direct communication including open forums with executives, employee surveys and engagement through focus groups, forums and committees. We endeavor to further refine our employee programs through our employee engagement survey as well as follow up quarterly pulse surveys. Our most recent survey was conducted in September 2026 where 96% of our employees responded.
We hold All Employee meetings twice per month as well as a monthly managers meeting for all people managers.
Community Engagement, Social and Relationship Capital
We are endeavoring to develop relationships, give back to our communities and engage in corporate social responsibility and sustainability initiatives. We provide all employees with eight fully paid hours each year to give back to the community at an organization of their choice. We are working to engage with the local community organizations to provide volunteer opportunities for our employees.
Government Regulation
Twist Bioscience is a leading provider of synthetic DNA products, serving customers across research, development and commercial applications. We offer a wide range of products intended for "Research Use Only" ("RUO") as well as a limited catalog of NGS Applications products that have been CE-marked pursuant to, and regulated by, the In Vitro Diagnostic Device Regulation (EU) 2017/746 (the "IVDR"), and sold as in vitro diagnostic medical devices ("IVDs") in the European market. Our RUO products are sold and promoted for non-diagnostic and non-clinical purposes to academic institutions, life sciences and research laboratories, and biopharmaceutical and biotechnology companies who then integrate our products into their workflows for further commercialization. These products serve as vital research tools, enabling our customers to develop a diverse spectrum of commercial products. However, if we expand our portfolio of IVDs, we may be subject to a variety of specialized regulatory requirements, including those set forth by the U.S. Food and Drug Administration (the "FDA") in the United States and the IVDR in the European Union ("EU").
Aside from certain labeling requirements, we believe that most of our products, as currently marketed, are largely unregulated by governmental bodies, including the FDA. Even so, we recognize that the applications of synthetic biology are rapidly evolving and we are actively involved in supporting our customers who are developing regulated products, including through contract manufacturing and specialized packaging solutions. As such, we may be subject to certain regulatory requirements, directly or indirectly, and maintain a robust QMS to ensure compliance. Furthermore, if we expand our own portfolio of IVDs, we anticipate further engagement with regulatory bodies such as the FDA. We are committed to navigating this evolving landscape and ensuring that our products and services meet the highest quality and regulatory standards. For example, we have been evaluated by an external third party who has determined that we have processes in place to support compliance with current Good Manufacturing Practices and to support the required regulatory requirements as future regulations are updated by the FDA. Currently, our QMS adheres to ISO 13485:2016 to ensure the quality and reliability of our products.
RUO is a term applicable to our target enrichment products for the NGS market and is applied to kits sold to this market segment. It is intended to restrict use of the kits to non-in vitro diagnostic purposes. Our NGS target enrichment and library preparation products are used in a more comprehensive workflow for NGS for research purposes only. In the future, we may develop this larger workflow as an in vitro diagnostic, for which we will obtain prior authorization from FDA or other applicable regulatory authorities before commercialization. In the EU, we have launched a limited line of IVDs that are CE-marked and IVDR compliant to support our European customers who are in the in vitro diagnostic medical device market.
FDA
Pursuant to its authority under the Federal Food, Drug, and Cosmetic Act, the FDA has jurisdiction over medical devices. Medical device manufacturers are subject to FDA's Quality Management System Regulation (21 C.F.R. Part 820), which, effective February 2, 2026, incorporates ISO 13485:2016 by reference. The FDA regulates, among other things, the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are not adulterated and are safe and effective for their intended uses. In addition, the FDA regulates the import and export of medical devices.
13
Medical Device Regulation in General
IVDs are a category of medical devices that include reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. IVDs are intended for use in the collection, preparation, and examination of specimens taken from the human body. An RUO IVD product is an IVD product that is in the laboratory research phase of development or is intended for use in the conduct of nonclinical laboratory research and not intended to produce results for clinical use. As such, an RUO IVD is not intended for use in clinical investigations or in clinical practice. Such RUO products do not require premarket clearance or approval from the FDA, provided that they are not intended for clinical use and that they are labeled “For Research Use Only. Not For Use In Diagnostic Procedures” pursuant to FDA regulations; otherwise they may be considered adulterated or misbranded.
As noted above, although our products are currently intended for research purposes only, the regulatory requirements related to marketing, selling, and supporting such products could be uncertain and depend on the totality of circumstances. This uncertainty exists even if a use by our customers occurs without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.
According to the FDA, including the RUO labeling statement will not necessarily render the device exempt from FDA premarket clearance, approval, or other regulatory requirements if the totality of circumstances surrounding the distribution of the product indicate that the manufacturer intended its RUO products for diagnostic use. Such circumstances may include, but are not limited to, the product’s advertising, labeling, or promotion, or the manufacturer’s assistance of a clinical laboratory in validating or verifying a test that incorporates products labeled RUO. This uncertainty exists even if our customers use our products in this manner without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.
Some of our customers may use our products in their own laboratory-developed tests ("LDTs"). The FDA has historically taken the position that LDTs are considered to be IVDs but has generally exercised enforcement discretion. However, in May 2024, the FDA attempted to regulate virtually all LDTs as medical devices by publishing a final rule that would have phased out the policy of enforcement discretion it historically applied to LDTs (the “LDT Final Rule”). On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the LDT Final Rule in its entirety. The FDA declined to appeal, and on September 19, 2025, it issued a final rule effective that date, reverting 21 C.F.R. § 809.3(a) to its pre-May 2024 text. Congressional efforts to establish a legislative framework for LDT oversight remain active, with the Enhancing CLIA Act of 2026 introduced in June 2026, and future legislation or regulatory action could affect how our customers use our products in their laboratory-developed tests.
EU Regulation
In the EU, the IVDR imposes stricter requirements for the marketing and sale of applicable medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance. Some of the IVDR requirements became effective in May 2022 while the complete enforcement of the entirety of IVDR will not happen until December 2029. We are subject to the IVDR directly as a manufacturer of IVDs, and indirectly as a supplier to customers who are placing IVDs in the EU market for clinical or diagnostic use. In February 2024, we introduced IVDR-compliant Precision Dx products for whole exome sequencing to meet the needs of our European customers and demonstrate our commitment to providing compliant solutions for clinical and diagnostic use in the EU.
Federal Select Agent Program
The Centers for Disease Control and Prevention (the "CDC") and the Animal and Plant Health Inspection Service (the "APHIS") administer requirements of the Federal Select Agent Program ("FSAP"). FSAP requirements govern possession, use, and transfer of select agents and toxins consisting of biological materials that have the potential to pose a severe threat to public, animal or plant health or to animal or plant products. The FSAP currently lists approximately 63 select agents and toxins. The registered entities primarily consist of academic, federal and non-federal government, commercial, and private facilities that conduct research studies or diagnostic activities. We are not a registered entity under the FSAP and it is our policy generally not to produce or otherwise work with any biological material that is subject to the FSAP license requirements. To the extent that we may possess, use, or transfer any material considered a select agent or toxin under the FSAP
14
prospectively, we would seek to register with the FSAP and obtain all necessary permits for possession, transfer, importation, or any other regulated activity.
Export Controls
Some sequences and synthetic controls we produce may be subject to licensing requirements for export outside of the United States under the U.S. Export Administration Regulations. Given the evolving nature of our industry, legislative bodies or regulatory authorities may adopt additional regulation or expand existing regulation to include our products. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time, and we may be unable to obtain or maintain comparable regulatory approval or clearance of our products, if required. For example, the U.S. government is expected to promulgate a new export control regarding DNA writers, which may require additional compliance considerations with respect to hiring. These regulations and restrictions may materially and adversely affect our business, financial condition, and results of operations.
OSTP Framework for Nucleic Acid Synthesis Screening
In April 2024, the Office of Science and Technology Policy published the Framework for Nucleic Acid Synthesis Screening, which took effect in April 2025. The Framework requires that U.S.-funded researchers and institutions purchase synthetic nucleic acids only from providers that publicly attest to adherence to the screening requirements of the Framework. We believe our biosecurity practices satisfy or exceed the requirements of the Framework and, as such, we have publicly attested to our adherence. We have also agreed, as required by the Framework, to amend our attestation within 72 hours should the status of our adherence to the Framework change.
In May 2025, the President issued Executive Order 14292, which directed the revision or replacement of the federal Framework for Nucleic Acid Synthesis Screening and the development of a strategy for comprehensive nucleic acid synthesis screening in non-federally funded settings. Several pending federal bills, including the Nucleic Acid Standards for Biosecurity Act (H.R. 3029) and the Biosecurity Modernization and Innovation Act of 2026 (S. 3741), would direct the development of technical standards for nucleic acid synthesis providers.
Available Information
Our corporate website address is www.twistbioscience.com. We use the investor relations page of our website for purposes of compliance with Regulation FD and as a routine channel for distribution of important information, including news releases, analyst presentations, financial information and corporate governance practices. Our filings with the SEC are posted on our website and available free of charge as soon as reasonably practical after they are electronically filed with, or furnished to, the SEC. The SEC’s website, www.sec.gov, contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. The content on any website referred to in this Form 10-K is not incorporated by reference in this Form 10-K unless expressly noted. Further, the Company’s references to website URLs are intended to be inactive textual references only.
Item 1A.Risk Factors
Risk Factor Summary
Investing in our common stock involves a high degree of risk. You should carefully consider all information in this Form 10-K and in subsequent reports we file with the SEC prior to investing in our common stock. These risks are discussed more fully in the section titled “Risk Factors.” These risks and uncertainties include, but are not limited to, the following:
•We have incurred net losses in every period to date, and we may continue to experience losses as we develop our business and may never achieve profitability;
•If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth prospects will be harmed;
•The continued success of our business relies heavily on our silicon-based DNA synthesis platform, and our position in the market as a leading provider of synthetic DNA using a silicon chip;
•We are substantially dependent on the success of our life sciences products and services;
15
•A significant portion of our recent growth has come from customers pursuing AI-enabled drug discovery. Demand from these customers may not continue at recent rates, and their use of our products and services in AI-enabled workflows could expose us to claims;
•We may not be able to scale our manufacturing capacity to meet future demand, which could harm our business;
•We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed;
•If we are unable to attract new customers and retain and grow sales from our existing customers, our business will be materially and adversely affected;
•Our revenue, results of operations, cash flows and reputation in the marketplace may suffer upon the loss of a limited number of large customers;
•If we, or our partners or suppliers, experience a significant disruption in our information technology systems, our business could be adversely affected;
•As we continue to grow our business, we will need to implement new systems and software successfully, otherwise our business and our financial condition and results of operations could be adversely affected;
•Cybersecurity threats are evolving and a cybersecurity incident could compromise our data and disrupt our operations, which could adversely affect our business;
•Rapidly changing technology and extensive competition in the life sciences industry could make the products and services we are developing and producing obsolete or non-competitive unless we continue to develop and manufacture new and improved products and services and pursue new market opportunities;
•We depend on one single-source supplier for a critical component for our DNA synthesis process. Although we have a reserve of supplies and alternative suppliers exist, the loss of this supplier or its failure to supply us with the necessary component on a timely basis could cause delays in the future capacity of our DNA synthesis process and adversely affect our business;
•We depend on the continuing efforts of our senior management team and other key personnel, including our scientific and engineering personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified researchers, engineering and other personnel, our ability to develop our products and services could be harmed, and we may be unable to achieve our goals;
•We may engage in strategic transactions, including acquisitions, collaborations, or investments in other companies or technologies, that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, or prove not to be successful;
•We have raised additional equity capital and may do so again, and our stockholders have experienced and may continue to experience dilution;
•If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business;
•Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain; and
•If we are unable to obtain, maintain and enforce intellectual property protection, others may be able to make, use, or sell products and technologies substantially the same as ours, which could adversely affect our ability to compete in the market.
Risk Factors
The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other statements in this Form 10-K. The following information should be read in
16
conjunction with Part II, Item 7, “Management’s discussion and analysis of financial condition and results of operations” and the consolidated financial statements and related notes in Part II, Item 8, “Consolidated financial statements and supplementary data” of this Form 10-K. The risks and uncertainties described below are not the only ones we face. Additional risk and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. If any of the events or circumstances described in the following risk factors actually occur, our business, operating results, financial condition, cash flows, and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.
Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price.
Because of the following factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.
Risks related to our business
We have incurred net losses in every period to date, and we may continue to experience losses as we develop our business and may never achieve profitability.
We have incurred net losses each year since inception and have generated limited revenue from product sales to date. We expect to incur increasing costs as we grow our business. We cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the success of our existing products and services and the development and commercialization of additional products and services in the synthetic biology and biologic drug industries as well as leveraging our investment in our manufacturing facility in Wilsonville, Oregon, and investing in technology to support our growth. Even if profitability is achieved, we may not be able to sustain profitability. We incurred net losses of $130.2 million, $77.7 million and $208.7 million for the years ended September 30, 2026, 2025 and 2024, respectively. As of September 30, 2026, we had an accumulated deficit of $1,449.8 million. We may continue to experience losses in the future as we continue to devote a substantial portion of our resources to market acceptance of our products and services, future product development, and our market penetration and margins as well as the other risks described in this Form 10-K, many of which are beyond our control. In addition, inflationary pressure could adversely impact our financial results by increasing operating costs. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our clients may choose to reduce their business with us if we increase our pricing.
If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth prospects will be harmed.
We have experienced significant revenue growth. We may not achieve similar growth rates in future periods. Investors should not rely on our operating results for any prior periods as an indication of our future operating performance. To effectively manage our anticipated future growth, we must continue to maintain and enhance our manufacturing, sales, financial and customer support administration systems, processes and controls. Failure to effectively manage our anticipated growth could lead us to over-invest or under-invest in development, operational, and administrative infrastructure; result in weaknesses in our infrastructure, systems, or controls; give rise to operational mistakes, losses, loss of customers, productivity or business opportunities; and result in loss of employees and reduced productivity of remaining employees.
Our continued growth could require significant capital expenditures and might divert financial resources from other projects such as the development of new products and services, including the development and commercialization of additional products in the synthetic biology and biologic drug industries. As additional products are developed and commercialized, we may need to incorporate new equipment, implement new technology systems, or hire new personnel with different qualifications. Failure to manage this growth or transition could result in delays in launching new products, turnaround time delays, higher manufacturing costs, declining product quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and services, and could damage our reputation and the prospects for our business.
17
If our management is unable to effectively manage our anticipated growth, our expenses may increase more than expected, our revenue could decline or grow more slowly than expected and we may be unable to implement our business strategy. In addition, the quality of our products and services may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.
We may encounter difficulties in managing our growth, and these difficulties could impair our profitability.
We are working simultaneously on multiple projects, expanding our capacity and targeting several market sectors, including activities in therapeutics, diagnostics, industry and applied, academic research and government, global supply partners and other sectors. In addition, we periodically renew our ISO certifications to maintain compliance with applicable standards and requirements. These diversified operations and activities place significant demands on our limited resources and require us to substantially expand the capabilities of our technical, administrative and operational resources and technology systems.
If we are unable to manage this growth and the periodic ISO recertification of our manufacturing facilities effectively, our shipments to our customers could be impacted, our time and resources could be diverted from other products and offerings and our business and operating results could suffer. In addition, if we fail to timely deliver products or meet quantity or quality requirements under our contracts with customers, we may have to offer discounts or reduce minimum purchase requirements, if applicable, and customers may delay or stop purchasing our products. Certain of our customer agreements require advance notice of, or prior approval for, changes to our manufacturing processes, specifications, facilities or use of subcontractors, which could delay or prevent changes needed to expand capacity or respond to supply constraints. Our ability to manage our operations and costs, including research and development, costs of components, manufacturing, sales and marketing, requires us to continue to invest in and improve our technology systems and processes and take other actions to enhance our operational, financial and management controls, reporting systems and procedures and to attract and retain sufficient numbers of talented employees. Failure to attract and retain sufficient numbers of talented employees will further strain our human resources and could impede our growth.
The continued success of our business relies heavily on our silicon-based DNA synthesis platform, and our position in the market as a leading provider of synthetic DNA using a silicon chip.
Our future profitability will depend on our ability to successfully execute and maintain a sustainable business model and generate continuous streams of revenue. Our business model is premised on the fact that we are the only DNA synthesis provider to synthesize DNA on a silicon chip on a large commercial level and the competitive advantages this creates. Our DNA synthesis methods, among other things, reduce the amount of raw materials required, speed up the synthesis process and deliver large volumes of high-quality synthetic DNA at low unit cost. However, if other competitors develop and commercialize a manufacturing process using a silicon chip or other similar technologies providing for the development of competitive synthetic DNA products at scale, this could be disruptive to our business model and could adversely affect our business prospects, financial condition and results of operations. If we are unable to convert a sufficient number of current manufacturers of synthetic DNA to buyers of our synthetic DNA, surpass our competitors regarding certain industry-related data points, and effectively implement our e-commerce platform which facilitates efficient order entry and fulfillment for our customers, our business, prospects, financial condition and results of operations will be adversely affected.
We are substantially dependent on the success of our life sciences products and services.
To date, we have invested a substantial portion of our efforts and financial resources towards the research and development and commercialization of our life sciences products and services. Our business is capital intensive, and we continue to make significant investments in the commercialization and marketing of our products and services.
Substantially all of our revenue generated to date is from products and services derived from our DNA synthesis platform. Our financial results are dependent on strengthening our DNA Synthesis and Protein Solutions and NGS Applications product groups while diversifying into other developing sectors.
Our near-term prospects, including our ability to finance our research and development activities and initiatives and enter into strategic collaborations, will depend heavily on the successful development and commercialization of our life sciences products and services. These initiatives will be substantially dependent on our ability to generate revenue from our products and services and obtain other funding necessary to support these initiatives. We continuously innovate to expand our portfolio of products and services. Our
18
inability to continue these initiatives and initiate new research and development efforts could result in a failure to develop or delay in developing new products and services, improve upon existing products and services, or expand our addressable market, which could have a material and adverse impact on our sales, business, financial position and results of operations.
We are also expanding into the nucleic acid therapeutics market, where we provide synthetic genes, plasmid DNA preparations and complex gene constructs used by customers developing cell and gene therapies, mRNA therapies, and other nucleic acid-based therapeutics. Revenue from these customers depends in part on the clinical and commercial success of their therapeutic programs, which is outside our control.
A significant portion of our recent growth has come from customers pursuing AI-enabled drug discovery. Demand from these customers may not continue at recent rates, and their use of our products and services in AI-enabled workflows could expose us to claims.
During fiscal 2026, orders from customers applying AI and other computational methods to therapeutic discovery grew substantially and represented a greater share of our DNA Synthesis and Protein Solutions revenue. We expect these customers to remain an important source of growth.
A portion of this demand is concentrated among a limited number of customers. While many customers engage us for repeated cycles of design, synthesis and testing, a customer may reduce its order volume, build internal production and characterization capacity or engage alternative providers. Customers may also reduce discovery spending if capital becomes less available to the biotechnology sector or if AI-enabled approaches do not improve the overall success rate of bringing compounds to market. Because we recognize revenue as we manufacture and deliver and most orders are fulfilled within a few weeks, we have limited contractual guarantees beyond the near term. A decline in incoming orders would adversely affect our revenue.
These customers use our synthetic DNA, expressed proteins and characterization data in their discovery workflows, but our customers generally build their own computational models and we do not control how customers use what we deliver. If a customer's model does not perform as expected, or if a therapeutic program based on such model fails, the customer may attribute the outcome to the quality or completeness of the material or data we supplied, whether or not that attribution is warranted, which could result in claims against us, loss of customer relationships, or reputational harm.
We may not be able to scale our manufacturing capacity to meet future demand, which could harm our business.
While we believe our current manufacturing capacity is sufficient to meet existing customer demand, we cannot predict the volume of demand we will face in the future, which may result in excess or obsolete inventories and resulting charges. If we are unable to scale our manufacturing capacity for current or future products in a timely manner to meet increased customer demand in the future, we could lose revenue, and our business, financial condition, and results of operations could be materially harmed. Our ability to successfully expand our manufacturing capacity is not guaranteed. Our technology and the production process for our equipment and tools are complex. We may encounter unexpected difficulties in manufacturing, improving or increasing the capacity of our equipment and tools, and addressing these difficulties may cause us to divert our time and resources from our other product offerings. If we are unable to expand our manufacturing capacity in a timely or cost-effective manner to meet future demand, our business, financial condition, and results of operations could be materially harmed.
In addition, our growing protein expression and data characterization services require different infrastructure, personnel, and third-party partnerships than our DNA synthesis operations. We are investing in characterization capacity ahead of anticipated demand and have entered into collaborations with third parties to expand our protein expression capabilities. If we are unable to attract and retain personnel with the specialized expertise these services require, if our third-party collaborators fail to perform, or if demand for these services does not develop as we expect, our investment may not generate the anticipated returns and our financial results could be adversely affected.
We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.
We face competition from a broad range of life sciences companies such as Integrated DNA Technologies, Inc. (owned by Danaher Corporation), GenScript Biotech Corporation, Agilent Technologies, Inc., Roche Holding AG, Illumina, Inc., Watchmaker Genomics, Inc., WuXi Biologics (Cayman) Inc., Specifica Inc. (owned by IQVIA
19
Holdings Inc.), Alloy Therapeutics, Inc., FairJourney Biologics S.A/IONTAS Limited and Biointron Biological, Inc., as well as a number of smaller and emerging companies. We may not be successful in maintaining our competitive position for a number of reasons. Some of our current competitors, as well as many of our potential competitors, have significant name recognition, substantial intellectual property portfolios, longer operating histories, greater resources to invest in new technologies, substantial experience in new product development and manufacturing capabilities and more established distribution channels to deliver products to customers than we do. These competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. Our competitors may develop disruptive technologies or products that are comparable or superior to our technologies and products. In light of these advantages, even though we believe our technology is superior to the product offerings of our competitors, current or potential customers might accept competitive products in lieu of purchasing our products. Increased competition is likely to result in continued pricing pressures, which could harm our sales, profitability or market share. Our failure to continue competing effectively or winning additional business with our existing customers could materially and adversely affect our business, financial condition or results of operations.
If we are unable to attract new customers and retain and grow sales from our existing customers, our business will be materially and adversely affected.
In order to grow our business, we must continue to attract new customers and retain and grow sales from our existing customers on a cost-effective basis. To do this, we aim to attract new and existing buyers of our DNA Synthesis and Protein Solutions products and services as well as our NGS Applications products, and expand the market opportunities available for our product portfolio and achieve widespread market acceptance by delivering both our current product offerings and new products and solutions at affordable cost, with high-quality, reliable turnaround times and throughput, superior e-commerce services and effective technical support. We cannot guarantee that our efforts to provide these key requirements will be consistently acceptable to, and meet the performance expectations of, our customers and potential customers. Furthermore, the commercialization of certain of the applications for which our customers use our products may be subject to clinical studies and/or coverage and reimbursement determinations by government and private payors, and if they are proven to have less clinical value than anticipated and/or fail to receive adequate coverage and reimbursement determinations it could have a negative impact on our sales and revenue. For example, we generate a significant portion of our NGS Applications revenue from sales to customers developing liquid biopsy assays. Our revenue from these customers depends on factors outside our control, including the coverage and reimbursement decisions from government and commercial payors, our customers' ability to successfully commercialize and scale, and the pace of adoption. These factors could cause our revenue from these customers to increase or decrease, and we have limited ability to predict or influence the direction or timing of such changes. A significant adverse reimbursement development, a decision by a customer to change or in-source its sample preparation workflow, or a shift to alternative technologies that do not use our products could reduce our revenue materially. If we are unable to successfully attract new customers and retain and grow sales from our existing customers, our business, financial position and results of operations would be negatively impacted.
Our revenue, results of operations, cash flows and reputation in the marketplace may suffer upon the loss of a limited number of large customers.
We have derived, and believe we may continue to derive, a significant portion of our revenue from a limited number of large customers. Our customers may buy less of our products depending on their own technological developments, the clinical efficacy and commercial success of the applications for which they use our products, end-user demand for our products and internal budget cycles. Customers may also buy less of our products during the transition period from product development to commercial production. In addition, existing customers may choose to produce some or all of their synthetic DNA requirements internally by using or developing manufacturing capabilities organically or by using capabilities from acquisitions of assets or entities from third parties with such capabilities. The loss of any significant customer or a significant reduction in the amount of product ordered by any significant customer would adversely affect our revenue, results of operations, cash flows and reputation in the marketplace.
If we, or our partners or suppliers, experience a significant disruption in our information technology systems, our business could be adversely affected.
We rely on several centralized information technology systems throughout our Company to provide products, keep financial records, process orders, manage inventories, process shipments to customers and operate other critical functions. In addition, we currently generate a growing portion of our revenue through sales on our e-
20
commerce platform. We manage our website and e-commerce platform internally and as a result any compromise of our security or misappropriation of proprietary information could have a material adverse effect on our business, financial condition and results of operations. We rely on encryption and authentication technology licensed from third parties to provide the security and authentication necessary to effect secure Internet transmission of confidential information, such as credit and other proprietary information. In 2024, we received ISO 27001:2022 certification, the most advanced information security standard published by the ISO, the world’s largest developer of voluntary international standards, and the International Electrotechnical Commission. Even though our information security management system received ISO 27001:2022 certification, our, and our partners’ or suppliers’, information technology systems have been and may still be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures, computer viruses, cyberattacks such as phishing, social engineering, ransomware, denial-of-service and other malware attacks, telecommunication failures, user errors, catastrophes or other unforeseen events. These attacks are becoming increasingly sophisticated, including through the use of AI. Our, or our partners’ or suppliers’ information technology systems also may experience interruptions, delays or cessations of service or produce errors in connection with system integration, software upgrades or system migration work that takes place from time to time. If we were to experience a prolonged system disruption in the information technology systems that involve our interactions with customers or suppliers, including negatively impacting our order fulfillment and order entry on our e-commerce platform, it could result in the loss of sales and customers and significant incremental costs, which could adversely affect our business.
As we continue to grow our business, we will need to implement new systems and software successfully, otherwise our business and our financial condition and results of operations could be adversely affected.
We will need to invest in improvements to our operational and IT systems and processes as part of our ongoing effort to improve the overall efficiency and competitiveness of our business, including improvements to prevent increasingly sophisticated cybersecurity incidents and improve standardization, systemization and automation to support growth. Transitioning to these new or upgraded processes and systems requires significant capital investments and personnel resources. Implementation is also highly dependent on the coordination of numerous employees, contractors and software and system providers. While these efforts have resulted in improvements to our operational systems, we expect to continue to incur expenses to implement additional improvements and upgrades to our systems. Many of these expenditures have been and may continue to be incurred in advance of the realization of any direct benefits to our business. Additionally, the effort to gain technological expertise, make use of data analytics, and develop new technologies in our business requires us to incur significant expenses. We cannot guarantee that we will be successful at improving our operational systems, adapting to changes in technology, including the successful utilization of data analytics, AI, and machine learning, or that our efforts will result in the anticipated benefits to us. In addition, the integration of emerging technologies, including data analytics, AI, and machine learning, into our systems and processes may require us to address rapidly developing laws and regulations governing AI. We may also experience difficulties in implementing or operating our new or upgraded operational or IT systems, including, but not limited to, ineffective or inefficient operations, significant system failures, system outages, delayed implementation and loss of system availability, which could lead to increased implementation and/or operational costs, loss or corruption of data, delayed shipments and interruptions of operations resulting in lost sales and/or profits. If our operational or IT system upgrades, improvements and associated implementation efforts are not successful or if we experience unexpected interruption in transition to new or upgraded processes or systems, our financial condition and results of operations could be adversely affected, and our business may become less competitive.
Cybersecurity threats are evolving and a cybersecurity incident could compromise our data and disrupt our operations, which could adversely affect our business.
Security breaches of our, or our partners’ or suppliers’, information technology systems could result in the misappropriation or unauthorized disclosure of confidential information belonging to us or to our employees, partners, customers or suppliers, including trade secrets or other intellectual property, proprietary business information, and personal information. Cybersecurity incidents, including phishing attacks, ransomware, nation-state attacks and other attempts to misappropriate or compromise confidential or proprietary information or sabotage enterprise IT systems, are becoming increasingly frequent and sophisticated. AI is enabling threat actors to conduct more targeted and convincing intrusions at greater scale and lower cost, including through AI-generated phishing, deepfake social engineering, and automated vulnerability discovery.
21
Threats involving the misuse of access to our network, systems, and information by our current or former employees, contractors, vendors, or partners, whether intentional or unintentional, also pose a risk to the security of our network, systems, and information and data. For example, employees may inadvertently share confidential information with unintended third parties, or departing employees may take, or create their own information based on, our confidential information upon leaving the Company. In addition, any such insiders may be the victims of social engineering attacks that enable third parties to access our network, systems, and information using an authorized person’s credentials. We and our network, systems, and information are also vulnerable to malicious acts by insiders, including leaking, modifying, or deleting confidential information, or performing other acts that could materially interfere with our operations and business.
We and our third-party providers are at heightened risk of theft or cyber attack of technology, data, and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by nation-state actors. This includes attacks which could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products and services. If any theft of, or attack on, our technology, data, or intellectual property is successful, we may be at heightened risk of losing our proprietary intellectual property rights, to the extent such theft, attack or intrusion destroys the proprietary nature of our intellectual property. While we implement security measures designed to reduce these risks, there is no guarantee these measures will be adequate to safeguard all systems and networks.
While we have not, to our knowledge, experienced any material security breach to date, techniques used to obtain unauthorized access to or to sabotage systems are constantly evolving and generally are not recognized until they are launched against a target. We cannot be certain that our data protection efforts will prevent significant breaches in our systems or those of our third-party contractors and collaborators. We may also not have sufficient logging to fully investigate a cybersecurity incident. A cybersecurity incident could materially disrupt our operations and trigger notification obligations under SEC rules, data protection laws, and our contracts, and could result in regulatory action, litigation or reputational harm. The costs of responding to a significant incident could be material and could exceed the limits of the cybersecurity insurance we maintain.
Rapidly changing technology and extensive competition in the life sciences industry could make the products and services we are developing and producing obsolete or non-competitive unless we continue to develop and manufacture new and improved products and services and pursue new market opportunities.
The life sciences industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry demands and standards. Our future success will depend on our ability to continually improve the products we are developing and producing, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of technological and scientific advances. These new market opportunities may be outside the scope of our proven expertise or in areas which have unproven market demand, and the utility and value of new products and services developed by us may not be accepted in the markets served by the new products. Our inability to gain market acceptance of existing products in new markets or market acceptance of new products could harm our future operating results. Our future success also depends on our ability to manufacture these new and improved products to meet customer demand in a timely and cost-effective manner, including our ability to resolve manufacturing issues that may arise as we commence production of any new products we develop. Unanticipated difficulties or delays in replacing existing products with new products we introduce or in manufacturing improved or new products in sufficient quantities to meet customer demand could diminish future demand for our products and harm our future operating results. Further, recent advances in AI capabilities could affect our business positively and negatively. AI-enabled drug discovery and protein design have been a significant source of demand growth for our DNA Synthesis and Protein Solutions business. The application of AI to drug discovery is at an early stage, and our customers’ demand for our products and services in connection with their AI-enabled programs depends on factors we do not control, including the pace of industry adoption, the evolution of computational workflows, and the competitive environment. Changes in any of these factors could affect our revenue from this customer base.
In addition, there is extensive competition in our end markets, and our future success will depend on our ability to maintain a competitive position with respect to technological advances. Technological development by others may result in our technologies, as well as products developed using our technologies, becoming obsolete. Our ability to compete successfully will depend on our ability to develop proprietary technologies and products that are technologically superior to and/or are less expensive than our competitors’ technologies and products. Our competitors may be able to develop competing and/or superior technologies and processes and compete more aggressively and sustain that competition over a longer period of time.
22
Issues relating to our use of AI and machine learning and compliance with evolving regulations and industry standards could adversely affect our business and operating results.
In our ongoing efforts to innovate and optimize operational efficiency, we have integrated AI and machine learning into various aspects of our workplace. While AI and machine learning present opportunities for enhanced productivity and innovation, they also introduce inherent risks, including legal and regulatory compliance risks and potential liability, that could adversely impact our business and reputation. Proper use of AI and machine learning can lead to improved decision-making, cost reduction, and competitive advantage. However, improper use, including algorithmic biases, ethical considerations, data privacy issues, the unauthorized or unapproved use of AI tools by employees or contractors (including the input of confidential, proprietary, or privileged information into third-party AI systems) and potential regulatory non-compliance, could result in reputational damage, legal liabilities, and financial losses. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity, and privacy and data protection. Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs and may limit our ability to develop, deploy, or use AI technologies. Failure to appropriately respond to this evolving landscape may result in legal liability, regulatory action, or brand and reputational harm. We have adopted policies and procedures designed to protect confidential information, including customer data, in our use of AI tools, but there can be no assurance that such measures will adequately prevent or mitigate the adverse effects that the integration and use of AI may have on our business, financial condition, and results of operations.
In addition, we are increasingly incorporating AI and machine learning capabilities into our product and service offerings. If these AI-driven tools produce inaccurate, unreliable, or biased outputs, or if our AI capabilities do not keep pace with those of our competitors, it could adversely affect customer confidence, our competitive position, and our results of operations.
Adverse global economic conditions and U.S. policy changes could have a negative effect on our business, financial condition and results of operations.
The global economy has been impacted by geopolitical tensions. For example, the U.S. federal administration has imposed significant new tariffs on imports, which, along with other U.S. trade actions, have triggered retaliatory actions by certain affected countries. These tariffs and other geopolitical tensions could result in, among other things, macroeconomic uncertainty, cyberattacks, supply chain disruptions, higher costs and changes to foreign exchange rates and financial markets. In addition, tariffs and trade restrictions may result in increased production costs and product pricing, supply chain disruptions, limited access to markets and uncertainty related to planning long-term investments and strategies. We manufacture our products in the United States and purchase raw materials and components from suppliers located both inside and outside the United States. Tariffs and other trade measures have increased, and may further increase, the cost of these materials and components. We may not be able to pass on increased costs to customers, particularly in markets where we compete on price or where customer budgets are fixed.
Additionally, pauses, restrictions or redirections in federal research funding may negatively impact our industry. Any prolonged reductions or delays in such funding could slow innovation, delay collaborations and limit the adoption of new technologies that contribute to our business growth. The U.S. federal government has imposed restrictions on certain categories of life sciences research, including federally funded dangerous gain-of-function research pursuant to Executive Order 14292. These restrictions could reduce the scope of research programs conducted by our customers, which could in turn reduce demand for our products. If these or similar policy changes continue or expand, we may face increased costs or reduced demand for our products. We are monitoring and evaluating any potential impacts that global economic conditions and other policy changes may have on our business, and we are considering ways in which we may offset any impacts. However, there is no assurance that we will be successful in mitigating the effects in the current environment. Although we cannot predict the full extent of these impacts, any such policy changes could adversely affect our business, financial condition and results of operations.
A significant portion of our sales depends on customers’ budgets that may be subject to significant and unexpected variation, including seasonality.
Our customers’ spending on research and development impacts our sales and profitability. Our customers and potential customers include those conducting research and development in therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners industries, and their budgets can have a significant effect on the demand for our products and services. Their research and development budgets are based on a wide variety of factors, including factors beyond our control, such as:
23
•the allocation of available resources to make purchases;
•funding from government sources;
•funding from research grants;
•changes in government programs that provide funding to research institutions and companies;
•changes in federal funding policies for life sciences research, including pauses, restrictions or redirections of grant funding;
•restrictions on or changes to the categories of federally funded life sciences research eligible for support, including certain research involving dangerous gain-of-function;
•the spending priorities among various types of research equipment;
•policies regarding capital expenditures during recessionary periods;
•political climate or macroeconomic conditions, including government shutdowns, economic downturns or market uncertainty or reduced spending in response to emergency public health situations;
•inability to raise sufficient funds in the capital markets;
•changes in the regulatory environment;
•healthcare legislative reform measures,
•differences in budgetary cycles;
•inflationary pressures; and
•market acceptance of relatively new technologies, such as ours.
Any decrease in spending or change in spending priorities of our customers and potential customers could significantly reduce the demand for our products and services. As we expand into new geographic markets, our revenue may be impacted by seasonal trends in the different regions, the seasonality of customer budgets in those regions and the mix of domestic versus international sales. In addition, access to capital markets is critical to many of our customers’ ability to fund their operations, including purchasing our products and services. Traditionally, biotechnology and life sciences companies have funded their research and development expenditures by raising capital in the equity markets. Declines and uncertainties in these markets have severely restricted raising new capital and have affected companies’ ability to fund existing research and development efforts which may lead them to delay project starts, reduce or cancel orders and or cancel projects. In the past, we experienced some cancellations of customer orders that we believe were due to customers' funding concerns. Moreover, we have no control over the timing and volume of purchases by these customers and potential customers, and as a result, revenue from these sources may vary significantly due to factors that can be difficult to forecast. Any delay or reduction in purchases by customers and potential customers or our inability to forecast fluctuations in demand could harm our future operating results.
We generally do not have long-term contracts with our customers requiring them to purchase any specified quantities from us.
We generally do not have long-term contracts with our customers requiring them to purchase any specified quantities from us and without such contracts our customers are not obligated to order or reorder our products. As a result, we cannot accurately predict our customers’ decisions to reduce or cease purchasing our products. Additionally, even where we enter into contracts with our customers, there is no guarantee that such agreements will be negotiated on terms that are commercially favorable to us in the long-term. Therefore, if many of our customers were to substantially reduce their transaction volume or cease ordering products from us, this could materially and adversely affect our financial performance.
We depend on one single-source supplier for a critical component for our DNA synthesis process. Although we have a reserve of supplies and alternative suppliers exist, the loss of this supplier or its failure to supply us with the necessary component on a timely basis could cause delays in the future capacity of our DNA synthesis process and adversely affect our business.
24
We depend on one single-source supplier for a critical component for our DNA synthesis process. We do not currently have the infrastructure or capability internally to manufacture this component. Although we have a reserve of supplies and although alternative suppliers exist for this critical component of our synthesis process, our existing DNA synthesis manufacturing process has been designed based on the functions, limitations, features and specifications of the components that we currently utilize. We have a supply agreement in place with this component supplier. However, there can be no assurance that our supply of this component will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. Additionally, we do not have any control over the process or timing of the acquisition or manufacture of materials by our supplier and cannot ensure that it will deliver to us the component we order on time, or at all.
The loss of this component provided by this supplier could require us to change the design of our manufacturing process based on the functions, limitations, features and specifications of the replacement components.
In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. Our dependence on this single-source supplier exposes us to certain risks, including the following:
•our supplier may cease or reduce production or deliveries, raise prices or renegotiate terms;
•we may be unable to locate a suitable replacement on acceptable terms or on a timely basis, if at all;
•if there is a disruption to our single-source supplier’s operations, and if we are unable to enter into arrangements with alternative suppliers, we will have no other means of completing our synthesis process until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply;
•delays caused by supply issues may harm our reputation, frustrate our customers and cause them to turn to our competitors for future projects; and
•our ability to progress our DNA synthesis products could be materially and adversely impacted if the single-source supplier upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory, operational or reputational issues.
Moreover, to meet anticipated market demand, our single-source supplier may need to increase manufacturing capacity, which could involve significant challenges. This may require us and our supplier to invest substantial additional funds and hire and retain the technical personnel who have the necessary experience. Neither we nor our supplier may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all.
We must continue to secure and maintain sufficient and stable supplies of raw materials. Any shortage of raw materials or materials necessary for our production capabilities may adversely affect our business.
Although historically we have not experienced price increases due to unexpected shortages in raw materials or other materials and other unanticipated events, there is no assurance that our supply of raw materials or other materials will not be significantly adversely affected in the future, which may in turn adversely affect our business, prospects, financial condition and results of operations.
In addition, as we grow, our existing suppliers may not be able to meet our increasing demand, and we may need to find additional suppliers. There is no assurance that we will always be able to secure suppliers who provide raw materials at the specification, quantity and quality levels that we demand (or at all) or be able to negotiate acceptable fees and terms of services with any such suppliers. Identifying a suitable supplier is an involved process that requires us to become satisfied with their quality control, responsiveness and service, financial stability and labor and other ethical practices. Even if we are able to expand existing sources, we may encounter delays in production and added costs as a result of the time it takes to train suppliers in our methods, products and quality control standards.
25
We typically enter into supply and quality agreements with our critical suppliers to ensure supply as well as maintain healthy levels of onsite inventories to support ongoing manufacturing processes. Our suppliers may reduce or cease their supply of raw materials, component parts and outsourced services and products to us at any time in the future. If the supply of raw materials, component parts and the outsourced services and products is interrupted due to shortages or other reasons, our production processes may be delayed. If any such event occurs, our operation and financial position may be adversely affected.
Although we believe that we have stable relationships with our existing suppliers, we cannot assure you that we will be able to secure a stable supply of raw materials going forward. A deterioration of our relationship with any of our suppliers, or problems experienced by these suppliers, could lead to shortages in our production capacity for some or all of our products. In such case, we may not be able to fulfill the demand of existing customers or supply new customers. In addition, shortages of raw materials or component parts or an increase in the cost of the raw materials or component parts we use could result in decreased revenue or could impair our ability to maintain or expand our business.
While we have experienced increased operating costs in recent periods, which we believe were due in part to a rise in inflation, we do not believe that inflation has had a material effect on our business, financial condition or results of operations. In the event of significant price increases for raw materials, we may have to pass the increased raw materials costs to our customers. However, we cannot assure you that we will be able to raise the prices of our products sufficiently to cover increased costs resulting from increases in the cost of our raw materials or overcome the interruption of a sufficient supply of qualified raw materials for our products. As a result, a price increase for our raw materials may negatively impact our business, financial position and results of operations.
We depend on the continuing efforts of our senior management team and other key personnel, including our scientific and engineering personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified researchers, engineering and other personnel, our ability to develop our products and services could be harmed, and we may be unable to achieve our goals.
Our future success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. We are highly dependent on Dr. Emily Leproust, our Chief Executive Officer ("CEO"), who is employed “at will,” meaning we or she may terminate the employment relationship at any time. In addition, our researchers and engineers are critical to our future technological and product innovations, and we will need to hire additional qualified personnel as we scale our operations and expand into new product areas. We have had, and may continue to have, difficulty attracting and retaining such talent. Our industry, particularly in the San Francisco Bay Area, is characterized by high demand and intense competition for talent, and the turnover rate can be high. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.
Our employees could leave our Company with little or no prior notice and would be free to work for a competitor. If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we might not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have “key person” life insurance policies covering members of our management team or other key personnel. While we conduct succession planning to identify the person(s) for key positions who possess the skills and capabilities to take on the responsibilities filled by our leaders, we cannot assure you that these strategies will successfully mitigate the loss of any key personnel. The loss of any of these individuals or our inability to attract or retain qualified personnel, including researchers, engineers and others, could prevent us from pursuing collaborations and adversely affect our product development and introductions, business growth prospects, results of operations and financial condition.
We may engage in strategic transactions, including acquisitions, collaborations, or investments in other companies or technologies, that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, or prove not to be successful.
We may enter into transactions to acquire other businesses, products or technologies and our ability to do so successfully cannot be ensured. While historically we have not completed many strategic transactions, we spun
26
out our DNA data storage application to Atlas Data Storage, Inc. (now AtlasBase Inc.) ("Atlas") in May 2025 and entered into a license agreement and equity investment with Invenra Inc. in February 2026. We are continuing to pursue opportunities in the life sciences industry that complement and expand our synthetic DNA product offering and our other products in both local and international markets. If we identify suitable opportunities, we may not be able to make such acquisitions on favorable terms or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of any acquired business that are not covered by any indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. In addition, we cannot guarantee that we will be able to fully recover the costs of such acquisitions or that we will be successful in leveraging any such strategic transactions into increased business, revenue or profitability. We also cannot predict the number, timing or size of any future acquisitions or the effect that any such transactions might have on our operating results.
From time to time, we may consider other strategic transactions, including collaborations or investments in other companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration. Any such collaboration may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management’s time and attention to manage a collaboration, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Antitrust or other competition laws may also limit our ability to acquire or work collaboratively with certain businesses or to fully realize the benefits of strategic transactions to acquire or collaborate with other businesses. Accordingly, although there can be no assurance that we will undertake or successfully complete any collaborations, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter into any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our products and technologies.
We may not achieve the anticipated benefits from the spin out of our DNA data storage application.
In May 2025, we completed the spin out of our DNA data storage application to Atlas, which allows us to focus on our DNA Synthesis and Protein Solutions and NGS Applications products and services. We retain an equity interest in Atlas and are entitled to potential milestone payments and royalties on any future sales of Atlas’ products and services. We may not achieve some or all of the anticipated benefits of the spin out if Atlas’ technology development and commercialization efforts are not successful, and the divestiture reduces our business diversification.
We may be subject to significant pricing pressures and if we are unable to pass on any cost increase to our customers, our business, financial position and results of operations could be adversely affected.
Over time, increasing customer demand for lower prices could force us to discount our products and services and result in lower margins. The impact may be further exacerbated if we are unable to successfully control production costs. In addition, if due to rising market prices as a result of inflation or otherwise, our suppliers increase prices or reduce discounts on their supplies, we may be unable to pass on any cost increase to our customers, thereby resulting in reduced margins and profits. Overall, these pricing pressures may adversely affect our business, financial position and results of operations.
We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.
27
We work with materials, including chemicals, biological agents and compounds that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.
In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs and business operations, as well as environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. While our property insurance policy provides limited coverage in the event of contamination from hazardous and biological products and the resulting cleanup costs, we do not currently have any additional insurance coverage for legal liability for claims arising from the handling, storage or disposal of hazardous materials. Accordingly, in the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected.
We could develop DNA sequences or engage in other activity that contravenes biosecurity requirements, international treaties, export controls, or other regulations, and changes in screening requirements could affect our operations or competitive position.
The FSAP involves rules administered by the CDC and the APHIS that regulate possession, use and transfer of biological select agents and toxins that have the potential to pose a severe threat to public, animal or plant health or to animal or plant products.
We have established a comprehensive biosecurity program under which we follow biosafety and biosecurity best practices and avoid DNA synthesis activities that trigger FSAP rules; however, we could inadvertently err in our observance of compliance program requirements in a manner that leaves us in noncompliance with FSAP or other biosecurity rules. In addition, authorities could promulgate new biosecurity requirements that restrict our operations. One or more resulting legal penalties, restraints on our business or reputational damage could have material adverse effects on our business and financial condition.
In addition, the manufacture and sale of synthetic nucleic acids are subject to an evolving framework of screening requirements in the United States and internationally. In May 2025, the President issued Executive Order 14292, which directed the revision or replacement of the federal Framework for Nucleic Acid Synthesis Screening and the development of a strategy for comprehensive nucleic acid synthesis screening in non-federally funded settings. Several pending federal bills, including the Nucleic Acid Standards for Biosecurity Act (H.R. 3029) and the Biosecurity Modernization and Innovation Act of 2026 (S. 3741), would direct the development of technical standards for nucleic acid synthesis providers.
We screen the sequences and customers of all orders and decline to ship orders that do not meet our criteria. Changes in screening requirements, including changes to the sequences or activities that must be screened, the technical standards screening systems must meet, or the records that must be maintained, could require us to modify our screening processes and could affect our costs, turnaround times, or the orders we are able to fulfill. If we were determined to have failed to screen adequately, or if material we manufactured were misused by a third party, we could face governmental action, litigation and significant reputational harm, and could lose the ability to sell to government-funded customers. Conversely, requirements that purchasers use only providers that meet specified screening standards could benefit providers, including us, that already maintain comprehensive screening programs.
Third parties may use our products in ways that could damage our reputation.
After our customers have received our products, we do not have any control over their use and our customers may use them in ways that are harmful to our reputation as a supplier of synthetic DNA products. In addition, while we have established a biosecurity program designed to comply with biosafety and biosecurity requirements and perform export control screening in an effort to ensure that third parties do not obtain our products for malevolent purposes, we cannot guarantee that these preventative measures will eliminate or reduce the risk of the domestic and global opportunities for the misuse of our products. Accordingly, in the event of such misuse, our reputation, future revenue and operating results may suffer.
28
Advances in AI and computational biology have made it easier for a broader range of actors to design nucleic acid sequences, including sequences that could pose biosecurity concerns. These tools may enable individuals or organizations to design potentially harmful sequences without the specialized expertise historically required, increasing the importance of effective sequence and customer screening. While we believe our biosecurity screening program is designed to identify and decline orders of concern, no screening process can eliminate all risk.
A violation of data privacy or data protection laws could harm our operating results and financial condition, damage our reputation or otherwise materially harm our business.
We are subject to data privacy and data protection laws in the jurisdictions where we operate as a result of producing, collecting, processing, storing and transmitting confidential, personal and/or sensitive data in the course of our business, in addition to customer-imposed controls. Evolving privacy and data protection laws, rules and regulations create significant compliance challenges as we seek to maintain our global reach. In some cases, there are restrictions on the transfer of personal data outside the home country. More recently, privacy and data protection regulators are paying special attention to emerging issues linked to new digital technologies, such as the use of AI, biometrics, and surveillance technologies, which pose unique challenges to existing privacy and data protection paradigms.
For example, California has enacted the California Consumer Privacy Act, or CCPA, which gives California residents expanded privacy rights. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches. Although the CCPA includes exemptions for certain categories of health information, the CCPA may increase our compliance costs and potential liability with respect to personal information we collect about California residents. Additionally, the CCPA was significantly amended by the California Privacy Rights Act, or the CPRA, which among other things, established the California Privacy Protection Agency, or the CPPA, a new regulatory authority tasked with enacting new regulations under the CPRA and expanded enforcement authority. The CPPA finalized new regulations in September 2025 that will require certain businesses, depending on their revenues, the volume of personal information and sensitive personal information they process, and the extent to which they derive revenue from selling or sharing personal information, to conduct annual cybersecurity audits, with initial audit certifications phased in beginning in 2028. In addition, beginning January 1, 2026, covered businesses must conduct risk assessments for certain kinds of processing that pose a significant risk to consumers, and beginning January 1, 2027, must provide pre-use notices and opt-out and access rights for the use of automated decision-making technology in connection with certain kinds of significant decisions involving consumers. In addition to California, more U.S. states have enacted, and are continuing to enact, similar legislation, all of which are likely to increase our regulatory compliance costs and risks, exposure to regulatory enforcement action, and other liabilities.
Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. For example, the General Data Protection Regulation ("GDPR") governs the collection and use of personal data in the European Union, including by companies outside of the European Union. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the legal basis for processing personal data, including consent where applicable, the information provided to the individuals to whom the personal data relates, the security and confidentiality of the personal data, data breach notification, and the use of third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Economic Area to countries, including the United States, that have not been deemed to provide an adequate level of protection, enhances enforcement authority and imposes penalties for noncompliance. The GDPR also provides data subjects with the right to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR has been and will continue to be a rigorous and time-intensive process that has increased and will continue to increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with any European activities, which could adversely affect our business, prospects, financial condition and results of operations.
Any actual or perceived noncompliance could result in significant consequences, including business interruption, sanctions and significant pecuniary fines, regulatory inquiries and investigations, adverse publicity, loss of competitive advantage and customer trust, as well as privacy litigation and other civil claims for damages, any of which may adversely affect our business, reputation, results of operations and financial condition.
29
Because we are subject to existing and potential additional governmental regulation, the markets for our products and services may be narrowed.
We are subject, both directly and indirectly, to the adverse impact of existing and potential future government regulation of our operations and markets. For example, the export of our products is subject to strict regulatory control in a number of jurisdictions. The failure to satisfy export control criteria or obtain necessary clearances could delay or prevent the shipment of products, which could adversely affect our revenue and profitability. Export controls have been the subject of increased regulatory attention with respect to biotechnology, and biosecurity screening requirements applicable to nucleic acid synthesis providers are evolving, as described elsewhere in these risk factors. Moreover, the life sciences industry, which is currently the primary market for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which can operate to narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulation that adversely affects our market opportunities. Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life sciences industry in particular. Failure to comply with these regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenue and could increase the cost of operating our business.
Our products could in the future be subject to additional regulation by the FDA or other domestic and international regulatory agencies, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.
The FDA regulates medical devices, including IVDs. IVDs are a category of medical devices that include reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. IVDs are intended for use in the collection, preparation, and examination of specimens taken from the human body. An RUO IVD product is an IVD product that is in the laboratory research phase of development or is intended for use in the conduct of nonclinical laboratory research and not intended to produce results for clinical use. As such, an RUO IVD is not intended for use in clinical investigations or in clinical practice. Such RUO products do not require premarket clearance or approval from the FDA, provided that they are not intended for clinical use and that they are labeled “For Research Use Only. Not For Use In Diagnostic Procedures” pursuant to FDA regulations. Our RUO IVD products sold in the United States are not intended for clinical or diagnostic use, and we market and label them as RUO. Our customers, however, may use our products in their own assay workflows, including LDTs or other clinical applications. If our distribution, marketing or support activities, or our customers’ use of our products, were viewed as evidence of an intended clinical use, the FDA could take a different view of the applicable requirements or our compliance obligations, and could consider our products misbranded or adulterated, require us to obtain clearance or approval, or take enforcement action.
The FDA has historically taken the position that LDTs are considered to be IVDs, but has generally exercised enforcement discretion. However, in May 2024, the FDA attempted to regulate virtually all LDTs as medical devices by publishing the LDT Final Rule. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the LDT Final Rule in its entirety. The FDA declined to appeal, and on September 19, 2025, it issued a final rule effective that date, reverting 21 C.F.R. § 809.3(a) to its pre-May 2024 text. While the LDT Final Rule was unsuccessful, in the future, certain of our products or related applications could be subject to additional FDA regulation. Even where a product is not subject to FDA clearance or approval requirements or deemed exempt, the FDA may impose restrictions as to the types of customers to which we can market and sell our products. Such regulation and restrictions may materially and adversely affect our business, financial condition and results of operations.
Many countries have laws and regulations that could affect our products and which could limit our ability to sell our products in those countries. The number and scope of these requirements are increasing. We may not be able to obtain regulatory approvals in such countries or may incur significant costs in obtaining or maintaining foreign regulatory approvals. For example, the EU requires manufacturers to adhere to the IVDR, for the marketing and sale of IVDs. In February 2024, we introduced IVDR-compliant Precision Dx products for whole exome sequencing to meet the needs of our European customers and provide compliant solutions for clinical and diagnostic use in the EU. Complying with the stricter regulatory requirements of the IVDR, including with respect to quality systems and post-market surveillance, may require us to incur significant expenditures. If we fail to remain in compliance with applicable EU laws and regulations, we would be unable to continue selling such products within the EU, and any other regions that tie their product registrations or regulations to EU requirements, which could adversely affect our business.
30
Certain of our activities or potential customers may require us to obtain certification under the Clinical Laboratory Improvement Amendments of 1988.
The Clinical Laboratory Improvement Amendment of 1988 ("CLIA") applies to a facility that performs laboratory testing on materials derived from the human body for the purpose of providing information for the diagnosis, prevention or treatment of disease or impairment, or the assessment of the health of human beings. We perform testing on human specimens solely for research purposes through an RUO service, and we do not provide results for the diagnosis, prevention or treatment of disease or the assessment of health. Based on our current activities, we believe we are not currently subject to CLIA. However, we may be required to obtain a CLIA certificate if we begin performing testing on human specimens for clinical purposes, if our customers use results from our research services for clinical purposes or if regulators otherwise view our activities as clinical laboratory testing. Our customers may also require us to hold a CLIA certificate as a contractual matter. If we obtain a CLIA certificate, we would be required to comply with applicable quality, personnel, proficiency testing, patient test management, quality control, quality assurance and inspection requirements, and would have to continually expend time, money and effort to maintain compliance, which may divert the attention of management and disrupt our core business operations.
We currently manufacture substantially all of our products and multiple sub-assemblies at our manufacturing facilities in Wilsonville, Oregon and South San Francisco, California, and if either of these facilities is destroyed or we experience any manufacturing difficulties, disruptions, or delays at either of these facilities, this could limit supply of our products or adversely affect our ability to sell products, and our business would be adversely impacted.
We currently manufacture substantially all of our products and multiple sub-assemblies at our manufacturing facilities in Wilsonville, Oregon and South San Francisco, California. We have consolidated all DNA Synthesis and Protein Solutions in Wilsonville, and our Express product line is manufactured solely in Wilsonville. We still manufacture a significant portion of our NGS products at our South San Francisco facility. Any manufacturing difficulties at our two manufacturing locations could result in turnaround time delays. With respect to our Wilsonville facility, if regulatory, manufacturing, or other problems require us to discontinue production at the facility, we may not be able to manufacture our synthetic genes, oligo pools or selected NGS products or create our DNA libraries, which would adversely impact our business. In addition, if either of our facilities or the equipment therein is significantly damaged, destroyed, or affected by fire, flood, power loss, or similar events, or is shut down for health and safety reasons, including public health emergencies, severe weather, or other reasons, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace the facility. In the event of a temporary or protracted loss of either of these facilities or the equipment therein, we might not be able to transfer manufacturing to another third party. Even if we could transfer manufacturing from one facility to another, the shift would likely be expensive and time-consuming, particularly if we were to maintain the current manufacturing standards procedures at such alternative facility.
Natural disasters, public health crises, political crises, severe weather events, and other catastrophic events or other events outside of our control may damage our facilities or the facilities of third parties on which we depend and could impact our ability to sell products.
Our headquarters in South San Francisco, California is located near known earthquake fault zones and is vulnerable to damage from earthquakes. Our primary manufacturing facility in Wilsonville, Oregon is vulnerable to extreme heat, wildfires, and severe weather events, all of which may be further exacerbated by the effects of climate change, as well as damage from earthquakes. An earthquake or other natural disaster or power shortages or outages could disrupt operations or impair critical systems at our headquarters or at any of our other facilities throughout the world. We, our suppliers, third-party service providers and customers are vulnerable to damage from natural disasters, including fire, floods or monsoons, power loss, communications failures, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflicts and similar events. If any disaster were to occur, our ability to operate our business at any of our facilities could be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business. Furthermore, our in vivo antibody discovery services involve mice. In the past, vivarium sites have been shut down by animal activists, and any disturbance or shut down at the site where our in vivo antibody discovery work is being conducted could disrupt our business operations or harm our reputation.
31
Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.
We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control, including travel restrictions, employee strikes, inclement weather, delays due to public health emergencies, and increased fuel costs. For example, in the past we have experienced shipment delays due to flight cancellations caused by inclement weather. Any failure to deliver products to our customers in a timely and accurate manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these third parties are unable to deliver our products, the delivery and acceptance of our products by our customers may be delayed which could harm our business and financial results. The failure to deliver our products in a timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.
We have raised additional equity capital and may do so again, and our stockholders have experienced and may continue to experience dilution.
We have incurred net losses since our inception, and we anticipate net losses and negative free cash flows for the near future. In June 2026, we filed an automatic shelf registration statement on Form S-3ASR and entered into a sales agreement providing for the offer and sale of up to $200.0 million of our common stock in at-the-market transactions. Through September 30, 2026, we sold 748,909 shares under that program for net proceeds of approximately $97.1 million, and approximately $100.0 million remained available. In August 2026, we completed an underwritten public offering of 3,593,750 shares of common stock at a public offering price of $96.00 per share, resulting in net proceeds of approximately $327.7 million after underwriting discounts, commissions and offering expenses.
We may issue additional equity or equity-linked securities in the future, including under our at-the-market program, and we are not required to give advance notice of, or obtain stockholder approval for, sales under that program. Any such issuance may dilute our stockholders, and sales, or the perception that sales may occur, could cause the market price of our common stock to decline. While we expect that our existing cash, cash equivalents and short-term investments, together with the net proceeds from our August 2026 offering and at-the-market transactions, are sufficient to fund our planned operating expenses and capital expenditure requirements and other contractual obligations through at least the next 12 months, our operating plan may change as a result of factors currently unknown to us, and as a result, we may need to seek additional funds sooner than planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
Our future capital requirements depend on many factors, including:
•the number and characteristics of any additional products and services or manufacturing processes we develop or acquire to serve new or existing markets;
•the scope, progress, results and costs of researching and developing future products and services or improvements to existing products or manufacturing processes, including increasing our manufacturing capabilities;
•the cost of manufacturing our DNA synthesis equipment and tools, our NGS sample preparation kits, and any future products we successfully commercialize, and the cost of expanding our protein expression and characterization service capacity;
•our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;
•the costs of acquiring or investing in complementary businesses or assets;
•the costs of expanding our sales, marketing and manufacturing capabilities in the United States and in other geographies;
•any lawsuits related to our products or services or commenced against us or any regulatory actions or proceedings commenced;
•the expenses needed to attract and retain skilled personnel;
32
•the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and
•the timing, receipt and amount of sales of, or royalties on, any future approved products, if any.
Additional funds, if needed, may not be available when we need them, on terms that are acceptable to us, or at all. Furthermore, any such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate our manufacturing, research and development activities, marketing and sales capabilities or other activities that may be necessary to generate revenue and achieve profitability.
As we expand our development and commercialization activities outside of the United States, we will be subject to an increased risk of inadvertently conducting activities in a manner that violates the U.S. Foreign Corrupt Practices Act (the "FCPA") and similar laws. If that occurs, we may be subject to civil or criminal penalties which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
We are subject to the FCPA, which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. We are also subject to the UK Anti-Bribery Act, which prohibits both domestic and international bribery, as well as bribery across both public and private sectors.
In the course of establishing and expanding our commercial operations and complying with non-U.S. regulatory requirements, we will need to establish and expand business relationships with various third parties and we will interact more frequently with foreign officials, including regulatory authorities. Expanded programs to maintain compliance with such laws will be costly and may not be effective. Any interactions with any such parties or individuals where compensation is provided that are found to be in violation of such laws could result in substantial fines and penalties and could materially harm our business. Furthermore, any finding of a violation under one country’s laws may increase the likelihood that we will be prosecuted and be found to have violated another country’s laws. We require that our employees annually certify that they understand and will comply with our Code of Ethics, our Anti-Money Laundering Policy and our Anti-Corruption Policy. Even so, if our business practices outside the United States are found to be in violation of the FCPA, UK Anti-Bribery Act, antitrust or other similar laws, we may be subject to significant civil and criminal penalties which could have a material adverse effect on our financial condition and results of operations.
We could engage in exporting or related activity that contravenes international trade restraints, or regulatory authorities could promulgate more far-reaching international trade restraints, which could give rise to one or more of substantial legal liability, impediments to our business and reputational damage.
Our international business activities must comport with U.S. export controls and other international trade restraints, including the U.S. Department of Commerce’s Export Administration Regulations and economic sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control.
We have established an international trade compliance program that encompasses best practices for preventing, detecting and addressing noncompliance with international trade restraints; however, we could fail to observe the compliance program requirements in a manner that leaves us in noncompliance with export controls or other international trade restraints. In addition, authorities could promulgate international trade restraints that impinge on our ability to pursue our business as planned. One or more of resulting legal penalties, restraints on our business or reputational damage could have material adverse effects on our business and financial condition.
In addition, regulations administered by the U.S. Department of Justice restrict, and in some cases prohibit, certain transactions that could give designated countries of concern, or persons associated with them, access to bulk U.S. sensitive personal data, including human genomic data. While we do not believe our current operations involve transactions subject to these restrictions, the scope of the regulations is broad and evolving, and compliance may require us to monitor data flows across our operations and supply chain.
Doing business internationally creates operational and financial risks for our business.
33
During our fiscal years ended September 30, 2026, 2025 and 2024, 41%, 42% and 40%, respectively, of our revenue was generated from customers located outside of the United States. In connection with our growth strategy, we intend to further expand in international markets. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be adversely affected. International sales entail a variety of risks, including longer payment cycles and difficulties in collecting accounts receivable outside of the United States, currency exchange fluctuations, challenges in staffing and managing foreign operations, tariffs and other trade barriers (including tariffs enacted and proposed by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods), unexpected changes in legislative or regulatory requirements of foreign countries into which we sell our products, difficulties in obtaining export licenses or in overcoming other trade barriers, laws and business practices favoring local companies, political instability, including conflicts and tensions involving Russia and China and the Israel-Hamas war, economic instability, difficulties protecting or procuring intellectual property rights, and restrictions resulting in delivery delays and significant taxes or other burdens of complying with a variety of foreign laws.
Changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers’ local currency could make our products more expensive, impacting our ability to compete. Our costs of materials from international suppliers may increase if in order to continue doing business with us they raise their prices as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations.
Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"), a corporation that undergoes an “ownership change” is subject to limitations on its ability to use its pre-change net operating loss carryforwards ("NOLs"), to offset future taxable income. We have experienced at least one ownership change in the past, and we may experience ownership changes in the future. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code, including changes resulting from our August 2026 public offering, any future sales under our at-the-market program or other equity issuances. Furthermore, our ability to use NOLs of companies that we may acquire in the future may be subject to limitations. For these reasons, we may not be able to use a material portion of the NOLs, even if we attain profitability.
The enactment of legislation implementing changes in taxation of international business activities, the adoption of other corporate tax reform policies, or changes in tax legislation or policies could impact our future financial position and results of operations.
Corporate tax reform, base-erosion efforts and tax transparency continue to be high priorities in many tax jurisdictions where we intend to have business operations. As a result, policies regarding corporate income and other taxes in numerous jurisdictions are under heightened scrutiny and tax reform legislation is being proposed or enacted in a number of jurisdictions. In July 2025, the U.S. government enacted The One Big Beautiful Bill Act (the “OBBBA”) which includes a broad range of tax reform provisions that may affect our financial results. The OBBBA includes, among other provisions, the allowance of immediate expensing of qualifying domestic research and development expenses and permanent extensions of certain provisions within the Tax Cuts and Jobs Act of 2017.
In addition, many countries have enacted or plan to enact legislation and other guidance to align their international tax rules with the Organization for Economic Co-operation and Development’s Base Erosion and Profit Shifting recommendations and action plan that aim to standardize and modernize global corporate tax policy, including changes to cross-border tax, transfer-pricing documentation rules, and nexus-based tax incentive practices. Such legislative initiatives may materially and adversely affect our plans to expand internationally and may negatively impact our financial condition and results of operations generally.
Ethical, legal and social concerns surrounding the use of genetic information could reduce demand for our technology.
34
Our products may be used to create DNA sequences of humans, agricultural crops and other living organisms. Our products could be used in a variety of applications, which may have underlying ethical, legal and social concerns. Governmental authorities could, for safety, social or other purposes, impose limits on or implement regulation of the use of gene synthesis or the collection, use or transfer of genetic information. Such concerns or governmental restrictions could limit the use of our products, which could have a material adverse effect on our business, financial condition and results of operations. In addition, public perception about the safety and environmental hazards of, and ethical concerns over, genetically engineered products and processes could influence public acceptance of our technologies, products and processes. These concerns could result in increased expenses, regulatory scrutiny, delays or other impediments to our programs.
Risks related to being a public company
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business.
As a public company, we are required to comply with Section 404 of the Sarbanes Oxley Act of 2002 (“SOX”), which requires, among other things, that companies maintain disclosure controls and procedures to ensure timely disclosure of material information, and that management review the effectiveness of those controls on a quarterly basis and that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting in this Form 10-K, among other additional requirements. Effective internal controls are necessary for us to provide reliable financial reports and to help prevent fraud, and our management and other personnel devote a substantial amount of time to these compliance requirements. These rules and regulations also increase our legal and financial compliance costs and make some activities more time-consuming and costly.
We cannot be certain that we will be able to maintain adequate controls over our financial processes and reporting in the future. Although management has concluded that our internal control over financial reporting was effective as of September 30, 2025 and September 30, 2026, weaknesses in our internal control over financial reporting could again be discovered in the future. If we fail to maintain effective internal controls, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our securities may be negatively affected, and we could be subject to sanctions or investigation by regulatory authorities, such as the SEC or Nasdaq.
The requirements of being a public company may strain our resources and require a substantial amount of management’s attention.
As a public company, we are subject to the reporting requirements of the Exchange Act, SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, Nasdaq listing requirements and other applicable securities rules and regulations. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact, in ways we cannot currently anticipate, the manner in which we operate our business. Compliance with these rules and regulations may cause us to incur additional accounting, legal and other expenses. We also incur costs associated with corporate governance requirements, including requirements under securities laws, as well as rules and regulations implemented by the SEC and Nasdaq, particularly as a large accelerated filer. These rules and regulations have increased our legal and financial compliance costs and we devote significant time to comply with these requirements. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
Risks related to our intellectual property
Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.
Our commercial success depends in part on our ability to protect our intellectual property and proprietary technologies. We rely on patent protection, where appropriate and available, as well as a combination of copyright, trade secret and trademark laws, and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage.
35
Worldwide, we own or exclusively in-license over 200 issued or allowed patents and more than 230 pending patent applications as of September 30, 2026. In addition to these owned and exclusively licensed patents and pending patent applications, we also license patents on a non-exclusive and/or territory restricted basis. Our intellectual property portfolio includes important patents and patent applications directed to DNA synthesis, NGS and antibody libraries.
Several patent applications covering our technologies have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or, if applicable in the future, licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of products that we may develop. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our technologies or products. Furthermore, an interference proceeding can be provoked by a third party or instituted by the U.S. Patent and Trademark Office ("USPTO"), or the European Patent Office ("EPO"), to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.
Patent law can be highly uncertain and involve complex legal and factual questions for which important principles remain unresolved. In the United States and in many international jurisdictions, policy regarding the breadth of claims allowed in patents can be inconsistent. The U.S. Supreme Court and the Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, international courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and international legislative bodies.
If we are unable to obtain, maintain and enforce intellectual property protection, others may be able to make, use, or sell products and technologies substantially the same as ours, which could adversely affect our ability to compete in the market.
We may not pursue or maintain patent protection for our products in every country or territory in which we sell our products and technologies. In addition, our pending U.S. and foreign patent applications may not issue as patents or may not issue in a form that will be sufficient to protect our proprietary technology and gain or keep our competitive advantage. Any patents we have obtained or do obtain may be subject to re-examination, reissue, opposition or other administrative proceedings, or may be challenged in litigation, and such challenges could result in a determination that the patent is invalid or unenforceable.
Patents have a limited lifespan. Patent terms may be shortened or lengthened by, for example, terminal disclaimers, patent term adjustments, supplemental protection certificates, and patent term extensions. Although extensions may be available, the life of a patent, and the protection it affords, is limited. Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may not significantly lengthen patent term. Non-payment or delay in payment of patent fees or annuities, delay in patent filings or delay in extension filing, whether intentional or unintentional, may also result in the loss of patent rights important to our business. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents.
We cannot be certain that the steps we have taken will prevent unauthorized use or unauthorized reverse engineering of our technology. In addition, competitors may be able to design alternative methods or devices that avoid infringement of our patents. To the extent our intellectual property, including licensed intellectual property, offers inadequate protection, or is found to be invalid or unenforceable, we are exposed to a greater risk of direct competition. If our intellectual property does not provide adequate protection against our competitors’ products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.
Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we review our competitors’ products, and may in the future seek to enforce our patents or other rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take
36
appropriate steps to enforce, our intellectual property rights. We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our products in any jurisdiction. For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed. Therefore, patent applications covering our product candidates or technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our products or the use of our products or technologies. The scope of a patent claim is determined by the interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates.
A court or other judicial body may decide that the patent we seek to enforce is invalid or unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that the patent in question does not cover the technology in question. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Some of our competitors may be able to devote significantly more resources to intellectual property litigation and may have significantly broader patent portfolios to assert against us if we assert our rights against them.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on our technologies and products in all countries throughout the world would be prohibitively expensive. In addition, the laws of some non-U.S. countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from using our inventions in countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own technologies and products and, may export otherwise infringing products to territories where we have patent protection. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, put our own patents at risk of being invalidated or interpreted narrowly, put our patent applications at risk of not being issued, and provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if any of our patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment
37
agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.
Trade secrets and know-how can be difficult to protect as trade secrets, and know-how will over time be disseminated within the industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company. In addition, because we may rely on third parties in the development of our products, we may, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with third parties prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If we are unable to prevent unauthorized material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.
Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either lawfully or through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. Competitors could willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.
We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third party claims of intellectual property infringement that could require us to spend significant time and money and could prevent us from selling our products or impact our stock price.
Litigation may be necessary for us to enforce our patent and proprietary rights and/or to determine the scope, coverage and validity of others’ proprietary rights. Litigation on these matters has been prevalent in our industry and we expect that this will continue. As the biotechnology and synthetic biology industries expand and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our technologies and products of which we are not aware or that we may need to challenge to continue our operations as currently contemplated. In addition, our competitors and others may have patents or may in the future obtain patents and claim that the use of our products or processes infringes these patents. As we move into new markets and applications for our products and processes, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us.
Patent infringement suits can be expensive, lengthy and disruptive to business operations and the outcome following legal assertions of invalidity and unenforceability is unpredictable. We could incur substantial costs and divert the attention of our management and technical personnel in prosecuting or defending against any claims and may harm our reputation. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. There can be no assurance that we will prevail in any suit initiated against us by third parties, successfully settle or otherwise resolve patent infringement claims. If we are unable to successfully settle claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our technologies and products. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to
38
develop, commercialize and sell products, and could result in the award of substantial damages against us, including treble damages and attorneys’ fees and costs in the event that we are found to be a willful infringer of third party patents.
In the event of a successful claim of infringement against us, we may be required to obtain one or more licenses from third parties, which we may not be able to obtain at a reasonable cost, if at all. We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any required licenses on favorable terms could prevent us from commercializing our products, and the risk of a prohibition on the sale of any of our products could adversely affect our ability to grow and gain market acceptance for our products.
Suppliers of certain equipment and technology platforms on which we rely for our business may also be subject to patent infringement lawsuits. Even if we are not a named party in such lawsuits, if such suppliers are enjoined by a court to stop selling their equipment and technology platforms or supporting our existing equipment and technology platforms, we may not have an alternative source for such equipment and technology platforms, which may have a material adverse effect on our business.
We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We were previously involved in litigation of this kind with Agilent. While we have settled this dispute, there can be no assurance that future litigation will not be initiated by these parties. Some of our employees were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our products and technologies. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Finally, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
In addition, our agreements with some of our suppliers, distributors, customers and other entities with whom we do business may require us to defend or indemnify these parties to the extent they become involved in infringement claims against us, including the claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify any of these third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.
We may not be successful in obtaining or maintaining necessary rights to our products and technologies through acquisitions and in-licenses, and our intellectual property agreements with third parties may involve unfavorable terms or be subject to disagreements over contract interpretation.
We may find that our programs require the use of proprietary rights held by third parties, and the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our products and technologies. The licensing and acquisition of third-party intellectual property rights is a competitive area, and other companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater
39
commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements. We also may be unable to license or acquire third-party intellectual property rights on terms that would be favorable to us or would allow us to make an appropriate return on our investment.
We engage in discussions regarding other possible commercial and cross-licensing agreements with third parties from time to time. There can be no assurance that these discussions will lead to the execution of commercial license or cross-license agreements or that such agreements will be on terms that are favorable to us. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. In addition, if we enter into cross-licensing agreements, there is no assurance that we will be able to effectively compete against others who are licensed under our patents.
In addition, provisions in our licensing and other intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.
Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.
In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks for marketing our products and technologies in those countries. Over the long-term, if we are unable to establish name recognition based on our trademarks, then our marketing abilities may be materially adversely impacted.
We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling our products.
We rely on, or may in the future rely on, licenses in order to be able to use various proprietary technologies that are material to our business. We do not or will not own the patents that underlie these licenses. Our rights to use the technology we license are subject to the negotiation of, continuation of and compliance with the terms of those licenses. In some cases, we do not or will not control the prosecution, maintenance, or filing of the patents to which we hold licenses, or the enforcement of these patents against third parties. Some of our patents and patent applications were either acquired from another company who acquired those patents and patent applications from yet another company or are licensed from a third party. Thus, these patents and patent applications are not written by us or our attorneys, and we did not have control over the drafting and prosecution. The former patent owners and our licensors might not have given the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owners of the patents and applications and had control over the drafting and prosecution. We cannot be certain that drafting and/or prosecution of the licensed patents and patent applications by the licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.
Our rights to use the technology we license is subject to the validity of the owner’s intellectual property rights. Enforcement of our licensed patents or defense or any claims asserting the invalidity of these patents is often subject to the control or cooperation of our licensors. Legal action could be initiated against the owners of the intellectual property that we license. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent these other companies or institutions from continuing to license intellectual property that we may need to operate our business.
40
Our licenses contain or will contain provisions that allow the licensor to terminate the license upon specific conditions. Our rights under the licenses are subject to or will be subject to our continued compliance with the terms of the license, including the payment of royalties due under the license. Termination of these licenses could prevent us from marketing some or all of our products. Because of the complexity of our products and the patents we have licensed, determining the scope of the license and related royalty obligation can be difficult and can lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from producing and selling some or all of our products.
Risks related to owning our common stock
We have never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.
We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after any price appreciation as the only way to realize any future gains on their investments.
Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock.
Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our Company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:
•providing for a classified board of directors with staggered, three-year terms;
•authorizing our board of directors to issue preferred stock with voting or other rights or preferences that could discourage a takeover attempt or delay changes in control;
•prohibiting cumulative voting in the election of directors;
•providing that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
•prohibiting the adoption, amendment or repeal of our amended and restated bylaws or the repeal of the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors without the required approval of at least 66.67% of the shares entitled to vote at an election of directors;
•prohibiting stockholder action by written consent;
•limiting the persons who may call special meetings of stockholders; and
•requiring advance notification of stockholder nominations and proposals.
These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, the provisions of Section 203 of the Delaware General Corporation Law (the "DGCL"), govern us. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time without the consent of our board of directors.
These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and under Delaware law could discourage potential takeover attempts, reduce the price investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions.
41
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, any action or proceeding asserting a claim as to which the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware or any action asserting a claim against us that is governed by the internal affairs doctrine, subject in each case to the Court of Chancery having personal jurisdiction over the parties named as defendants therein. The exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. The choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. If a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions.
In addition, our amended and restated certificate of incorporation provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.
The enforceability of similar federal court choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find our federal court choice of forum provision to be inapplicable or unenforceable. If a court were to find either of the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. Additionally, while the Delaware Supreme Court recently determined that choice of forum provisions for actions arising under the Securities Act are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against us, our directors, officers, or other employees in a venue other than in the federal district courts of the United States. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation, and this may require significant additional costs associated with resolving such action in other jurisdictions.
General risk factors
The market price of our common stock is likely to be volatile and could fluctuate or decline, resulting in a substantial loss of your investment.
The market price of our common stock could be subject to wide fluctuations in response to, among other things, the factors described in this “Risk Factors” section or otherwise, and other factors beyond our control, such as fluctuations in the valuations of companies perceived by investors to be comparable to us.
Furthermore, the stock markets have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, systemic, political and market conditions, such as recessions, interest rate changes or international currency fluctuations, may negatively affect the market price of our common stock.
Factors that could cause the market price of our common stock to fluctuate significantly include:
•actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in our quarterly and annual results;
•announcements of technological innovations by us or our competitors;
42
•overall conditions in our industry and the markets in which we operate;
•addition or loss of significant customers, or other developments with respect to significant customers;
•changes in laws or regulations applicable to our products;
•actual or anticipated changes in our growth rate relative to our competitors;
•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
•additions or departures of key personnel;
•operational impacts resulting from a reduction in force;
•competition from existing products or new products that may emerge;
•issuance of new or updated research or reports by securities analysts;
•fluctuations in the valuation of companies perceived by investors to be comparable to us;
•disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies;
•announcement or expectation of additional financing efforts;
•sales of our common stock by us or our stockholders;
•the addition or removal of our stock to or from a stock index fund;
•share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
•the expiration of contractual lock-up agreements with our executive officers, directors and stockholders, which we may enter into in the future from time to time;
•trade and national security disputes, particularly with China, including the effect of sanctions, tariffs and other trade restrictions that may affect supply chain or sales opportunities in the United States, China and Europe;
•general economic and market conditions, including economic downturns or uncertainty in financial markets; and
•other factors beyond our control, such as terrorism, war, natural disasters and pandemics.
In the past, many companies that have experienced volatility in the market price of their stock have become subject to securities class action litigation. We have been the target of securities class action litigation, including a class action that resulted in a proposed settlement, as described in Part I, Item 3, “Legal Proceedings.” We may be the target of similar litigation in the future, and there can be no assurance that our insurance coverage will be sufficient to cover future claims or that such coverage will continue to be available on acceptable terms. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could harm our business.
Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, causing the value of our common stock to decline substantially.
Numerous factors, many of which are outside our control, may cause or contribute to significant fluctuations in our quarterly and annual operating results. These fluctuations may make financial planning and forecasting difficult. In addition, these fluctuations may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the others. As a result, comparing our operating results on a period-to-period basis might not be meaningful. You should not rely on our past results as indicative of our future performance. Moreover, our stock price might be based on expectations of future performance that are unrealistic or that we might not meet and, if our revenue or operating results fall
43
below the expectations of investors or securities analysts, the price of our common stock could decline substantially.
Our operating results have varied in the past. As a result, our operating results could be unpredictable, particularly on a quarterly basis. Some of the important factors that may cause fluctuations in our quarterly and annual operating results are further described in other risk factors listed in this section.
In addition, a significant portion of our operating expense is relatively fixed in nature, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls will decrease our gross margins and could cause significant changes in our operating results from quarter to quarter. If this occurs, the trading price of our common stock could fall substantially.
If securities or industry analysts do not publish research or reports about our business or publish negative reports about our business, our share price and trading volume could decline.
The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business and we will not have any control over such analysts. If one or more of the analysts who cover us downgrade our shares or change their opinion of our shares, our share price would likely decline. If one or more of these analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.
Our actual operating results may differ significantly from our guidance.
From time to time, we may release guidance in our quarterly earnings conference calls, quarterly earnings releases, or otherwise, regarding our future performance that represents our management’s estimates as of the date of release. This guidance, which includes forward-looking statements, is based on projections prepared by our management. This guidance is not prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants regarding projections, and neither our independent registered public accounting firm nor any other independent expert or outside party compiles or examines the projections. Accordingly, no such person will express any opinion or any other form of assurance with respect to the projections.
Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. Our aim is to state possible outcomes as high and low ranges to provide a sensitivity analysis as variables are changed but are not intended to imply that actual results could not fall outside of the suggested ranges. The principal reason that we release guidance is to provide a basis for our management to discuss our business outlook with analysts and investors. We do not accept any responsibility for any projections or reports published by any such third parties.
Our guidance is only an estimate of what management believes is realizable as of the date of release, and some or all of the assumptions underlying the guidance furnished by us may not materialize or may change significantly. In light of the foregoing, investors are urged not to rely upon our guidance in making an investment decision regarding our common stock.
Any failure to successfully implement our operating strategy or the occurrence of any of the events or circumstances set forth in the “Risk Factors” section in this Form 10-K could result in the actual operating results being different from our guidance, and the differences may be adverse and material.
We have in the past and may in the future be subject to short selling strategies that may drive down the market price of our common stock.
Short sellers have in the past and may attempt in the future to drive down the market price of our common stock. Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. The short seller hopes to profit from a decline in the value of the securities between the time the securities are borrowed and the time they are replaced. As it is in the short seller’s best interests for the price of the stock to decline, many short sellers (sometimes known as “disclosed shorts”) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the
44
rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (“blogging”) have allowed many disclosed shorts to publicly attack a company’s credibility, strategy and veracity by means of so-called “research reports” that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the United States and they are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions, omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including shareholder suits against the company that may be prompted by such allegations. We have been and may in the future be the subject of shareholder suits that we believe were prompted by allegations made by short sellers.
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the stock price of our common stock to decline.
We have issued equity securities in the past, including in our August 2026 public offering, and may do so again in the future, including under our at-the-market program pursuant to which we may sell shares from time to time without advance notice. We have also issued and expect to issue common stock to employees and directors pursuant to our equity incentive plans. We may sell additional common stock, convertible securities or other equity securities in the future, and any such sales, or the perception that such sales may occur, could cause the market price of our common stock to decline. Investors in future transactions could gain rights, preferences and privileges senior to those of holders of our common stock.
Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
Our amended and restated certificate of incorporation provides that directors and officers of the company shall not be personally liable to the company or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.
In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:
•we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law, which provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the company and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;
•we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;
•we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;
•we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;
•the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and
•we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.
45
Increasing scrutiny and evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (“ESG”) matters, from investors, lenders, customers, government regulators and other market participants may impose additional costs and expose us to reputational and other risks.
Companies across all industries and around the globe are facing increasing scrutiny relating to their ESG policies, initiatives and activities by investors, lenders, customers, government regulators and other market participants. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are increasingly focused on ESG practices and corporate social responsibility endeavors and reporting and may use these factors to guide investment strategies. In some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. In contrast, “anti-ESG” sentiment has gained momentum across the United States, with several proposed or enacted “anti-ESG” policies, legislation, or initiatives, and the U.S. federal administration having recently issued an executive order opposing diversity, equity and inclusion initiatives in the private sector. Any initiatives, goals, or commitments we disclose related to ESG matters in light of evolving, and sometimes, conflicting, laws, regulations, policies and investor and other stakeholder expectations involve risks and uncertainties and could be difficult to achieve and costly to implement. Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or which are perceived to have not responded appropriately, may suffer from reputational damage and result in the business, financial condition and/or stock price of a company being materially and adversely affected.
Further, this increased focus on ESG issues may result in new regulations and/or third-party requirements that could adversely impact our business. For example, regulatory authorities have begun to impose mandatory disclosure requirements with respect to ESG matters, such as regulations proposed or adopted by federal agencies related to climate-related disclosures, claims, practices or initiatives, the EU’s Corporate Sustainability Reporting Directive, and California’s Climate-Related Financial Risk Act and the Climate Corporate Data Accountability Act. If we fail to implement sufficient oversight or accurately capture and disclose on environmental matters, our reputation, business, operating results and financial condition may be materially adversely affected. In addition, enhancements to our processes and controls to reflect evolving reporting standards may be costly and require additional resources, and any allegation or perception that we have not taken sufficient action in these areas could harm our reputation.
Item 1B.Unresolved Staff Comments
None.
Item 1C. Cybersecurity
Cybersecurity Risk Management and Strategy
Processes Used to Assess, Identify, and Manage Material Risks from Cybersecurity Threats
Risk Assessment and Management
We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, hardware and software, and our critical data, including, among other things, intellectual property, trade secrets, confidential information that is proprietary, strategic or competitive in nature, and personal data.
Our Chief Information Officer (“CIO”) together with other members of the Information and Business Technology (“IBT”) Security team, are responsible for establishing and implementing cybersecurity policies and procedures, which includes developing and updating our Security Incident Response Policy (“IRP”), managing incident response, and overseeing any policy exceptions and potential compensating controls.
Our cybersecurity program and risk management strategy leverage principles from the ISO 27001 security controls and the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF 2.0). We maintain an ISO 27001:2022 certification and we undergo routine audits by an independent, certified accreditation body to maintain this certification. Our cybersecurity program includes policies, procedures, technologies and controls, as well as cybersecurity training for employees. We also engage third party advisors, including assessors, cybersecurity consultants, and auditors to assess, validate, and enhance our cybersecurity program, such as through penetration testing conducted by a third-party red team throughout the year. We also
46
Incident Response and Escalation
Our IBT Security team is responsible for developing and updating our IRP, which addresses detection, analysis of impact, containment, mitigation, remediation and recovery. This team collaborates closely with other teams within the Company, including IT, Legal, Finance and Corporate Communications, in identifying, analyzing, and responding to cybersecurity incidents. We also conduct tabletop exercises to practice and test our readiness.
Material Risks from Cybersecurity Threats
We maintain cyber insurance with coverage amounts and terms that we believe are appropriate for a company of our size and in our industry. This insurance may not be sufficient to cover us against all types of claims or losses relating to security breaches, cyberattacks or related events.
Cybersecurity Governance
Board Oversight of Risks from Cybersecurity Threats
Management’s Role in Assessing and Managing Material Risks from Cybersecurity Threats
47
Item 2.Properties
Our principal facilities are described below:
| Principal Facilities | Approximate Square Footage | Lease Expiration | Principal Use | Owned or Leased | ||||||||||||||||||||||
| Wilsonville, OR | 211,995 | 2044 | General & Administration and Manufacturing | Leased | ||||||||||||||||||||||
South San Francisco, CA [1] | 91,799 | 2037 | General & Administration, R&D and Manufacturing | Leased | ||||||||||||||||||||||
Brisbane, CA[2] | 24,786 | 2031 | Warehouse facility | Leased | ||||||||||||||||||||||
| Quincy, MA | 38,853 | 2032 | General & Administration, R&D and Antibody Services | Leased | ||||||||||||||||||||||
| Guangzhou, China | 9,956 | 2028 | General & Administration, Sales & Marketing and Supply Chain activities | Leased | ||||||||||||||||||||||
Carlsbad, CA[3] | 8,772 | 2026 | Sales & Marketing | Leased | ||||||||||||||||||||||
| Singapore | 1,353 | 2028 | Sales & Marketing | Leased | ||||||||||||||||||||||
[1] In November 2025 and September 2026, we amended the lease for our South San Francisco headquarters to add approximately 66,000 square feet on the third and fourth floors of the building (approximately 33,000 square feet each) and to extend the lease term for the entire premises to June 2037. The lease term for the additional space is expected to commence on January 1, 2027. This square footage is not included in the table above, as we did not occupy the space as of September 30, 2026. See Note 9, Leases, to our consolidated financial statements.
[2] In October 2026, we extended the lease for our Brisbane warehouse facility through October 2031.
[3] Our current Carlsbad lease is on a month-to-month basis. We have entered into a lease for new Carlsbad premises expected to commence in April 2027 and expire in 60 months.
The Company believes its existing facilities are in good operating condition and are suitable for the conduct of its business.
Item 3.Legal Proceedings
For a description of material pending legal proceedings, see Note 10. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Form 10-K, which is incorporated herein by reference. In addition, we are subject to various legal proceedings and claims arising in the ordinary course of business. Although occasional adverse decisions or settlements may occur, management believes that the final disposition of such matters will not have a material adverse effect on our business, financial position, results of operations or cash flows.
Item 4.Mine Safety Disclosures
Not applicable.
PART II
48
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information for Common Stock
Our common stock is traded on The Nasdaq Global Select Market under the symbol “TWST”.
Performance Graph
This graph is not “soliciting material” or subject to Regulation 14A, deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
The following graph compares the cumulative total shareholder return on our common stock to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on September 30, 2021 and its performance is presented as of the end of each our fiscal years through September 30, 2026. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends; however, no dividends have been declared on our common stock to date. The returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future returns.

| * | $100.00 invested on September 30, 2021 in stock or index, including reinvestment of dividends. | ||||
| September 30 | ||||||||||||||||||||||||||||||||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |||||||||||||||||||||||||||||||||
| Twist Bioscience Corporation | $ | 100.00 | $ | 32.94 | $ | 18.94 | $ | 42.24 | $ | 26.31 | $ | 180.65 | ||||||||||||||||||||||||||
| Nasdaq Composite Index | $ | 100.00 | $ | 73.75 | $ | 93.00 | $ | 128.94 | $ | 161.71 | $ | 192.83 | ||||||||||||||||||||||||||
| Nasdaq Biotechnology Index | $ | 100.00 | $ | 74.74 | $ | 79.07 | $ | 96.14 | $ | 99.20 | $ | 145.45 | ||||||||||||||||||||||||||
49
Holders of Record
As of November 11, 2026, there were approximately 27 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.
Dividend Policy
We have never declared or paid, and do not anticipate declaring or paying in the foreseeable future, any cash dividends on our capital stock. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors may deem relevant.
Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
None.
Item 6.[Reserved]
50
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to promote understanding of the results of operations and financial condition. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” and elsewhere in this Form 10-K. The last day of our fiscal year is September 30, and we refer to our fiscal year ended September 30, 2024 as fiscal year 2024 or 2024, September 30, 2025 as fiscal year 2025 or 2025 and our fiscal year ended September 30, 2026 as fiscal year 2026 or 2026.
Additional information related to the comparison of our results of operations and liquidity and capital resources between the fiscal years 2025 and 2024 is included in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the fiscal year ended September 30, 2025 filed with the U.S. Securities and Exchange Commission on November 17, 2025.
Overview
We provide customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. Our proprietary silicon-based platform delivers precision, scale and speed, supporting consistent, high-quality performance across a broad range of applications.
At the core of our platform is a differentiated method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including our e-commerce platform, we achieve high levels of precision, automation, and throughput at a lower cost relative to legacy methods.
We have extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, pooled DNA, next-generation sequencing, or NGS, applications, sample preparation tools, antibody libraries, and biologics discovery services. These solutions are designed to improve research efficiency, accelerate development timelines, and deliver reproducible, high-quality data. Leveraging the same platform, we also manufacture synthetic RNA, express antibody proteins, perform characterization assays and deliver data to customers and partners.
Our solutions support a wide range of applications, including traditional and AI-enabled therapeutics discovery, diagnostic development, industry and applied research, agricultural biotechnology, and academic research. By increasing efficiency and scalability in research and development, we support efforts to improve human health and sustainability.
We serve approximately 4,100 customers annually across therapeutics, diagnostics, industry and applied markets, academic research and government, and global supply partners industries. Our multi-channel commercial strategy includes direct sales teams aligned to key markets and an e-commerce platform that enables customers to design, validate, and order customized products on demand, with real-time pricing and order tracking.
We generate revenue primarily from DNA Synthesis and Protein Solutions and NGS Applications. As we have expanded from DNA fragments to genes, sample preparation, protein expression, and biologics discovery, the integration of our offerings has strengthened. Beginning in fiscal 2026, we combined synthetic biology tools and biopharma services into a single category, DNA Synthesis and Protein Solutions, and renamed NGS tools to NGS Applications to reflect their role in sequencing workflows.
In February 2026, we entered into a co-exclusive license agreement with Invenra Inc. for its proprietary B-Body bispecific antibody discovery platform and simultaneously acquired a 6.24% ownership interest on a fully-diluted basis in Invenra through the purchase of Series B Preferred Stock. Together, these transactions represent a total commitment of $33.8 million, settled through a combination of cash and common stock.
51
In August 2026, we completed an underwritten public offering of 3,593,750 shares of our common stock for net proceeds of $327.7 million, after deducting underwriting discounts, commissions, and offering expenses of $17.3 million at a public offering price of $96.00 per share.
Through September 30, 2026, 748,909 shares had been sold under an at-the-market equity offering program (the "ATM Program") for net proceeds of $97.1 million after deducting discounts, commissions and offering expenses and $100.0 million capacity remained available.
We generated revenue of $459.4 million, $376.6 million, and $313.0 million in the years ended September 30, 2026, September 30, 2025, and September 30, 2024, respectively, while incurring net losses of $130.2 million, $77.7 million and $208.7 million in the years ended September 30, 2026, 2025 and 2024, respectively. Since our inception, we have incurred significant operating losses and have an accumulated deficit of $1,449.8 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the success of our existing products and the development and commercialization of additional products in the therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners industries as well as leveraging our investment in our manufacturing infrastructure.
The following trends affected our results in fiscal 2026, or we expect will affect our results in future periods, and should be read together with Part I, Item 1A, "Risk Factors."
Demand from customers engaged in AI-enabled drug discovery grew substantially in fiscal 2026 and was a meaningful contributor to growth in DNA Synthesis and Protein Solutions. We expect it to grow further in fiscal 2027. That demand is directed at an emerging use case, and carries a higher proportion of services than our mature products. In NGS Applications, our largest customers are increasingly commercial diagnostics companies whose purchases scale with market demand, including MRD workflows, which concentrates our NGS Applications revenue and makes it more sensitive to reimbursement, regulatory and commercial developments affecting those customers that we do not control. A portion of our revenue comes from academic and government customers whose purchasing depends on research appropriations and grant timing; order patterns in this group have been variable and we expect them to remain so, and our expansion in this market through offerings priced to allow researchers to do more within existing budgets has increased unit volumes at lower average prices.
A significant portion of our cost of revenue does not vary with volume, so revenue growth is the principal driver of gross margin. That relationship has been, and may continue to be, offset in individual periods by revenue mix, by new product introductions, and by capacity and automation investments made ahead of anticipated demand. We expect to continue to invest in our higher-growth areas while managing overall operating expense growth, and we periodically realign resources across functions to support those priorities.
Selected financial information
Financial highlights from fiscal year 2026 compared with fiscal year 2025 include:
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | 2025 | Change | % | ||||||||||||||||||||||
| Revenue | $459,433 | $376,572 | $ | 82,861 | 22% | |||||||||||||||||||||
Gross margin [1] | 52.4 | % | 50.7 | % | 1.7 pts | |||||||||||||||||||||
| Loss from operations | $(139,455) | $(136,259) | $(3,196) | (2)% | ||||||||||||||||||||||
| Net cash used in operating activities | $(41,431) | $(47,628) | $6,197 | 13% | ||||||||||||||||||||||
[1] Change in gross margin is presented in percentage points.
•Revenue growth of 22% to $459.4 million from $376.6 million, driven by strong performance in DNA Synthesis and Protein Solutions and NGS Applications;
•Gross margin increased to 52.4% from 50.7%, primarily due to leverage on fixed manufacturing costs as revenue grew;
•Loss from operations increased to $139.5 million from $136.3 million as a $54.2 million increase in selling, general and administrative investment and $7.2 million of litigation settlement costs, net of
52
recoveries, offset a $49.8 million increase in gross profit and an $8.4 million decrease in research and development expenses;
•Net cash used in operating activities for the year ended September 30, 2026 decreased to $41.4 million from $47.6 million for the year ended September 30, 2025.
See “Results of Operations” below for discussion of our results for the periods presented.
Key Business Metrics
We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business and make strategic decisions. These are operating metrics, not financial measures, and they may change or be replaced by other metrics as our business grows.
| Metrics | Year ended September 30, | |||||||||||||||||||||||||
| (in thousands, except number of customers and percentages) | 2026 | 2025 | Change | % | ||||||||||||||||||||||
| Genes shipped | 1,341 | 938 | 403 | 43% | ||||||||||||||||||||||
| Number of customers | 4,100 | 3,800 | 300 | 8% | ||||||||||||||||||||||
Genes shipped. We believe genes shipped is an indicator of demand for our DNA synthesis products and of our manufacturing throughput. We define genes shipped as the number of synthetic genes, including clonal genes and gene fragments, shipped to customers during the period. Because our genes vary in length, complexity and price, genes shipped does not change in proportion to revenue.
Number of customers. We believe the number of customers is an indicator of our ability to drive adoption of our products. We define a customer as a unique “Bill To” account that purchased products or services from us during the fiscal year; a single customer may have many “Ship To” locations and points of contact. Because customers vary significantly in size, changes in the number of customers do not necessarily result in proportional changes in revenue.
Components of the Results of Operations
Revenue
We generate revenue primarily from DNA Synthesis and Protein Solutions and NGS Applications. Our ability to increase our revenue will depend on our ability to further penetrate the domestic and international markets, generate sales through our direct sales force, distributors, and over time, from our e-commerce digital platform and the launch of new products.
Cost of Revenue
Cost of revenue reflects the aggregate cost incurred in the production and delivery of our products and consists of production materials, personnel costs, cost of expensed equipment and consumables, laboratory supplies, consulting costs, depreciation, production overhead costs, information technology (“IT”), maintenance and facility costs. Personnel costs consist of salaries, employee benefit costs, bonuses, and stock-based compensation expense. In addition, cost of revenue includes royalty costs for licensed technologies included in the Company’s products and provisions for slow-moving and obsolete inventories. We expect that our cost of revenue will vary with changes in our revenue and our revenue mix.
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for the development of our products, which include personnel costs, laboratory equipment and supplies, consulting costs, depreciation, rent, IT, maintenance and facility costs. Personnel costs consist of salaries, employee benefit costs, bonuses, and stock-based compensation expense. We expense our research and development expenses in the period in which they are incurred.
Selling, General and Administrative Expenses
53
Selling expenses consist of personnel costs, customer service expenses, direct marketing expenses, educational and promotional expense, market research and analysis. General and administrative expenses are incurred for executive, finance and accounting, legal and human resources functions and consist of personnel costs, audit and legal expenses, consulting costs, depreciation, insurance costs, travel expenses, rent, IT, maintenance and facility costs. Personnel costs consist of salaries, employee benefit costs, bonuses, commissions and stock-based compensation expense. We expense all selling, general and administrative expenses as incurred. We expect our selling costs will continue to increase in absolute dollars, primarily driven by our efforts to expand our commercial capability, with an increased presence both within and outside the United States, and to expand our brand awareness and customer base through targeted marketing initiatives.
Interest and Other Income (Expense), Net
Other income (expense), net, consists of realized foreign exchange gains and losses, loss on disposal of property and equipment, impairment of equity investments, and sub-lease income.
Results of Operations
Comparison of the Years Ended September 30, 2026 and 2025
Revenue
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | 2025 | Change | % | ||||||||||||||||||||||
| Revenue | $ | 459,433 | $ | 376,572 | $ | 82,861 | 22% | |||||||||||||||||||
Revenue by Geography
We have one reportable segment from the manufacturing of DNA Synthesis and Protein Solutions and NGS Applications products. The following table shows our revenue by geography, based on our customers’ shipping addresses. Americas consists of United States, Canada, Mexico and South America; EMEA consists of Europe, Middle East and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia, New Zealand, Thailand and Taiwan.
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | % | 2025 | % | ||||||||||||||||||||||
| Americas | $ | 278,763 | 60.7% | $ | 225,580 | 59.9% | ||||||||||||||||||||
| EMEA | 147,992 | 32.2% | 124,240 | 33.0% | ||||||||||||||||||||||
| APAC | 32,678 | 7.1% | 26,752 | 7.1% | ||||||||||||||||||||||
| Total revenue | $ | 459,433 | 100% | $ | 376,572 | 100% | ||||||||||||||||||||
Revenue by Products
We historically reported our revenue by the following products: synthetic genes, oligo pools and DNA libraries (collectively, synthetic biology), antibody discovery, and NGS tools. Beginning in fiscal 2026, we combined revenue from synthetic genes, oligo pools, DNA libraries, and biopharma services for antibody discovery into DNA Synthesis and Protein Solutions. We also changed the name of NGS tools to NGS Applications, as these products and services facilitate DNA reading and sequencing workflows. The table below summarizes revenue by the new products:
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | % | 2025 | % | ||||||||||||||||||||||
| DNA Synthesis and Protein Solutions | $ | 221,892 | 48.3% | $ | 168,468 | 44.7% | ||||||||||||||||||||
| NGS Applications | 237,541 | 51.7% | 208,104 | 55.3% | ||||||||||||||||||||||
| Total revenue | $ | 459,433 | 100% | $ | 376,572 | 100% | ||||||||||||||||||||
Revenue by Industry
54
We historically reported revenue by industrial chemicals/materials, academic research, healthcare, and food/agriculture. Beginning in fiscal 2026, we disclose revenue by therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners. These updated categories better align with our operations and increase clarity around our key customer groups. The table below summarizes revenue by industry:
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | % | 2025 | % | ||||||||||||||||||||||
| Therapeutics | $ | 162,297 | 35.3% | $ | 110,544 | 29.4% | ||||||||||||||||||||
| Diagnostics | 164,311 | 35.8% | 145,411 | 38.6% | ||||||||||||||||||||||
| Industry and applied | 24,219 | 5.3% | 24,508 | 6.5% | ||||||||||||||||||||||
| Academic research and government | 56,598 | 12.3% | 49,893 | 13.2% | ||||||||||||||||||||||
| Global supply partners | $ | 52,008 | 11.3% | $ | 46,216 | 12.3% | ||||||||||||||||||||
| Total revenue | $ | 459,433 | 100% | $ | 376,572 | 100% | ||||||||||||||||||||
Revenue by Timing of Transfer
The table below summarizes revenue by timing of transfer:
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | % | 2025 | % | ||||||||||||||||||||||
| Revenue recognized over time | $ | 58,670 | 12.8% | $ | 26,537 | 7.0% | ||||||||||||||||||||
| Revenue recognized at a point in time | 400,763 | 87.2% | 350,035 | 93.0% | ||||||||||||||||||||||
| Total revenue | $ | 459,433 | 100% | $ | 376,572 | 100% | ||||||||||||||||||||
Revenue increased 22% to $459.4 million for the year ended September 30, 2026, as compared to $376.6 million for the year ended September 30, 2025. The increase in revenue primarily reflects growth in both NGS Applications revenue of $29.4 million and in DNA Synthesis and Protein Solutions revenue of $53.4 million. These improvements in revenue from NGS Applications and DNA Synthesis and Protein Solutions are largely due to higher sales to our customers in the therapeutics, diagnostics, academic research and government and global supply partners, as well as an increase in the number of customers. The number of our genes shipped for the year ended September 30, 2026 increased to approximately 1,341,000 genes, compared to approximately 938,000 genes for the year ended September 30, 2025, an increase of 43%.
Costs and Expenses
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | 2025 | Change | % | ||||||||||||||||||||||
| Cost of revenue | $ | 218,632 | $ | 185,570 | $ | 33,062 | 18 | % | ||||||||||||||||||
| Gross profit | $ | 240,801 | $ | 191,002 | $ | 49,799 | 26 | % | ||||||||||||||||||
Gross margin[1] | 52.4 | % | 50.7 | % | 1.7 pts | |||||||||||||||||||||
| Research and development | $ | 71,836 | $ | 80,285 | $ | (8,449) | (11) | % | ||||||||||||||||||
| % of Revenue | 15.6 | % | 21.3 | % | ||||||||||||||||||||||
| Selling, general and administrative | $ | 301,215 | $ | 246,976 | $ | 54,239 | 22 | % | ||||||||||||||||||
| % of Revenue | 65.6 | % | 65.6 | % | ||||||||||||||||||||||
| Litigation settlement costs, net of recoveries | $ | 7,205 | $ | — | $ | 7,205 | NA | |||||||||||||||||||
[1] Change in gross margin is presented in percentage points.
Cost of Revenue
Cost of revenue increased 18% to $218.6 million for the year ended September 30, 2026, as compared to $185.6 million for the year ended September 30, 2025. The increase is primarily attributable to an increase in
55
material costs of $26.3 million, due to higher sales volume and an increase in personnel costs of $4.2 million and an increase in depreciation and amortization of $1.6 million. Gross margin increased 1.7 percentage points to 52.4% for the year ended September 30, 2026, as compared to 50.7% for the year ended September 30, 2025, primarily due to leverage on fixed manufacturing costs as revenue grew.
Research and Development Expenses
Research and development expenses decreased 11% to $71.8 million for the year ended September 30, 2026, as compared to $80.3 million for the year ended September 30, 2025. This decrease is primarily driven by the sale of our DNA data storage business to Atlas in fiscal year 2025, which contributed to a reduction in outside services costs of $6.1 million, facilities costs of $1.3 million and stock-based compensation expense of $1.3 million.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased 22% to $301.2 million for the year ended September 30, 2026, as compared to $247.0 million for the year ended September 30, 2025. The increase is primarily due to increases in personnel costs of $28.5 million, driven mainly by additions to our commercial team and, to a lesser extent, growth in our general and administrative functions. Other increases were driven by an increase in outside services costs of $8.5 million, including marketing programs and professional services, stock-based compensation expense of $7.9 million, and IT services costs of $6.7 million.
Litigation settlement costs, net of recoveries
We recorded litigation settlement costs, net of recoveries, of $7.2 million for the year ended September 30, 2026, primarily reflecting the settlement of the securities class action and derivative action, net of expected insurance recoveries. See Note 10, Commitments and Contingencies, of the notes to the consolidated financial statements included elsewhere in this Form 10-K.
Nonoperating Expenses/Income and Income Taxes
| Year ended September 30, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2026 | 2025 | Change | % | ||||||||||||||||||||||
| Gain on sale of business | $ | — | $ | 48,847 | $ | (48,847) | (100)% | |||||||||||||||||||
| Interest income | $ | 8,803 | $ | 11,364 | $ | (2,561) | (23) | % | ||||||||||||||||||
| Other income (expense), net | $ | 856 | $ | (903) | $ | 1,759 | NM[1] | |||||||||||||||||||
| Income tax expense | $ | (406) | $ | (719) | $ | 313 | (44) | % | ||||||||||||||||||
[1] NM — Not meaningful
Gain on Sale of Business
We recognized a gain on the sale of business of $48.8 million related to the sale of our DNA data storage business to Atlas during the year ended September 30, 2025.
Interest Income
Interest income decreased 23%, to $8.8 million in the year ended September 30, 2026, as compared to $11.4 million for the year ended September 30, 2025, due to lower average cash equivalents and short-term investment balances for most of the year, prior to our August 2026 public offering, and lower interest rates.
Other income (expense), net
Other income (expense), net was $0.9 million in fiscal year 2026, as compared to $(0.9) million in fiscal year 2025, mainly due to higher sublease income of $1.2 million and the impairment losses of $1.1 million on an equity investment recognized in fiscal year 2025, partially offset by foreign exchange losses.
Income Tax Expense
For the years ended September 30, 2026 and 2025, we recognized income tax provisions of $0.4 million and $0.7 million, respectively, mainly attributable to our foreign operations.
56
Financial Condition, Liquidity and Capital Resources
Selected financial data was as follows:
| (In thousands) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Cash and cash equivalents | $ | 533,992 | $ | 183,049 | ||||||||||
| Short-term investments | 47,915 | 49,385 | ||||||||||||
| Total assets | 1,121,808 | 641,861 | ||||||||||||
| Accumulated deficit | (1,449,780) | (1,319,578) | ||||||||||||
| Total stockholders’ equity | 888,016 | 472,958 | ||||||||||||
Cash and Cash Equivalents and Short-Term Investments
As of September 30, 2026, we had a balance of $534.0 million of cash and cash equivalents and $47.9 million in short-term investments. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. As of September 30, 2026, $6.6 million of our cash and cash equivalents was held by our foreign subsidiaries.
Sources of Liquidity and Funding Requirements
Since our inception, we have financed our operations and capital expenditures principally through public offerings of our common stock, private placements of our convertible preferred stock, borrowings under credit facilities, the sale of future revenue under our royalty purchase agreement, the sale of our DNA data storage business and revenue from our commercial operations.
Our primary short-term cash needs are for operating expenses, working capital and capital expenditures to support the growth of our business. We believe that our existing cash, cash equivalents and short-term investments as of September 30, 2026 will be sufficient to fund our operating expenses, capital expenditure requirements and the material cash requirements described below for at least the next 12 months from the date of this Form 10-K. This assessment is based on our current operating plan, which contemplates continued investment in manufacturing capacity and new product development, and does not assume any proceeds from sales under our at-the-market program or from any other financing that has not been completed. Beyond the next 12 months, our capital requirements will depend on many factors, including our revenue growth rate, research and development efforts, the timing and extent of capital expenditures to invest in existing and new facilities, the expansion of sales and marketing and international activities, legal costs associated with defending and enforcing intellectual property rights, and any investments in or acquisitions of complementary businesses, technologies or intellectual property rights, which could significantly increase our capital needs. We take a long-term view in growing and scaling our business, and we regularly review opportunities to acquire or invest in businesses, services and technologies, including intellectual property rights, that meet our long-term growth objectives. Any such acquisitions or investments could significantly increase our capital needs.
We may need to obtain additional financing in the future, and there can be no assurance that we will be able to raise additional financing on terms acceptable to us, or at all. Our operating plans may change as a result of factors currently unknown to us, and we may seek additional funds sooner than planned, including to take advantage of favorable market conditions or for strategic considerations. Any such financing may result in dilution to our stockholders, the imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. See Part I, Item 1A, “Risk Factors—We have raised additional equity capital and may do so again, and our stockholders have experienced and may continue to experience dilution.”
Financial Arrangements
On June 18, 2026 we filed an automatic shelf registration statement on Form S-3ASR registering an indeterminate amount of common stock, preferred stock, debt securities, warrants and units, and concurrently entered into a sales agreement with TD Securities (USA) LLC providing for the offer and sale of up to $200.0
57
million of common stock in "at-the-market" transactions, with a commission of up to 3% of gross proceeds. As of September 30, 2026 we had sold 748,909 shares for net proceeds of $97.1 million under that agreement, leaving $100.0 million available.
On August 6, 2026 we completed an underwritten public offering of 3,593,750 shares of common stock (including 468,750 shares issued on exercise in full of the underwriters' option to purchase additional shares) at a public offering price of $96.00 per share, resulting in net proceeds of $327.7 million after underwriting discounts and commissions and estimated offering expenses. We intend to use the net proceeds, together with our existing cash, to fund research and development, to expand our manufacturing capacity and product offerings, and for working capital and other general corporate purposes.
On October 21, 2024, we executed the Royalty Purchase Agreement with XOMA (US) LLC ("XOMA Royalty"). Under the Royalty Purchase Agreement, XOMA Royalty provided us an upfront payment of $15.0 million in cash in exchange for the right to receive half of the future potential milestone and royalty payments resulting from certain antibody discovery and biopharma services agreements between us and our customers.
On May 2, 2025, we executed the Contribution Agreement with Atlas for the sale and transfer of its DNA data storage assets including the related intellectual property, equipment and contracts and the license of certain other intellectual property for a consideration of 73.0 million shares of Series Seed-1 Preferred Shares of Atlas, upfront cash consideration of $2.5 million, promissory notes of $2.0 million issued by Atlas, contingent manufacturing and commercial milestone payments of up to $75.0 million, and royalty payments based on a percentage of Atlas sales of the DNA data storage products (see note 6. Investment in Equity Securities of the consolidated financial statements included elsewhere in this Form 10-K).
Cash Flows
The following table summarizes our sources and uses of cash and cash equivalents:
| Year ended | ||||||||||||||
| September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
| Net cash used in operating activities | $ | (41,431) | $ | (47,628) | ||||||||||
| Net cash provided by (used in) investing activities | (53,088) | (24,762) | ||||||||||||
| Net cash provided by financing activities | 446,678 | 28,540 | ||||||||||||
Operating Activities
Net cash used in operating activities was $41.4 million in fiscal 2026, compared with $47.6 million in fiscal 2025. Cash used in fiscal 2026 consisted of a net loss of $130.2 million, adjusted for non-cash items of $96.6 million, primarily stock-based compensation expense of $69.9 million and depreciation and amortization of $26.5 million, and a net cash outflow from changes in operating assets and liabilities of $7.8 million. The net cash outflow from changes in operating assets and liabilities was primarily due to increases in prepaid expenses and other current assets of $21.8 million, primarily driven by the insurance receivable for litigation settlement costs and higher contract assets; inventories of $18.1 million to support anticipated demand; and accounts receivable of $13.8 million due to the increase in revenue and the timing of collections. These were partially offset by increases in accrued expenses and other liabilities of $26.3 million, primarily related to litigation accruals, indirect taxes payable and the timing of payments to vendors, and in accounts payable of $13.9 million and accrued compensation of $7.1 million due to the timing of payments to vendors and employees.
Net cash used in operating activities was $47.6 million in fiscal year 2025, which resulted from a net loss of $77.7 million and changes in our operating assets and liabilities of $12.6 million, partially offset by non-cash adjustments of $42.6 million. Non-cash adjustments primarily consisted of stock-based compensation expense of $64.5 million, depreciation and amortization expenses of $24.9 million, and gain on sale of business of $48.8 million. The change in operating assets and liabilities was mainly due to increases in accounts receivable of $22.4 million, inventories of $4.2 million, prepaid and other current assets of $3.7 million, and other non-current assets of $1.6 million, offset by net increase in accounts payable, accrued compensation and accrued expenses and other liabilities $19.3 million.
Investing Activities
58
In fiscal year 2026, our net cash used in the investing activities was $53.1 million primarily due to purchases of property and equipment of $47.6 million and purchases of intellectual property of $7.0 million consisting of the $5.0 million cash payment for the Invenra license and $2.0 million for other intellectual property licenses, partially offset by net maturities of investments of $1.4 million.
In fiscal year 2025, our net cash used in the investing activities was $24.8 million primarily as a result of purchases of property and equipment of $28.0 million, offset by the proceeds from the sale of our data storage business of $2.5 million, and the net result of purchases and maturity of investments of $0.7 million.
Consideration for the Atlas sale also included Series Seed-1 Preferred Shares of Atlas, $2.0 million of promissory notes, contingent manufacturing and commercial milestone payments of up to $75.0 million, and royalties on Atlas sales of DNA data storage products. Given the uncertainty of their timing and receipt, we have not included the contingent milestone or royalty payments in our assessment of liquidity. See Note 6. Investment in Equity Securities of the notes to the consolidated financial statements included elsewhere in this Form 10-K.
Financing Activities
Net cash provided by financing activities was $446.7 million in fiscal year 2026, primarily consisting of net proceeds of $424.8 million from our August 2026 underwritten public offering and sales under our at-the-market program, $17.6 million from the exercise of stock options, and $4.3 million from proceeds from issuance of shares under our employee stock purchase plan.
Net cash provided by financing activities was $28.5 million in fiscal year 2025, which consisted of $15.0 million from XOMA for the sale of future revenue, $9.3 million from the exercise of stock options, and $4.2 million from proceeds from issuance of shares under our employee stock purchase plan.
Material Cash Requirements
In addition to our ongoing operating expenses, which consist primarily of compensation and related expenses, manufacturing costs, laboratory and related supplies, legal and other regulatory expenses and general overhead, our material cash requirements from known contractual and other obligations as of September 30, 2026 consist primarily of the following:
Operating leases
As of September 30, 2026, we had operating lease obligations of $149.9 million on an undiscounted basis, of which $8.5 million is payable within the next 12 months, related to various operating lease arrangements for facilities. In November 2025 and September 2026, we amended the lease for our South San Francisco, California headquarters to add approximately 66,000 square feet on the third and fourth floors of the building and extend the lease term for the entire premises to June 30, 2037. Base rent on our existing premises is abated through October 31, 2027. The third- and fourth-floor space is expected to commence on January 1, 2027 and is not included in the obligations above. Base rent for that space is expected to total approximately $42.7 million through June 30, 2037, with payments beginning in fiscal 2028 after rent abatement periods. The landlord will provide tenant improvement and other allowances under the lease of $34.8 million. See Note 9, Leases, of the notes to the consolidated financial statements included elsewhere in this Form 10-K.
In September 2026, we entered into a lease for new office space in Carlsbad, California, which is expected to commence in April 2027; undiscounted base rent totals approximately $2.2 million over the 5-year term.
Capital expenditures
As of September 30, 2026, we had $18.4 million in commitments for capital expenditures substantially all of which we expect to pay within the next 12 months. Over the next fiscal two years, we expect to invest approximately $150 million in capital expenditures and to receive $34.8 million of landlord-funded tenant improvement allowances, to enable us to bring manufacturing capacity at our existing facilities to support more than $1.0 billion of annual revenue.
59
Invenra License and Investment Agreements
In February 2026, we entered into a co-exclusive license agreement with Invenra for its proprietary B-Body bispecific antibody discovery platform and simultaneously acquired a 6.24% ownership interest in Invenra on a fully-diluted basis through the purchase of Series B Preferred Stock, for a total consideration of $33.8 million. The license was acquired for total consideration of $20.0 million, of which $5.0 million was paid in cash at closing, $10.0 million settled through the issuance of common stock at closing, and $5.0 million in common stock was issued upon the successful completion of technology transfer on August 19, 2026. The equity investment was acquired for $13.8 million, settled entirely through the issuance of common stock, comprising $10.0 million issued at initial closing and $3.8 million issued in a subsequent closing on April 7, 2026. We are also required to pay royalties to Invenra based on gross revenue we receive from licenses to third-parties. See note 8, Goodwill and Intangible Assets of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Form 10-K.
Royalty purchase agreement
Our obligations under the royalty purchase agreement with XOMA Royalty are limited to remitting a share of the milestone and royalty payments we receive, as described under “Financial Arrangements” above, and do not require the use of our existing cash.
We expect to fund these requirements with our existing cash, cash equivalents and short-term investments.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations are based upon our audited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the reasonableness of its estimates. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily available from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.
We believe the following critical accounting policies require that we make significant judgments and estimates in preparing our consolidated financial statements.
Revenue Recognition — Over Time Arrangements
Revenue under which we perform antibody discovery, optimization, and characterization offerings for customers, is recognized over time and is the area of revenue recognition that requires estimates. Because our performance creates materials and data that have no alternative use to us and we have an enforceable right to payment for performance completed to date, we recognize revenue using an input method based on costs incurred relative to total estimated costs. We recognized $58.7 million of revenue over time in fiscal 2026, or 13% of total revenue.
The transaction price generally consists of fixed fees for the activities in the research plan, and each research plan is generally a single performance obligation. Where consideration is variable, such as prorated fee reductions for deliverables that do not meet specified acceptance criteria or research milestone payments that depend on specified research outcomes, we estimate it using the most likely amount and include it only to the extent a significant reversal of cumulative revenue is not probable.
The estimate is total estimated costs, which we reassess each reporting date. It requires judgment about the labor, materials and time needed to complete each arrangement. The estimate is subject to more uncertainty early in an arrangement and for new or complex programs, although most arrangements are completed within three months. We recognize changes in estimates, including the likelihood of meeting acceptance criteria or success-based milestones, as cumulative catch-up adjustments. There have not been any material adjustments recorded relating to this estimate.
Stock-Based Compensation — Performance-Based Awards
60
We grant performance-based restricted stock units ("PRSUs") to employees. We measure PRSUs at a grant date fair value equal to the closing price of our common stock on the date of grant and recognize expense over the requisite service period based on the number of units we assess as probable of vesting.
The critical estimate is our assessment of whether the performance conditions are probable of achievement, which we reassess at each reporting date. Those conditions relate to multiple year revenue, gross margin, and profitability metrics, and their achievement depends on our future operating performance. Because we account for forfeitures as they occur rather than estimating them, this probability assessment is the only significant estimate in measuring the expense.
A change in that assessment is recognized as a cumulative adjustment in the period of the change. If an award previously assessed as probable becomes not probable, we reverse the expense recognized to date; if an award previously assessed as not probable becomes probable, we recognize in that period the expense attributable to service already rendered.
Assessment of Long-Lived Asset Impairment
Our long-lived assets consist principally of property and equipment, operating lease right-of-use assets and finite-lived intangible assets. We review these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. We group long-lived assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets.
When an indicator is identified, we compare the carrying amount of the asset group with the undiscounted cash flows expected from its use and eventual disposition over the remaining useful life of the group's primary asset. That forecast requires estimates of the level and timing of revenue, operating expenses and working capital, which are inherently uncertain. If the carrying amount is not recoverable, we measure the loss as the amount by which carrying amount exceeds fair value, estimated using a discounted cash flow model, and the loss allocated to an individual asset does not reduce its carrying amount below fair value when that fair value is determinable without undue cost and effort. We base our estimates on the best information available at the time. If actual results are not consistent with the assumptions used, the impairment expense may be overstated or understated.
We did not identify any indicators of impairment with respect to any asset or asset group during fiscal 2026, and we recorded no impairment of long-lived assets in fiscal 2026 or fiscal 2025. We recorded an impairment charge of $44.9 million in fiscal 2024 relating to our antibody discovery services asset group.
Equity Investments in Privately Held Companies
We hold equity investments in privately held companies that do not have readily determinable fair values, including Atlas, Invenra and other individually immaterial investments. Each is a variable interest entity in which we hold a variable interest but of which we are not the primary beneficiary, and none qualifies for the equity method. The aggregate carrying amount was $68.1 million at September 30, 2026, compared with $54.3 million at September 30, 2025.
We account for these investments using the measurement alternative, under which they are carried at cost, less impairment, and adjusted for observable price changes in orderly transactions for identical or similar securities of the same issuer. Our assessment focuses on whether any transaction we encounter reflects an observable price change in an identical or similar security, as well as whether prevailing events signal that the carrying amount may not be fully recoverable. Because these companies are private, information about their financings reaches us only through our position as an investor, and a transaction in a class of equity with different rights and preferences may not be an observable price change for the class we hold.
Where an adjustment is required, or where an investment is acquired for consideration other than cash, we estimate fair value using an option pricing allocation method, which treats each class of a company's equity as a call option on total equity value and requires assumptions about total equity value, the rights and preferences of each class, the expected time to a liquidity event and volatility. Where a recent third-party financing is available we solve for implied total equity value from its terms and apply a discount for lack of marketability.
Because these investments are not remeasured absent an observable transaction, a change in the underlying value of any of these companies is recognized in a single period rather than over time, and could be material to
61
our results. We did not record any upward or downward adjustments for observable price changes, or any impairment, during the year ended September 30, 2026. The Company impaired $1.1 million and $2.2 million during the year ended September 30, 2025 and September 30, 2024, respectively.
Recently Issued Accounting Pronouncements
For a description of accounting changes and recent accounting pronouncements, including the expected dates of adoption and estimated effects, if any, on our consolidated financial statements, see Note 2, Summary of Significant Accounting Policies in the notes to consolidated financial statements included elsewhere in this Form 10-K.
Item 7A.Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Sensitivity
We are exposed to market risk related to changes in interest rates. As of September 30, 2026, we had cash, cash equivalents and short-term investments of $581.9 million compared with $232.4 million as of September 30, 2025. The increase primarily reflects the net proceeds from our August 2026 underwritten public offering and sales under our at-the-market program. Our cash equivalents and short-term investments consist primarily of money market funds and investment-grade, short-term fixed income securities.
The primary objective of our investment activities is to preserve capital to fund our operations while maximizing income without assuming significant risk. We maintain a portfolio of high credit quality, short-duration securities in accordance with our board-approved investment policy. Our investments are subject to interest rate risk and could decline in value if market interest rates increase. Because of the short-term nature of our portfolio, a hypothetical 10% relative change in interest rates as of September 30, 2026 would not have had a material effect on the fair value of our portfolio. A hypothetical 100 basis point decrease in interest rates would reduce our annual interest income by approximately $5.2 million, based on our balances as of September 30, 2026.
Foreign Currency Sensitivity
The majority of our transactions are denominated in U.S. dollars. However, certain of our transactions are denominated in other currencies, primarily the Euro, Chinese Yuan, Japanese Yen and British Pound, and we are therefore subject to foreign exchange risk. A hypothetical 10% change in the value of the U.S. dollar against these currencies as of September 30, 2026 would not have had a material effect on our consolidated financial statements.
We do not currently hedge our foreign currency exposure or use derivative financial instruments for speculative or trading purposes.
Equity Investment Risk
We hold investments in the preferred stock of privately held companies, including Invenra and Atlas, with an aggregate carrying value of $68.1 million as of September 30, 2026. These investments are not publicly traded and are accounted for under the measurement alternative, at cost less impairment, adjusted for observable price changes. Changes in the investees’ financial condition or in the valuation of comparable companies could require us to recognize impairments or other losses in earnings. See Note 6, Investment in Equity Securities, of the notes to the consolidated financial statements included elsewhere in this Form 10-K.
62
Item 8.Consolidated Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
63
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Twist Bioscience Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Twist Bioscience Corporation (the Company) as of September 30, 2026 and 2025, the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended September 30, 2026, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2026, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of September 30, 2026, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated November 16, 2026 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
64
| Revenue Recognition | ||||||||
| Description of the Matter | As described in Note 2 to the consolidated financial statements, the Company’s revenue for certain products is generated through the sale of DNA products, including synthetic genes (clonal genes and non-clonal genes), oligo pools, and Next Generation Sequencing (NGS) Applications products, for which revenue is recognized at a point in time when control of the product transfers to the customer, which generally occurs upon shipment. The Company’s revenue for these sales recognized at a point in time was $ | |||||||
| Auditing the Company's accounting for this revenue from contracts with customers was challenging and complex primarily due to the high volume of transactions, as well as the multiple applications and data sources associated with the revenue recognition process. | ||||||||
| How We Addressed the Matter in Our Audit | We evaluated and tested the design and operating effectiveness of the Company’s internal controls over the recognition of revenue for these products, including testing the completeness and accuracy of data utilized in these controls. To test the Company’s accounting for revenue from contracts with customers for these transactions, we performed substantive audit procedures that included, among others, performing testing of sales transactions on a sample basis and tracing such transactions to supporting documentation, performing data analytics to test recorded revenue amounts, testing a sample of cash collections, and testing credit memo activity. | |||||||
/s/ Ernst & Young LLP
We have served as the Company's auditor since 2022.
November 16, 2026
65
Twist Bioscience Corporation
Consolidated Balance Sheets
| (In thousands except per share data) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | $ | ||||||||||||
| Short-term investments | ||||||||||||||
Accounts receivable, net [1] | ||||||||||||||
| Inventories | ||||||||||||||
Prepaid expenses and other current assets [1] | ||||||||||||||
| Total current assets | $ | $ | ||||||||||||
| Property and equipment, net | ||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||
Investment in equity securities [1] | ||||||||||||||
| Goodwill | ||||||||||||||
| Intangible assets, net | ||||||||||||||
| Restricted cash, non-current | ||||||||||||||
Other non-current assets [1] | ||||||||||||||
| Total assets | $ | $ | ||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | $ | ||||||||||||
| Accrued compensation | ||||||||||||||
| Current portion of operating lease liability | ||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||
| Total current liabilities | $ | $ | ||||||||||||
| Operating lease liability, net of current portion | ||||||||||||||
| Liability related to the sale of future revenue | ||||||||||||||
Other non-current liabilities[1] | ||||||||||||||
| Total liabilities | $ | $ | ||||||||||||
| Commitments and contingencies (Note 10) | ||||||||||||||
| Stockholders’ equity | ||||||||||||||
Common stock, $ | $ | $ | ||||||||||||
| Additional paid-in capital | ||||||||||||||
| Accumulated other comprehensive loss | ( | ( | ||||||||||||
| Accumulated deficit | ( | ( | ||||||||||||
| Total stockholders’ equity | $ | $ | ||||||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||||||||
[1] Includes related party balances, see Note 6 - Investment in Equity Securities and Note 11 - Related Party Transactions .
The accompanying notes are an integral part of these consolidated financial statements.
66
Twist Bioscience Corporation
Consolidated Statements of Operations and Comprehensive Loss
| Year ended September 30, | ||||||||||||||||||||
| (In thousands, except per share data) | 2026 | 2025 | 2024 | |||||||||||||||||
Revenue [1] | $ | $ | $ | |||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||
| Cost of revenue | $ | $ | $ | |||||||||||||||||
| Research and development expenses | ||||||||||||||||||||
Selling, general and administrative expenses[1] | ||||||||||||||||||||
| Litigation settlement costs, net of recoveries | ||||||||||||||||||||
| Impairment of long-lived assets | ||||||||||||||||||||
| Total costs and expenses | $ | $ | $ | |||||||||||||||||
| Loss from operations | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Gain on sale of business | ||||||||||||||||||||
| Interest income | ||||||||||||||||||||
Other income (expense), net [1] | ( | ( | ||||||||||||||||||
| Loss before income taxes | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Income tax expense | ( | ( | ( | |||||||||||||||||
| Net loss | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||||||
| Change in unrealized gain (loss) on investments | $ | ( | $ | ( | $ | |||||||||||||||
| Foreign currency translation adjustment | ( | |||||||||||||||||||
| Comprehensive loss | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Net loss per share —basic and diluted | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | ||||||||||||||||||||
[1] Includes related party balances, see Note 6 - Investment in Equity Securities and see Note 11 - Related Party Transactions .
The accompanying notes are an integral part of these consolidated financial statements.
67
Twist Bioscience Corporation
Consolidated Statements of Stockholders’ Equity
| Common stock | Additional paid-in capital | Accumulated other comprehensive income / (loss) | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||
| (In thousands) | Shares | Amount | ||||||||||||||||||||||||||||||||||||
| Balances as of September 30, 2023 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
| — | $ | — | $ | — | $ | — | $ | ( | $ | ( | ||||||||||||||||||||||||||||
| Vesting of restricted stock units | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Issuance of shares under the employee stock purchase plan | — | — | — | |||||||||||||||||||||||||||||||||||
| Exercise of stock options | — | — | — | |||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Repurchase of common stock for income tax withholdings | ( | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
| Balances as of September 30, 2024 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
| Restricted common stock canceled | ( | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||||||||||
| Vesting of restricted stock units | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Issuance of shares under the employee stock purchase plan | — | — | — | |||||||||||||||||||||||||||||||||||
| Exercise of stock options | — | — | — | |||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
| Repurchase of common stock for income tax withholdings | — | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
| Balances as of September 30, 2025 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
Issuance of common stock in public offerings, net of underwriting discounts, commissions and offering expenses of $ | $ | — | $ | $ | — | $ | — | $ | ||||||||||||||||||||||||||||||
| Issuance of common stock for equity investment | — | — | — | |||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with asset acquisition | — | — | — | |||||||||||||||||||||||||||||||||||
| Vesting of restricted stock units | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Issuance of shares under the employee stock purchase plan | — | — | ||||||||||||||||||||||||||||||||||||
| Exercise of stock options | — | — | — | |||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
| Repurchase of common stock for income tax withholdings | ( | — | ( | — | — | ( | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
| Balances as of September 30, 2026 | $ | $ | $ | ( | $ | ( | $ | |||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
68
Twist Bioscience Corporation
Consolidated Statements of Cash Flows
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Operating activities | ||||||||||||||||||||
| Net loss | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||||||||||||||
| Depreciation and amortization expense | $ | $ | $ | |||||||||||||||||
| Impairment of long-lived assets | ||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||
| Gain on sale of business | ( | |||||||||||||||||||
| Other non-cash adjustments | ||||||||||||||||||||
| Changes in assets and liabilities: | ||||||||||||||||||||
Accounts receivable, net [1] | ( | ( | ||||||||||||||||||
| Inventories | ( | ( | ||||||||||||||||||
Prepaid expenses and other current assets [1] | ( | ( | ||||||||||||||||||
| Other non-current assets | ( | ( | ||||||||||||||||||
| Accounts payable | ( | |||||||||||||||||||
| Accrued compensation | ( | |||||||||||||||||||
Accrued expenses and other liabilities [1] | ||||||||||||||||||||
| Net cash used in operating activities | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Investing activities | ||||||||||||||||||||
| Purchases of property and equipment | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Purchases of investments | ( | ( | ( | |||||||||||||||||
| Proceeds from maturity of investments | ||||||||||||||||||||
| Proceeds from sale of business | ||||||||||||||||||||
| Purchases of intangible assets | ( | |||||||||||||||||||
| Cash paid for investment in equity securities | ( | |||||||||||||||||||
| Net cash provided by (used in) investing activities | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Financing activities | ||||||||||||||||||||
| Proceeds from exercise of stock options | $ | $ | $ | |||||||||||||||||
| Proceeds from public offerings, net of underwriting discounts, commissions and offering expenses | ||||||||||||||||||||
| Proceeds from the issuance of liability related to sale of future revenue | ||||||||||||||||||||
| Proceeds from issuance under employee stock purchase plan | ||||||||||||||||||||
| Repurchases of common stock for income tax withholding | ( | ( | ( | |||||||||||||||||
| Net cash provided by financing activities | $ | $ | $ | |||||||||||||||||
| Effect of exchange rates on cash, cash equivalents and restricted cash | $ | $ | $ | |||||||||||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | ( | ( | ||||||||||||||||||
| Cash, cash equivalents, and restricted cash at beginning of year | ||||||||||||||||||||
| Cash, cash equivalents, and restricted cash at end of year | $ | $ | $ | |||||||||||||||||
| Supplemental disclosure of cash flow information | ||||||||||||||||||||
| Total income taxes paid, net of refunds | $ | $ | $ | |||||||||||||||||
| Non-cash investing and financing activities | ||||||||||||||||||||
69
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Property and equipment additions included in accrued expenses and accounts payable | $ | $ | $ | |||||||||||||||||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | ||||||||||||||||||||
| Tenant improvement allowance capitalized in property and equipment | ||||||||||||||||||||
| Equity securities received as consideration for sale of business | ||||||||||||||||||||
| Promissory note receivable received as consideration for sale of business | ||||||||||||||||||||
| Issuance of common stock for investment in equity securities | ||||||||||||||||||||
| Issuance of common stock in connection with asset acquisition | ||||||||||||||||||||
[1] Includes immaterial changes in a related party's balances .
The accompanying notes are an integral part of these consolidated financial statements.
70
Twist Bioscience Corporation
Notes to Consolidated Financial Statements
1. Organization and Description of Business
Twist Bioscience Corporation (the “Company”) was incorporated in the state of Delaware on February 4, 2013. The Company has developed a proprietary silicon-based platform for manufacturing synthetic DNA. Using this platform, the Company offers synthetic genes, next-generation sequencing (“NGS”) target enrichment tools, sample preparation tools, synthetic RNA, antibody libraries, and biologics discovery services, including antibody protein expression and characterization. The Company’s customers include pharmaceutical and biotechnology companies, diagnostics companies, industrial and agricultural companies, and academic and government research institutions.
The Company has recognized annual losses from operations since inception and has an accumulated deficit of $1,449.8 million as of September 30, 2026. The Company incurred net losses of $130.2 million, $77.7 million and $208.7 million for the years ended September 30, 2026, 2025, and 2024, respectively.
As of September 30, 2026, the Company had cash and cash equivalents of $534.0 million and short-term investments of $47.9 million. The Company expects that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations for a period of at least one year from the date the consolidated financial statements are issued.
2. Summary of Significant Accounting Policies
Basis of Presentation
The consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are prepared in accordance with U.S. generally accepted accounting principles (or “GAAP”). All intercompany balances and accounts are eliminated in consolidation.
Beginning fiscal 2026, the Company updated its revenue disaggregation disclosures and recast the comparative figures in the disclosure to conform to the current-period presentation (see Note 3, Revenue). Beginning in the current period, the Company presents accrued expenses and other current liabilities on a combined basis in the consolidated balance sheets, with the detailed components, including litigation accruals, disclosed in the accompanying footnotes; prior-period amounts have been reclassified to conform to the current presentation. The presentation of the consolidated statement of cash flows has also been updated to conform to this revised classification, and prior‑period amounts have been reclassified to conform to the current presentation.
Use of Estimates
The presentation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include the valuation of deferred tax assets, stock-based compensation expense, transaction price and progress toward completion of performance obligation under the contracts with customers, determination of the net realizable value of inventories, useful life of developed technology, valuation assumptions used in the calculation of the impairment of long-lived assets, impairment of equity investments and incremental borrowing rate for operating leases. Actual results could differ from those estimates.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments, accounts receivable and other assets. Substantially all of the Company’s cash and cash equivalents, short-term investments are held with two financial institutions that management believe are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s investment policy addresses the level of credit exposure by establishing a minimum allowable credit rating and by limiting the concentration in any one investment.
The Company’s accounts receivable is derived from customers located principally in the United States, Europe and Asia-Pacific region ("APAC"). The Company performs ongoing credit evaluations of its customers and
71
maintains allowances for potential credit losses on customers’ accounts when deemed necessary. The Company does not typically require collateral from its customers. Credit losses historically have not been material. See Note 3, Revenue, for more information for customer concentration.
The Company relies on a limited number of suppliers, and in some cases a single supplier, for certain materials and components used in its manufacturing processes. A disruption in supply from these sources could adversely affect the Company’s operations.
Cash and Cash Equivalents and Restricted Cash
Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments with an original or remaining maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents consist of investments in money market funds as of September 30, 2026 and 2025.
Restricted cash represents cash held at financial institutions that are pledged as collateral for stand-by letters of credit for lease commitments and the litigation payments into the settlement fund. The lease related letters of credit will lapse at the end of the respective lease terms through 2044.
The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s consolidated statements of cash flows:
| September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
| Cash and cash equivalents | $ | $ | ||||||||||||
Restricted cash, current[1] | ||||||||||||||
| Restricted cash, non-current | ||||||||||||||
| Total cash, cash equivalents and restricted cash | $ | $ | ||||||||||||
[1] Restricted cash, current balance is included in Prepaid expenses and other current assets, See note 7. Balance Sheet Components.
Short-term Investments
The Company invests in various types of securities, including United States government, commercial paper, and corporate debt securities. The Company classifies its investments as available-for-sale and records them at fair value based upon market prices at period end.
The Company regularly reviews its short-term investments to identify and evaluate investments that have indications of possible impairment from credit losses or other factors. For available-for-sale debt securities in an unrealized loss position, the Company evaluates whether a current expected credit loss exists based on available information relevant to the credit rating of the security, current economic conditions and supportable forecasts. The allowance for credit loss is recorded in other income (expense), net, on the consolidated statements of operations and comprehensive loss, not to exceed the amount of the unrealized loss. Any excess unrealized loss other than the credit loss is recognized in accumulated other comprehensive income or loss in the stockholders' equity section of the consolidated balance sheets. The Company made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. The accrued interest balance as of September 30, 2026 and 2025 was $1.8 million and $1.2 million. There was no allowance for credit losses relating to the short-term investments recognized as of September 30, 2026.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable include amounts billed and currently due from customers, recorded at the net invoice value and are not interest bearing. The Company has a short order-to-invoice lifecycle, as most products can be manufactured within one month. Upon delivery of the products to the customer, the Company invoices the
72
customer. The typical timing of payment is net 30 days. If the right to payment for services performed was conditional on something other than the passage of time, the unbilled amount would be recorded as a separate contract asset.
The Company is exposed to credit losses primarily through accounts receivable from sales of its products and services. The Company maintains an allowance for credit losses for expected uncollectible accounts receivable and contract assets, which is recorded as an offset to accounts receivable or contract assets and provisions for credit losses are recorded in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.
The allowance for current expected credit losses is based on a review of customer accounts and considers historical credit loss information that is adjusted for current economic and business conditions that may impact collectability. In developing its expected credit loss estimate, the Company evaluated the appropriate grouping of accounts receivable and contract assets based upon its evaluation of risk characteristics, including consideration of region and industries of the customers. Specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. The allowance for credit losses is reviewed on a regular basis to assess the adequacy of the allowance and once a receivable is deemed to be uncollectible, such balance is charged against the allowance.
The Company elected the practical expedient under ASC 326-20 to estimate expected credit losses on current accounts receivable, assuming balance sheet date conditions remain unchanged. As current conditions are consistent with historical data collection periods, no adjustment to historical loss information was necessary.
Fair Value of Financial Instruments
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost which approximates actual cost on a first-in, first-out basis. The Company periodically reviews its inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventories, the Company records a write-down to net realizable value through a charge to cost of revenue on the Company's consolidated statements of operations and comprehensive loss. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, past experience, product net selling prices, current and future market conditions, the age and nature of inventories, and potential product obsolescence, among others.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets or the lesser of the useful life and the remaining lease term of the respective leasehold improvements assets, if any. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is credited or charged to operations in the period recognized. Repairs and maintenance costs are expensed as incurred.
Estimated lives of property and equipment are as follows:
73
| Laboratory equipment | |||||
| Furniture, fixtures and other equipment | |||||
| Computer equipment | |||||
| Vehicles | |||||
| Computer software | |||||
| Leasehold improvements | Lesser of useful life or lease term | ||||
Internal-Use Software and Cloud Computing Arrangements
Costs associated with internal-use software systems during the application development stage are capitalized. Capitalization of costs begins when the preliminary project stage is completed, management has committed to funding the project, and it is probable that the project will be completed and the software will be used to perform the function intended. Costs include external direct costs of services and applicable personnel costs of employees devoted to specific software application development. Personnel costs consist of salaries, employee benefit costs, bonuses and stock-based compensation expense. The capitalized amounts are included in property and equipment, net on the consolidated balance sheets.
Capitalization ceases at the point when the project is substantially complete and is ready for its intended purpose. Capitalized costs are amortized from the project completion date, using the straight-line method over an estimated useful life of the assets.
Implementation costs incurred in cloud computing arrangements that are service contracts are capitalized and included in prepaid expenses and other current assets and other noncurrent assets. These costs are amortized on a straight-line basis over the term of the related hosting arrangement, including reasonably certain renewals, and the amortization is recognized in the same line items as the related hosting fees.
Finite-lived Intangible Assets
Impairment of Long-lived Assets
Leases
The Company determines if an arrangement is or contains a lease at inception and classifies each lease as operating or financing. Operating lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments made during the lease term, net of any tenant improvement allowance. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of committed lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date which includes significant assumptions made including the Company’s estimated credit rating, annual percentage yields from corporate debt financings of companies of similar size and credit rating over a loan term approximating the remaining term of each lease, and government bond yields for terms approximating the remaining term of each
74
lease in countries where the leased assets are located. Certain leases include payments of operating expenses that are dependent on the landlord’s estimate, and these variable payments are therefore excluded from the lease payments used to determine the operating lease right-of-use asset and lease liability. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Operating lease right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Lease expense is recognized on a straight-line basis over the expected lease term.
The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term. The Company elected to account for lease and non-lease components as a single lease component.
Goodwill
The Company assesses goodwill for impairment at the reporting unit level annually as of July 1 and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances may include a significant adverse change in the business climate or market conditions, a sustained decline in the Company’s share price, or a significant shortfall in actual or forecasted results relative to plan. The Company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the Company performs a quantitative goodwill impairment test. The Company may bypass the qualitative assessment for a reporting unit in any period and proceed directly to the quantitative goodwill impairment test. The Company estimates the fair value of its reporting unit using forecasts of discounted future cash flows and peer market multiples. The Company would record an impairment charge for the excess of a reporting unit’s carrying amount over its fair value, limited to the amount of goodwill. For the annual impairment tests performed in fiscal 2026 and 2025, the Company elected to bypass the qualitative assessment and performed a quantitative impairment test, which indicated that the fair value of its single reporting unit substantially exceeded its carrying amount.
Segment Information
The Company operates as one reportable and operating segment, through which it develops, manufactures and sells DNA Synthesis and Protein Solutions and NGS Applications products and services. The Company’s chief operating decision-maker, its Chief Executive Officer (CEO), reviews the Company’s operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Foreign Currency Transactions and Translation
The Company's consolidated financial statements are presented in U.S. dollars. The functional currency for certain foreign subsidiaries is their local currency. Revenue, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of accumulated other comprehensive loss on the Company's consolidated balance sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on the consolidated statements of operations.
Revenue Recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company generates revenue from DNA Synthesis and Protein Solutions and from NGS Applications.
Contracts with customers are generally in the form of a quotation or purchase order and, for certain customers, a master supply, distribution or services agreement that establishes pricing, payment and delivery terms. Payment is generally due within 30 days of invoicing, and within up to 90 days for certain customers. The
75
Company sells directly, through its e-commerce platform and through distributors. Distributors are the Company's customers, and revenue from sales to distributors is recognized when control transfers to the distributor.
Products
The Company manufactures and sells synthetic DNA products, including synthetic genes (clonal genes and non-clonal genes), oligo pools, and NGS Applications products, including library preparation kits, human exome kits, fixed and custom panels, panels for MRD research as well as Alliance panels, synthetic controls and enzymes. Each ordered product, or group of products that is distinct within the context of the contract, represents a performance obligation. Revenue is recognized at a point in time when control transfers to the customer, which is generally when the products are tendered to the carrier at the Company's facility under Ex Works (Incoterms 2020) delivery terms. The transaction price is based on the agreed rates in the quotation, purchase order or supply agreement applied to the quantity of product shipped, net of discounts, credits and other price concessions. The transaction price for an order is allocated to each product based on the price stated in the order, which represents its standalone selling price. For the years ended September 30, 2026, 2025 and 2024, revenue recognized at a point of time was $400.8 million, $350.0 million, and $292.6 million, respectively.
Over-time Arrangements
Revenue under which we perform antibody discovery, optimization, and characterization offerings for customers, is recognized over time and is the area of revenue recognition that requires estimates. At contract inception, the Company assesses whether the promised services are distinct; each research plan, including phases subsequently added to it, is generally a single performance obligation. The transaction price generally consists of fixed fees for the activities in the research plan, payable through up-front payments, upon completion of specified research milestones or as the activities are performed. Up-front payments are recorded as contract liabilities, and research milestone payments made represent payment of fixed fees.
At contract inception, the Company also evaluates whether each performance obligation is satisfied over time or at a point in time. Over-time arrangements are generally recognized over time because the Company’s performance creates materials and data that are specific to the customer’s targets and have no alternative use to the Company, and the Company has an enforceable right to payment for performance completed to date, including if the customer terminates the arrangement; the customer also receives research data throughout the arrangement. The Company recognizes revenue using an input method based on costs incurred relative to total estimated costs, which faithfully depicts the transfer of services because costs are incurred as the research activities are performed. Estimating total costs requires judgment; the Company reviews these estimates at each reporting date and recognizes changes on a cumulative catch-up basis. Arrangements that require customer acceptance or provide for billing only upon completion are recognized at a point in time when the deliverables are accepted. For the years ended September 30, 2026, 2025 and 2024, revenue recognized over time was $58.7 million, $26.5 million, and $20.3 million, respectively.
Variable Consideration, Milestones and Licenses
Certain research plans provide for prorated fee reductions if deliverables do not meet specified acceptance criteria, or for research milestone payments that are payable only if specified research outcomes are achieved. These amounts are variable consideration. The Company estimates variable consideration using the most likely amount and includes it in the transaction price only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty is resolved. The Company reassesses the transaction price at each reporting date and recognizes changes on a cumulative catch-up basis.
The Company also licenses its antibody libraries to customers for their own antibody discovery, providing ongoing access, support and updates over the license term, and recognizes the revenue ratably over that term.
Certain protein solutions agreements also provide for development, regulatory and commercial milestone payments and royalties that depend on the customer’s development or commercialization of products; these payments are excluded from the transaction price until the related uncertainty is resolved, and none has been received or recognized to date.
Customer Prepayments
76
Customers may prepay for future purchases, including through the Company's Twist Wallet program, under which prepaid amounts are non-refundable and may be applied only to the Company's products and services. Prepayments are recorded as contract liabilities and recognized as revenue when the related products or services are transferred.
Practical Expedients and Policy Elections
Shipping and handling fees billed to customers are included in revenue, and the related costs, which the Company accounts for as fulfillment costs, are included in cost of revenue. The Company has elected to exclude from revenue sales, use, value-added and similar taxes collected from customers; amounts collected and not yet remitted are included in accrued expenses and other current liabilities. The Company does not adjust the transaction price for a significant financing component when the period between transfer of a promised good or service and payment is one year or less, and its other arrangements, including customer prepayments, do not contain a significant financing component.
See Note 3, Revenue, for disaggregation of revenue, contract balances, remaining performance obligations and customer concentration.
Cost of Revenue
Cost of revenue primarily consists of cost incurred in the production and delivery of the Company's products and consists of production materials, personnel costs, cost of expensed equipment and consumables, laboratory supplies, consulting costs, depreciation, production overhead costs, information technology, maintenance and facility costs. Personnel costs consist of salaries, employee benefit costs, bonuses, and stock-based compensation expense. In addition, cost of revenue includes royalty costs for licensed technologies included in the Company’s products, and provisions for slow-moving and obsolete inventories.
Research and Development
Research and development expenses consist of compensation costs, employee benefits, subcontractors, research supplies, allocated facility related expenses and allocated depreciation and amortization. All research and development costs are expensed as incurred.
Advertising Costs
Stock-based Compensation
The Company maintains performance incentive plans under which incentive and nonqualified stock options, performance-based stock options, restricted stock units, and performance-based stock units may be granted to employees, members of the board of directors, and certain non-employee consultants. The Company also offers eligible employees the opportunity to purchase shares of its common stock under an Employee Stock Purchase Plan ("ESPP").
The Company recognizes stock compensation in accordance with the Accounting Standard Codification ("ASC") 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair value-based method, for costs related to all stock-based payments including stock options, restricted stock units and employee stock purchase plan.
The Company recognizes fair value of stock options granted to employees and non-employees as a stock-based compensation expense over the period in which the related services are received. The Company recognizes forfeitures as they occur. The Company believes that the estimated fair value of stock options is more readily measurable than the fair value of the services rendered.
For performance-based awards, expense is recognized over the period from the grant date to the estimated attainment date, which is the derived service period of the award, if management determines that it is probable that the performance-based vesting conditions will be achieved.
Net Loss Per Share Attributable to Common Stockholders
77
The Company calculates its basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for companies with participating securities. In computing diluted net loss attributable to common stockholders, undistributed earnings are re-allocated to reflect the potential impact of dilutive securities. For purposes of the calculation of diluted net loss per share attributable to common stockholders, unvested shares of common stock issued upon the early exercise of stock options, shares issuable for employee stock purchase plan contributions received, unvested restricted common stock, unvested restricted stock units and stock options to purchase common stock are considered potentially dilutive securities but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is antidilutive.
Basic and diluted net loss per share of common stock attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of employee stock-based awards and warrants. Because the Company has reported a net loss for the years ended September 30, 2026, 2025 and 2024, diluted net loss per common share is the same as the basic net loss per share for those years.
Income Taxes
The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply in the years in which those tax assets and liabilities are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized.
The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not (greater than 50% likely) to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision.
The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income tax paid is subject to examination by U.S. and foreign tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of the relevant risks, facts and circumstances existing at that time. To the extent the assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made.
Liability Related to the Sale of Future Revenue
Investment in equity securities
78
The Company determines at the inception of each arrangement whether an investment or other interest is considered a variable interest entity (“VIE”). If the investment or other interest is determined to be a VIE, the Company evaluates whether it is considered the primary beneficiary. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) has the obligation to absorb losses or the right to receive benefits from the VIE. For investments in VIEs in which the Company is considered the primary beneficiary, the assets, liabilities and results of operations of the VIE are included in the Company’s consolidated financial statements.
Investments in common stock or in-substance common stock where the Company has significant influence over the financial and operating policies of the investee are accounted for as equity-method investments.
If the Company's equity investment does not meet the requirements of equity method of accounting, the Company accounts for the investment at fair value and has elected to account for its equity investments without a readily determinable fair value using a measurement alternative. Equity investments without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on the Company's consolidated statements of operations and comprehensive income (loss).
Contingent Consideration
Recent Accounting Pronouncements
New Accounting Guidance Adopted
In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740)". The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 on a prospective basis for the fiscal year ended September 30, 2026 and provided required disclosure in Note 12. Income taxes. As a result, the income tax disclosures for the fiscal years ended September 30, 2025 and 2024 are presented under the guidance in effect before adoption.
In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The ASU provides a practical expedient for estimating expected credit losses on current accounts receivable: an entity may assume that conditions as of the balance sheet date do not change for the remaining life of the asset. The Company early adopted ASU 2025-05 prospectively effective October 1, 2025 and elected the practical expedient. Because current conditions are consistent with the historical periods used to develop the Company’s loss rates, no adjustment to historical loss information was necessary. Adoption did not have a material impact on the consolidated financial statements.
New Accounting Guidance Issued but Not Yet Effective
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures, which requires disclosure, in the notes to the financial statements, of disaggregated information about specific expense categories (including purchases of inventories, employee compensation, depreciation, and intangible asset amortization) within each relevant expense caption, as well as total selling expenses and, annually, the entity’s definition of selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments may be applied prospectively or retrospectively. The Company is currently evaluating the incremental disclosures that will be required in its consolidated financial statements.
79
In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software ("ASU 2025-06") simplifies the capitalization guidance by removing all references to software development project stages so that the guidance is neutral to different software development methods. The standard is effective for all entities for annual periods beginning after December 15, 2027 and interim periods within those annual periods, with early adoption permitted. The amendments may be applied using a prospective, modified, or retrospective transition approach. The Company is currently evaluating the impact of this standard to its consolidated financial statements.
The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.
3. Revenue
Disaggregation of Revenue
The Company disaggregates revenue by geographic region, product line, and industry: timing of transfer is disclosed in Note 2.
The table below sets forth revenue by geographic region, based on ship-to destinations. Americas consists of the United States, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC primarily consists of Japan, China, South Korea, India, Singapore, Malaysia, Australia, New Zealand, Thailand and Taiwan.
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Americas | $ | $ | $ | |||||||||||||||||
| EMEA | ||||||||||||||||||||
| APAC | ||||||||||||||||||||
| Total | $ | $ | $ | |||||||||||||||||
Revenue from the United States represented 59 %, 58 % and 60 % of the total revenue for the years ended September 30, 2026, 2025 and 2024, respectively. No individual foreign country accounted for 10% or more of total revenue for the years ended September 30, 2026, 2025 and 2024.
The table below sets forth revenue by product line. The Company previously reported revenue by product categories: synthetic genes, oligo pools and DNA libraries (collectively, synthetic biology), antibody discovery, and NGS tools. As customers increasingly leverage both synthetic biology tools and antibody discovery services together to accelerate discovery and identify breakthrough therapeutics, beginning fiscal 2026, the Company combined synthetic genes, oligo pools, DNA libraries, and antibody discovery services into DNA Synthesis and Protein Solutions. Additionally, NGS tools were renamed NGS Applications to better reflect their role in DNA sequencing workflows. Prior-period amounts have been recast to conform to the current-period presentation.
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| DNA Synthesis and Protein Solutions | ||||||||||||||||||||
| NGS Applications | ||||||||||||||||||||
| Total | $ | $ | $ | |||||||||||||||||
80
The table below sets forth revenue by industry. The Company historically reported revenue by industrial chemicals/materials, academic research, healthcare, and food/agriculture. Beginning fiscal 2026, the Company discloses revenue by therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners, and prior-period amounts have been recast to conform to the current-period presentation. These updated categories better align with the Company's operations and increase clarity around the Company's key customer groups.
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Therapeutics | $ | $ | $ | |||||||||||||||||
| Diagnostics | ||||||||||||||||||||
| Industry and applied | ||||||||||||||||||||
| Academic research and government | ||||||||||||||||||||
| Global supply partners | ||||||||||||||||||||
| Total revenue | $ | $ | $ | |||||||||||||||||
Contract Balances
The following table summarizes the contract balances:
| September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
| Contract assets | $ | $ | ||||||||||||
| Contract liabilities | ||||||||||||||
| Contract liabilities - non current | ||||||||||||||
Contract assets represent revenue recognized on protein solutions arrangements in excess of amounts billed, where the right to payment is conditioned on something other than the passage of time, such as completion of a phase of the research plan. Contract assets are reclassified to accounts receivable when the right to payment becomes unconditional. Contract liabilities consist of customer prepayments, including Twist Wallet balances, and up-front and advance payments received before the related performance obligations are satisfied. Amounts expected to be recognized as revenue more than twelve months after the balance sheet date are classified as non-current.
The increase in the contract asset balance during the year ended September 30, 2026 was primarily a result of revenue recognized on protein solutions arrangements in advance of billing. The increase in the contract liability balance during the year ended September 30, 2026 was primarily a result of cash payments received in advance of satisfying performance obligations, including up-front and advance payments under protein solutions arrangements and Twist Wallet prepayments, partially offset by amounts recognized as revenue. For the years ended September 30, 2026, 2025 and 2024 the Company recognized revenue of $4.6 million, $1.4 million and $1.7 million, respectively, from the amount that was included in the contract liability balance at the beginning of each year.
Remaining Performance Obligations
As of September 30, 2026, the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied was $21.6 million, of which the Company expects to recognize $15.9 million over the next twelve months and the remainder thereafter. These amounts exclude constrained variable consideration, including contingent milestone payments. The Company has elected not to disclose remaining performance obligations for contracts with an original expected duration of one year or less, which includes substantially all product orders.
For all periods presented, there was no revenue recognized in a reporting period from performance obligations satisfied in previous periods.
Customer Concentration
81
There are no major customers who accounted for 10% or more of the Company’s revenue for the fiscal year ended September 30, 2026, September 30, 2025 and September 30, 2024.
4. Cash, Cash Equivalents and Short-term Investments
The following table sets forth the cash and cash equivalents, and short-term investments as of September 30, 2026:
| (in thousands) | Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair value | ||||||||||||||||||||||
| Cash | $ | $ | — | $ | — | $ | ||||||||||||||||||||
| Cash equivalents - money market funds | — | — | ||||||||||||||||||||||||
| Total cash and cash equivalents | $ | $ | — | $ | — | $ | ||||||||||||||||||||
| Short-term investments: | ||||||||||||||||||||||||||
| U.S. government treasury bills | $ | $ | $ | ( | $ | |||||||||||||||||||||
| Total short-term investments | $ | $ | $ | ( | $ | |||||||||||||||||||||
| Total cash, cash equivalents and short-term investments | $ | $ | $ | ( | $ | |||||||||||||||||||||
The following table sets forth the cash and cash equivalents, and short-term investments as of September 30, 2025:
| (in thousands) | Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair value | ||||||||||||||||||||||
| Cash | $ | $ | — | $ | — | $ | ||||||||||||||||||||
| Cash equivalents - money market funds | — | — | ||||||||||||||||||||||||
| Total cash and cash equivalents | $ | $ | — | $ | — | $ | ||||||||||||||||||||
| Short-term investments: | ||||||||||||||||||||||||||
| U.S. government treasury bills | $ | $ | $ | $ | ||||||||||||||||||||||
| Total short-term investments | $ | $ | $ | $ | ||||||||||||||||||||||
| Total cash, cash equivalents and short-term investments | $ | $ | $ | $ | ||||||||||||||||||||||
During the years ended September 30, 2026, 2025 and 2024, gross realized gains and losses related to the Company's short-term investments were not material.
During the years ended September 30, 2026, 2025 and 2024, the Company did not recognize any credit losses related to cash, cash equivalents and short-term investments.
5. Fair Value Measurement
The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
82
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its assessment of fair value.
Assets Measured at Fair Value on a Recurring Basis
As of September 30, 2026, financial assets and liabilities measured and recognized at fair value are as follows:
| (in thousands) | Level 1 | Level 2 | Level 3 | Fair value | ||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||
| Money market funds | $ | $ | $ | $ | ||||||||||||||||||||||
| U.S. government treasury bills | ||||||||||||||||||||||||||
| Total financial assets | $ | $ | $ | $ | ||||||||||||||||||||||
As of September 30, 2025, financial assets measured and recognized at fair value are as follows:
| (in thousands) | Level 1 | Level 2 | Level 3 | Fair value | ||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||
| Money market funds | $ | $ | $ | $ | ||||||||||||||||||||||
| U.S. government treasury bills | ||||||||||||||||||||||||||
| Total financial assets | $ | $ | $ | $ | ||||||||||||||||||||||
Contractual maturities of short-term investments, as of September 30, 2026, were less than 12 months. The Company does not intend to sell the money market funds and short term investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis. Accrued interest receivable of $1.8 million and $1.2 million as of September 30, 2026 and September 30, 2025, respectively, are included in the prepaid expenses and other current assets within the consolidated balance sheets.
As of September 30, 2026 and 2025, there are no financial liabilities measured and recognized at fair value.
6. Investment in Equity Securities
The Company entered into separate agreements with third-party investors to purchase shares of Series B Preferred Stock of Invenra Inc. (“Invenra”) for a consideration of $13.8 million to be settled by the issuance of the shares of the Company's common stock. The Company concluded that while Invenra is a variable interest entity ("VIE"), the Company is not the primary beneficiary of Invenra as the Company does not have the power, whether through contractual relationships or other factors, to direct the activities that most significantly impact the economic performance of Invenra. Therefore, the Company did not consolidate Invenra. The investment also did not qualify for the equity method of accounting because the Series B Preferred Stock has substantive liquidation preferences and is not considered in-substance common stock. Accordingly, the investment is accounted for as an investment in equity securities of a privately held company. The investment was recorded at $13.8 million, consisting of an upfront issuance of shares of the Company's common stock of $10.0 million at initial closing and a subsequent issuance of the Company's common stock of $3.8 million on April 7, 2026. Simultaneously, the Company entered into a License Agreement (the “Agreement”) with Invenra. See note 8. Goodwill and Intangible Assets. Invenra is considered to be a related party of the Company.
In May 2025, the Company sold its DNA data storage business to AtlasBase Inc. (formerly Atlas Data Storage, Inc.) ("Atlas") in exchange for 73.0 million shares of Atlas Series Seed-1 Preferred Stock, $2.5 million in cash, $2.0 million in promissory notes, contingent milestone payments of up to $75.0 million, and royalties on Atlas DNA data storage sales. The Company recorded a $48.8 million gain on the sale in fiscal year 2025.
83
The Company holds investments in other privately-held companies in the form of equity securities without readily determinable fair values. The Company concluded that these entities are VIEs and the Company holds variable interests in these VIEs but is not their primary beneficiary and therefore does not consolidate them. These entities also do not meet the requirements of equity method of accounting.
The Company elected to account for its investment in privately-held companies using the measurement alternative method. Under the measurement alternative, these investments are carried at cost, less any impairment, and adjusted for observable price changes from orderly transactions for identical or similar investments of the same issuer. As of September 30, 2026 and September 30, 2025, the carrying value of the Company’s investments in equity securities without readily determinable fair values was $68.1 million and $54.3 million, respectively. There were no upward or downward adjustments for observable price changes or impairment charges recorded during the year ended September 30, 2026. The Company impaired $1.1 million and $2.2 million during the year ended September 30, 2025 and September 30, 2024, respectively. For investments held as of September 30, 2026, cumulative impairments and downward adjustments since acquisition were $3.3 million, and the Company has not recorded any cumulative upward adjustments.
Assets, liabilities, and maximum exposure with unconsolidated VIEs are as follows:
| (in thousands) | Financial statements line item | September 30, 2026 | September 30, 2025 | |||||||||||||||||
| Assets | ||||||||||||||||||||
Other receivables[1] | Prepaid and other current assets | $ | $ | |||||||||||||||||
Investments[2] | Investment in equity securities | |||||||||||||||||||
Promissory note receivable[1] | Other non-current assets | |||||||||||||||||||
| Total assets | $ | $ | ||||||||||||||||||
| Liabilities | ||||||||||||||||||||
Sublease security deposit[1] | Other non-current liabilities | |||||||||||||||||||
| Total liabilities | $ | $ | ||||||||||||||||||
Maximum exposures to VIEs[3] | $ | $ | ||||||||||||||||||
[1] Represents a related party balance.
[2] As of September 30, 2026 and September 30, 2025 includes a related party balance of $67.6 million and $53.9 million, respectively.
[3] Maximum exposure to the VIEs is limited to the carrying value of assets as the Company does not have any future funding commitments to the VIEs.
Accounts receivable from an unconsolidated VIE and considered a related party was less than $0.1 million as of September 30, 2026 and September 30, 2025.
Transactions with unconsolidated VIEs and considered related parties were as follows:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Sublease income | $ | $ | $ | |||||||||||||||||
| Interest income | ||||||||||||||||||||
7. Balance Sheet Components
Allowance for Credit Losses
Allowance for credit losses related to accounts receivable were $0.6 million and $0.6 million as of September 30, 2026 and 2025, respectively.
84
Prepaid Expenses and Other Current Assets
| (in thousands) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Prepaid expenses | $ | $ | ||||||||||||
| Contract assets | ||||||||||||||
| Restricted cash | ||||||||||||||
| Insurance receivable for litigation settlement costs | ||||||||||||||
| Other current assets | ||||||||||||||
| $ | $ | |||||||||||||
The Company has determined that recovery of approximately $16.7 million from its liability insurers is probable and has accounted for insurance receivable for litigation settlement costs as of September 30, 2026 (see note 10. Commitments and Contingencies).
Inventories
Inventories consist of the following:
| September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
| Raw Materials | $ | $ | ||||||||||||
| Work-in-process | ||||||||||||||
| Finished Goods | ||||||||||||||
| $ | $ | |||||||||||||
Property and Equipment, net
Property and equipment, net consists of the following:
| September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
| Laboratory equipment | $ | $ | ||||||||||||
| Furniture, fixtures and other equipment | ||||||||||||||
| Vehicles | ||||||||||||||
| Computer equipment | ||||||||||||||
| Computer software | ||||||||||||||
| Leasehold improvements | ||||||||||||||
| Construction in progress | ||||||||||||||
| $ | $ | |||||||||||||
| Less: Accumulated depreciation and amortization | ( | ( | ||||||||||||
| $ | $ | |||||||||||||
Construction in progress mainly represents equipment costs, leasehold improvements, and internal use software development costs. For the year ended September 30, 2026 and 2025 the total depreciation and amortization expense was $25.3 million and $23.8 million, respectively.
During the year ended September 30, 2024, the Company recognized an impairment of property and equipment of $9.1 million as part of a $44.9 million impairment of the antibody discovery services asset group.
85
The net book value of capitalized computer software held for internal use included in property and equipment, net were $5.9 million and $3.2 million as of September 30, 2026 and 2025, respectively. For the year ended September 30, 2026 and 2025, the amortization expense of capitalized computer software held for internal use was $3.1 million and $2.9 million, respectively.
Property and equipment, net located in the United States were $122.3 million and $102.3 million as of September 30, 2026 and 2025, respectively. Property and equipment, net located outside of the United States were immaterial as of September 30, 2026 and 2025.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following:
| September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
| Accrued Expenses | $ | $ | ||||||||||||
| Accrued legal and related costs | ||||||||||||||
| Income and other taxes payable | ||||||||||||||
| Contract liabilities | ||||||||||||||
| Other current liabilities | ||||||||||||||
| $ | $ | |||||||||||||
8. Goodwill and Intangible Assets
The goodwill balance is presented below:
| (in thousands) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Balance at beginning of year | $ | $ | ||||||||||||
| Sale of business | ( | |||||||||||||
| Balance at end of year | $ | $ | ||||||||||||
The finite-lived intangible assets balances are presented below:
| September 30, 2026 | ||||||||||||||||||||||||||
| (in thousands, except for years) | Weighted-average remaining Amortization period in years | Gross carrying amount | Accumulated amortization | Net book value | ||||||||||||||||||||||
| Developed Technology | $ | $ | ( | $ | ||||||||||||||||||||||
| Total finite-lived intangible assets | $ | $ | ( | $ | ||||||||||||||||||||||
86
| September 30, 2025 | ||||||||||||||||||||||||||
| (in thousands, except for years) | Weighted- average remaining Amortization period in years | Gross carrying amount | Accumulated amortization | Net book value | ||||||||||||||||||||||
| Developed Technology | $ | $ | ( | $ | ||||||||||||||||||||||
| Total finite-lived intangible assets | $ | $ | ( | $ | ||||||||||||||||||||||
Total amortization expense related to intangible assets was $1.2 million, $1.1 million, and $4.1 million for the years ended September 30, 2026, 2025 and 2024, respectively.
During the year ended September 30, 2024, the Company recognized an of $35.9 million as part of the $44.9 million impairment of the antibody discovery services asset group.
During fiscal 2026, the Company acquired intangible assets of $22.0 million, consisting primarily of the Invenra license, with a weighted-average amortization period of 10.4 years.
Future annual amortization expense is as follows (in thousands):
Years ending September 30, | ||||||||
| 2027 | $ | |||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 | ||||||||
| 2031 | ||||||||
| Thereafter | ||||||||
| $ | ||||||||
Invenra license agreement
In February 2026, the Company entered into a License Agreement (the “Agreement”) with Invenra for a co-exclusive, royalty-bearing license to Invenra’s proprietary B-Body bispecific antibody discovery platform for an initial term of 7 years. The Company may exercise an option to extend the co-exclusive license for the duration of all patent rights in the platform for a consideration of $10.0 million payable in the Company's common stock. If the Company does not choose to exercise the option, then the term will continue non-exclusively through the duration of all patent rights. The transaction was accounted for as an asset acquisition. The total consideration paid by the Company in exchange for the license was $20.0 million, consisting of:
•$5.0 million upfront cash payment
•$10.0 million in shares of the Company’s common stock issued on the effective date of the Agreement, and
•$5.0 million in shares of the Company's common stock issued upon the successful completion of the transfer of certain technology from Invenra to the Company (the “Tech Transfer") in August 2026.
The asset acquisition purchase consideration originally was included within prepaid expenses and other current assets on the consolidated balance sheet because the Company did not obtain control of the license until Tech Transfer was completed. Upon completion of Tech Transfer in August 2026, the amount was reclassified to an intangible asset and amortized in cost of revenue, on a straight-line basis over the useful life of the intangible asset. The Invenra license is amortized over eleven years, to the earliest patent expiration, as the Company retains non-exclusive rights after the co-exclusive term and the period over which we expect to realize the majority of the economic benefit.
Under the terms of the Agreement, the Company is required to pay royalties to Invenra based on gross revenue the Company receives from licensing to third-parties. These royalties will be recognized as cost of revenue in
87
the period the underlying sale occurs. Invenra will provide ongoing sales, marketing, and technical support to the Company and may act as a subcontractor for biopharma services associated with the platform.
9. Leases
The Company leases certain of its facilities under non-cancelable operating leases expiring at various dates through 2044. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases. The lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, as well as payments for common-area-maintenance and administrative services. The Company often receives customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases. Leases are classified as operating or financing at commencement. The Company does not have any material financing leases.
On November 13, 2025, the Company entered into an amendment to the lease agreement for the Company's premises in South San Francisco, California, in order to consolidate other offices in South San Francisco into a single location. This amendment increased the leased premises by approximately 33,000 square feet on the third floor of the building ("Third Floor Premises"), extended the termination date of the lease until June 30, 2036 and provided a tenant improvement and furniture, fixtures and equipment allowances ("TI Allowances") of $24.4 million.
On September 18, 2026, the Company entered into a further amendment to the lease (the "Third Amendment"). The Third Amendment (i) adds approximately 33,000 square feet on the fourth floor of the building ("Fourth Floor Premises"), (ii) extends the termination date of the lease for the entire premises to June 30, 2037, (iii) changes the expected commencement date of the Third Floor Premises to January 1, 2027, and (iv) extends base rent abatement on the original premises to 16 months, through October 31, 2027. Base rent for the Third Floor Premises and the Fourth Floor Premises begins on August 1, 2027, subject to abatement of 13 and 18 months, respectively. When base rent begins on the Third and Fourth Floor Premises, monthly base rent for the entire premises of approximately 127,000 square feet will be approximately $0.7 million before abatement, increasing by 3 % annually. The Company is also responsible for utilities, maintenance, insurance, and property taxes. The landlord will provide additional TI Allowances of $10.4 million for the Fourth Floor Premises, increasing total TI Allowances under the lease to $34.8 million.
The Company accounted for the Third Amendment as a lease modification. For the original premises, the Company remeasured the operating lease liability on the modification date, which increased the operating lease liability and the right-of-use asset by $2.1 million. The $9.9 million of TI Allowances for the original premises was excluded from the remeasurement and will be recognized as a reduction to the right-of-use asset as the qualifying improvement costs are incurred. The Third Floor Premises and the Fourth Floor Premises are separate lease components that had not commenced as of September 30, 2026, and are therefore not included in the operating lease liabilities or the maturity table below. The Company will recognize operating lease right-of-use assets and liabilities for these components on their commencement dates, currently expected to be January 1, 2027. Undiscounted base rent payments for the Third Floor Premises and the Fourth Floor Premises total approximately $42.7 million through June 30, 2037, before tenant improvement and furniture, fixtures and equipment allowances of approximately $24.9 million. The Company is designing and constructing the tenant improvements for these premises.
In September 2026, the Company entered into a lease for new office space in Carlsbad, California, which is expected to commence in April 2027; undiscounted base rent totals approximately $2.2 million over the 5 year term and is not included in the operating lease liabilities or the maturity table below.
Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants.
88
As part of the sale of DNA data storage business, the Company subleased specific office and lab space to Atlas in South San Francisco.
Future minimum lease payments and sublease income under all non-cancelable operating leases as of September 30, 2026 are as follows:
| (in thousands) | Operating leases | Sublease income | ||||||||||||
| Years ending September 30: | ||||||||||||||
| 2027 | $ | $ | ||||||||||||
| 2028 | ||||||||||||||
| 2029 | ||||||||||||||
| 2030 | ||||||||||||||
| 2031 | ||||||||||||||
| Thereafter | ||||||||||||||
| Total minimum lease payments | $ | $ | ||||||||||||
| Less: imputed interest | ( | |||||||||||||
| Total operating lease liabilities | $ | |||||||||||||
| Less: current portion | ( | |||||||||||||
| Operating lease liabilities, net of current portion | $ | |||||||||||||
The components of lease expense and supplemental information were as follows:
| Year ended September 30, | ||||||||||||||
| (in thousands except years and percentage) | 2026 | 2025 | ||||||||||||
| Operating lease costs | $ | $ | ||||||||||||
| Variable lease costs | ||||||||||||||
| Sublease income | ||||||||||||||
| Weighted-average remaining lease term (in years) - operating leases | ||||||||||||||
| Weighted-average discount rate - operating leases | % | % | ||||||||||||
Supplemental cash flow information related to leases are as follows:
| Year ended September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
Cash payments included in the measurement of operating lease liabilities | $ | $ | ||||||||||||
Substantially all of the Company’s operating lease right-of-use assets are located in the United States.
10. Commitments and Contingencies
Legal Proceedings
The Company may be subject to litigation, claims and disputes in the ordinary course of business. Certain significant matters are described below. The Company recognizes accruals for matters to the extent that the Company concludes that a loss is both probable and reasonably estimable. If the Company determines that a material loss is reasonably possible and the loss or range of loss can be estimated, the Company discloses the possible loss.
Securities Class Action
On December 12, 2022, a putative securities class action lawsuit captioned Peters v. Twist Bioscience Corporation, et al., Case No. 22-cv-08168 (N.D. Cal.) (“Securities Class Action”) was filed in federal court in the
89
Northern District of California (“Court”) against the Company, its Chief Executive Officer, and its Chief Financial Officer (the “Defendants”) alleging violations of federal securities laws. On March 31, 2026, the parties engaged in mediation and reached a settlement in principle under which the Company would pay, or cause its insurance carriers to pay, a settlement payment of approximately $17.1 million. The Defendants have denied and continue to deny the allegations and any wrongdoing or liability, and the settlement, if approved, will not constitute an admission of wrongdoing or liability by any Defendant. The Defendants agreed to the settlement to eliminate the uncertainty, burden and expense of further litigation. The settlement in principle was presented to the Court in a motion for preliminary approval on April 30, 2026. On July 17, 2026, the Court granted the motion for preliminary approval. The final settlement approval hearing will take place before the Court on November 18, 2026. The settlement remains subject to final court approval. The Company expects its liability insurers to directly fund the majority of the settlement liability, with the Company contributing the remainder as its remaining retention under its insurance policy.
Derivative Action
On September 25, 2023, a shareholder derivative suit captioned Shumacher v. Leproust et al., No. 1:23-cv-01048-UNA, was filed in the United States District Court for the District of Delaware against directors of the Company and an employee (the “Shumacher Action”). The suit is based on substantially the same allegations in the Securities Class Action and seeks to recover, on behalf of the Company, damages to the Company arising from, among other things, the Securities Class Action. On November 13, 2023, the parties to the Shumacher Action entered into a stipulation staying the Shumacher Action pending further proceedings in the Securities Class Action. On November 13, 2025, another derivative lawsuit captioned Sell v. Leproust, et al., Case No. 1:25-cv-01380-MN was filed in the United States District Court for the District of Delaware, alleging similar claims and seeking similar recovery as the Shumacher Action (the “Sell Action”), and on December 2, 2025 the Sell Action was consolidated with the Shumacher Action and stayed pending further proceedings in the Securities Class Action. On July 2, 2026, the parties to the consolidated action filed a stipulation for continued stay of the action pending mediation. On July 15, 2026, the parties engaged in mediation and reached a settlement in principle under which the Company will formally adopt and codify certain corporate governance policies and the Company’s liability insurers will pay a fee of approximately $1.0 million to the plaintiffs’ counsel. On October 15, 2026, the parties filed a stipulation of settlement with the court, and on October 20, 2026, the court granted the motion for preliminary approval. The final settlement approval hearing will take place before the court on January 22, 2027. The settlement remains subject to court approval.
Indemnifications
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. From time to time, the Company has entered into indemnification agreements with its directors and officers that requires it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by law. The Company also has directors’ and officers’ insurance.
11. Related Party Transactions
During the years ended September 30, 2026, 2025, and 2024, transactions with related parties excluding an unconsolidated VIE that is considered a related party were as follows:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Revenue | $ | $ | $ | |||||||||||||||||
| Purchased raw materials | ||||||||||||||||||||
As of September 30, 2026 and September 30, 2025, accounts receivable balances with related parties, excluding an unconsolidated VIE that is considered a related party were as follows:
90
| (in thousands) | September 30, 2026 | September 30, 2025 | ||||||||||||
| Accounts receivable | $ | $ | ||||||||||||
See Note 6, Investment in Equity Securities, for transactions and balances with unconsolidated VIEs that are considered related parties.
12. Income Taxes
The Company recorded income tax expense of $0.4 million, $0.7 million and $0.6 million for the years ended September 30, 2026, 2025 and 2024, respectively.
The domestic and foreign components of pre-tax loss for the years ended September 30, 2026, 2025, and 2024 are as follows:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| US | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Foreign | ||||||||||||||||||||
| Total | $ | ( | $ | ( | $ | ( | ||||||||||||||
The components of the income tax expense for the years ended September 30, 2026, 2025, and 2024 are as follows:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Current | ||||||||||||||||||||
| Federal | $ | $ | $ | |||||||||||||||||
| State | ||||||||||||||||||||
| Foreign | ||||||||||||||||||||
| Total current | $ | $ | $ | |||||||||||||||||
| Deferred | ||||||||||||||||||||
| Federal | $ | $ | $ | |||||||||||||||||
| State | ||||||||||||||||||||
| Foreign | ||||||||||||||||||||
| Total deferred | $ | $ | $ | |||||||||||||||||
| Total provision (benefit) | $ | $ | $ | |||||||||||||||||
The Company adopted ASU 2023-09 prospectively for the year ended September 30, 2026. The following table presents the reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for fiscal 2026 in accordance with ASU 2023-09. Reconciliations for fiscal 2025 and 2024 are presented below under the guidance in effect before adoption. See Note 2, Summary of Significant Accounting Policies, for additional information.
91
| Year Ended September 30, 2026 | ||||||||||||||
| (in thousands except for percentages) | Amounts | % | ||||||||||||
| ( | % | |||||||||||||
State and local income taxes - net of federal income tax effect[1] | ( | % | ||||||||||||
| Foreign tax effects | ( | % | ||||||||||||
| Effect of changes in tax laws or rates enacted in the current period | % | |||||||||||||
| Effect of cross-border tax laws | % | |||||||||||||
| Tax credits | ||||||||||||||
| Research and development credit | ( | % | ||||||||||||
| Changes in federal valuation allowance | ( | % | ||||||||||||
| Nontaxable or nondeductible items | ||||||||||||||
| Stock-based compensation | ( | % | ||||||||||||
| Section 162(m) limitation on compensation | ( | % | ||||||||||||
| Others | ( | % | ||||||||||||
| Changes in unrecognized tax benefits | ( | % | ||||||||||||
| Total income tax expense | $ | ( | % | |||||||||||
[1] State and local income taxes, net of federal benefit, consist primarily of taxes in California, and Texas, which made up the majority (greater than 50%) of the effect in this category. This line includes California research and development credit; the associated unrecognized tax benefits are presented in the “Changes in unrecognized tax benefits” line.
92
| Year ended September 30, | ||||||||||||||
| 2025 | 2024 | |||||||||||||
| U.S. federal tax at statutory rate | % | % | ||||||||||||
| Change in valuation allowance | ( | % | ( | % | ||||||||||
| Research and development credit | % | % | ||||||||||||
| Section 162(m) limitation on compensation | ( | % | ( | % | ||||||||||
| Stock-based compensation | % | ( | % | |||||||||||
| Change in fair value of contingent consideration and holdbacks | % | % | ||||||||||||
| Gain on sale of intangible assets | % | % | ||||||||||||
| Others | ( | % | ( | % | ||||||||||
| Total income tax expense | ( | % | ( | % | ||||||||||
The significant components of the Company’s deferred tax assets and liabilities are as follows for the years ended September 30, 2026, and 2025:
| September 30, | ||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||
| Net operating loss carryforwards | $ | $ | ||||||||||||
| Research and development credit carryforwards | ||||||||||||||
| Capitalized research and development | ||||||||||||||
| Operating lease liability | ||||||||||||||
| Stock-based compensation | ||||||||||||||
| Accruals and reserves | ||||||||||||||
| Other | ||||||||||||||
| Gross deferred tax assets | $ | $ | ||||||||||||
| Less: Valuation allowance | ( | ( | ||||||||||||
| Net deferred tax assets | $ | $ | ||||||||||||
| Operating lease right-of-use asset | $ | ( | $ | ( | ||||||||||
| Intangible assets | ( | ( | ||||||||||||
| Gross deferred tax liabilities | $ | ( | $ | ( | ||||||||||
| Total net deferred tax asset | $ | $ | ||||||||||||
Based on the available evidence, management believes it is more likely than not that the deferred tax assets will not be fully realizable. Accordingly, the Company has provided a full valuation allowance against its deferred tax assets at September 30, 2026 and 2025. The valuation allowance was $417.5 million and $383.4 million as of September 30, 2026 and 2025, respectively. The change in the valuation allowance was mainly due to an increase in the current year net operating loss during the fiscal year 2026.
The Company intends to continue maintaining a full valuation allowance on the Company’s deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of the allowance. The release of all, or a portion, of the valuation allowance would result in the recognition of certain deferred tax assets and a decrease to income tax expense for the period the release is recorded.
As of September 30, 2026, the Company had net operating loss carryforwards of approximately $1,139.2 million and $709.8 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. Of the total federal net operating loss carryforwards, $938.2 million never expires and the remaining carryforwards of $201.0 million expire at various dates beginning in 2032 through 2039. Of the total state net operating loss carryforwards, the California State tax loss carryforwards of $362.3 million begin to expire in 2033 and the remaining carryforwards of $347.5 million for other states begin to expire at various dates beginning 2027 and beyond.
93
The Company also had federal and state research and development credit carryforwards of approximately $46.0 million and $34.8 million, respectively, at September 30, 2026. The federal credits will expire starting in 2033 if not utilized. The California research and development credits have no expiration date. Utilization of the net operating losses and tax credits is subject to annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations may result in the expiration of the net operating losses and tax credits before utilization.
The provisions of ASC 740-10, Accounting for Uncertainty in Income Taxes, prescribe a comprehensive model for the recognition, measurement, and presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. The Company has identified uncertain tax positions related to federal and state research and development credits and foreign jurisdictions.
The aggregate changes in the balance of gross unrecognized tax benefits are as follows:
| September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Unrecognized tax benefits at beginning of year | $ | $ | $ | |||||||||||||||||
| Increase related to tax positions taken during year | ||||||||||||||||||||
| Increase/(decrease) related to tax positions taken in the prior year | ( | ( | ||||||||||||||||||
| Unrecognized tax benefits at end of year | $ | $ | $ | |||||||||||||||||
The Company does not expect a material change in unrecognized tax benefits in the next twelve months. As of September 30, 2026 and 2025, approximately $0.6 million and $0.6 million of unrecognized tax benefit would, if recognized, impact the Company’s effective income tax rate, respectively.
The Company’s management determined that no accrual for interest and penalties was required as of September 30, 2026 and 2025.
The Company files federal and state income tax returns with varying statutes of limitations. All tax years remain open to examination due to the carryover of net operating losses or tax credits. The Company currently has no federal, state or foreign tax examinations in progress.
In fiscal year 2022, the Company began recognizing an additional component of total Federal tax expense, the tax on Global Intangible Low-Taxed Income (“GILTI”) provision of the Tax Act (the Tax Cuts and Jobs Act of 2017), which became applicable to the Company in fiscal year 2022. The Company elected to account for GILTI as a period cost, and therefore included GILTI expense in the effective tax rate calculation. This provision did not have a material effect on the effective tax rate for the years ended September 30, 2026, 2025 and 2024.
On July 4, 2025, H.R.1, commonly referred to as the One Big Beautiful Bill Act, was enacted in the U.S., which includes a broad range of tax reform provisions, including extending and modifying certain key Tax Cuts and Jobs Act provisions (both domestic and international). The legislation has multiple effective dates, with certain provisions effective in 2025 and others to be implemented through 2027. The Company has evaluated the impact of the guidance provided to date and determined that it did not have a material impact related to fiscal year ended September 30, 2026.
Income Tax payments
Disclosed below is a summary of income taxes paid, net of refunds, by jurisdiction pursuant to the disclosure requirements of ASU 2023-09 for the year ended September 30, 2026:
94
| Year ended September 30, | ||||||||
| (in thousands) | 2026 | |||||||
| US Federal | $ | |||||||
| US State: | ||||||||
| Texas | ||||||||
| Foreign: | ||||||||
| United Kingdom | ||||||||
| France | ||||||||
| Sweden | ||||||||
| Italy | ||||||||
| Singapore | ||||||||
| Switzerland | ||||||||
| Israel | ( | |||||||
| Other foreign jurisdictions | ||||||||
| $ | ||||||||
13. Common Stock
As of September 30, 2026, the Company had reserved sufficient shares of common stock with a par value of $0.00001 per share for issuance upon exercise of outstanding stock options. Each share of common stock is entitled to one vote. The holders of shares of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors.
In February 2025, the Company amended its Amended and Restated Certificate of Incorporation to provide for an increase in its authorized share capital. The authorized common stock increased to 200.0 million shares at a par value of $0.00001 per share.
Follow-On Public Offering
In August 2026, the Company completed an underwritten public offering of 3,593,750 shares of its common stock, par value $0.00001 per share, at a public offering price of $96.00 per share. The shares sold include 468,750 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. The offering closed on August 6, 2026. Gross proceeds from the offering were $345.0 million. Net proceeds were $327.7 million, after deducting underwriting discounts, commissions and offering expenses of $17.3 million. Because the par value of the Company's common stock is $0.00001 per share, substantially all of the net proceeds were recorded in additional paid-in capital. The shares were issued pursuant to the Company's automatic shelf registration statement on Form S-3ASR (File No. 333-296897), which was filed with the Securities and Exchange Commission on June 18, 2026, and became effective upon filing.
At-the-Market Equity Offering Program
In June 2026, the Company entered into a Sales Agreement (the "Sales Agreement") with TD Securities (USA) LLC, as sales agent (the "Sales Agent"), pursuant to which the Company may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $200.0 million through the ATM Program. A commission of up to 3.0 % of the gross proceeds from each share sold under the Sales Agreement will be paid by the Company to the Sales Agent. The Company is not obligated to sell any shares under the Sales Agreement.
The shares to be sold under the ATM Program are registered under the Company's automatic shelf registration statement on Form S-3ASR and related prospectus supplement, each filed with the SEC on June 18, 2026. The Form S-3ASR replaced the Company’s prior shelf registration statement and permits the Company to offer and sell, from time to time, common stock, preferred stock, debt securities, units and warrants in one or more offerings.
95
As of September 30, 2026, 748,909 shares had been sold under the ATM Program for net proceeds of $97.1 million after deducting discounts, commissions and offering expenses and $100.0 million capacity remained available.
14. Stock-based Compensation
2018 Equity Incentive Plan
On September 26, 2018, the board of directors adopted the 2018 Equity Incentive Plan (the 2018 Plan) as a successor to the 2013 Stock Plan (the 2013 Plan). In February 2025, as approved at the Annual Meeting of Stockholders, the Company amended its 2018 Plan, to increase the authorized shares issuable under the 2018 Plan by 3.7 million shares and eliminate the “evergreen” provision which provides for an automatic annual increase in the number of shares reserved for issuance of future awards under the Plan. The maximum aggregate number of shares that may be issued under the 2018 Plan was 10,068,911 of the Company’s common stock.
On August 22, 2023, the board of directors adopted an inducement equity incentive plan (the "Inducement Plan"). The maximum aggregate number of shares that may be issued under the Inducement Plan is 1,400,000 of the Company's common stock. The Inducement Plan permits the grant of non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares.
As of September 30, 2026, a total of 2,889,835 shares of the Company’s common stock have been reserved for issuance in connection with grant of future awards under the 2018 Plan and the Inducement Plan.
Total stock-based compensation expense recognized was as follows:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Cost of revenue | $ | $ | $ | |||||||||||||||||
| Research and development | ||||||||||||||||||||
| Selling, general and administrative | ||||||||||||||||||||
| Total stock-based compensation expense | $ | $ | $ | |||||||||||||||||
An immaterial amount of stock-based compensation expense was capitalized to inventories attributable to employees who support the manufacturing of the Company's products for the years ended September 30, 2026, 2025, and 2024. The balance sheet as of September 30, 2026 and 2025 includes $1.3 million and $1.3 million, respectively, of stock-based compensation expense primarily related to internal use software development costs that was capitalized in property and equipment.
Restricted Stock Units
Restricted stock consists of restricted stock unit awards (RSUs) which have been granted to employees and non-employee directors. The value of an RSU award is based on the Company’s stock price on the date of grant. Employee grants generally vest over four years and non-employee director grants generally vest over one year . Forfeitures of RSUs are recognized as they occur. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock.
96
Activity with respect to the Company’s restricted stock units during the year ended September 30, 2026 is as follows:
| (in thousands, except per share data) | Shares | Weighted average grant date fair value per share | ||||||||||||
Nonvested shares at September 30, 2025 | $ | |||||||||||||
| Granted | $ | |||||||||||||
| Vested/Issued | ( | |||||||||||||
| Forfeited | ( | |||||||||||||
Nonvested shares at September 30, 2026 | $ | |||||||||||||
As of September 30, 2026, there was $80.3 million of total unrecognized compensation cost related to these issuances that is expected to be recognized over a weighted average period of 2.7 years. The total grant date fair value of RSUs awarded during the year ended September 30, 2026, 2025 and 2024 were $61.5 million, $57.9 million and $42.7 million, respectively. The total grant date fair value of RSUs vested during the year ended September 30, 2026, 2025 and 2024 were $35.6 million, $37.0 million and $31.0 million, respectively.
Performance-based Restricted Stock Units
During the year ended September 30, 2026, the Company granted additional performance-based restricted stock units to executives and employees that will vest upon achievement of multiple year revenue, gross margin, and profitability metrics as determined by the board of directors. Stock compensation expense for these awards is recorded over the vesting period based on the grant date fair value of the awards and probability of the achievement of specified performance targets. The grant date fair value is equal to the closing share price of the Company’s common stock on the date of grant. These awards will vest from a minimum of 22 months to a maximum of 46 months service period following the grant date, provided that the recipient is a Company employee at the time of vesting and the performance targets applicable to each award are achieved. The percentage of these awards that vest will depend on the achievement of specified performance targets at the end of the performance period and can range from 0 % to 150 % of the number of units granted.
Activity under the PRSUs during the year ended September 30, 2026 is summarized below:
| (in thousands, except per share data) | Shares | Weighted average grant date fair value per share | ||||||||||||
Nonvested shares at September 30, 2025 | $ | |||||||||||||
| Granted | $ | |||||||||||||
| Vested/Issued | ( | |||||||||||||
| Forfeited | ( | |||||||||||||
Nonvested shares at September 30, 2026 | $ | |||||||||||||
Stock-based compensation expense for performance-based restricted stock units is recorded over the requisite service period based on the grant date fair value and management's assessment of the probability that the specified performance conditions will be achieved. As of September 30, 2026, the unrecognized compensation costs related to these awards was $28.6 million, based on management’s assessment that achievement of the performance targets at the maximum level is probable, and is expected to be recognized over a weighted average period of 1.4 years. The total grant date fair value of PRSUs awarded during the year ended September 30, 2026, 2025 and 2024 were $26.5 million, $66.9 million and $11.5 million, respectively. The total grant date fair value of PRSUs vested during the year ended September 30, 2026, 2025 and 2024 were $9.3 million, $14.0 million and $6.9 million, respectively.
Options
Options are generally granted to employees and were granted to non-employee directors until fiscal year 2022. Stock options entitle the holder to purchase, at the end of the vesting term, a specified number of shares of Company common stock at an exercise price per share equal to the closing market price of the common stock
97
on the date of grant. Stock options have a contractual life from the date of the grant and a vesting schedule as established by the board of directors. The maximum term of stock options granted under the 2018 Plan is 10 years and the awards generally vest over a four-year period. Forfeitures of options are recognized as they occur. The fair value of each service-based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company historically had been a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, it estimated its expected stock price volatility based on the historical volatility of publicly traded peer companies and utilized the “simplified” method for awards that qualify as “plain-vanilla” options. As determined under the simplified method, the expected term of stock options granted is calculated based on contractual and vesting terms of the option award, the risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award and the expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.
Options activity during the year ended September 30, 2026 is summarized below:
| (in thousands, except per share and contractual term data) | Shares | Weighted average exercise price per share | Weighted average remaining contractual term (years) | Aggregate intrinsic value | ||||||||||||||||||||||
Outstanding at September 30, 2025 | $ | $ | ||||||||||||||||||||||||
| Forfeited | ( | $ | — | $ | — | |||||||||||||||||||||
| Exercised | ( | — | ||||||||||||||||||||||||
Outstanding at September 30, 2026 | $ | $ | ||||||||||||||||||||||||
Vested and exercisable at September 30, 2026 | $ | $ | ||||||||||||||||||||||||
As of September 30, 2026, all compensation costs associated with these awards had been fully recognized. The Company did not grant any options during the year ended September 30, 2026, 2025 and 2024. The aggregate intrinsic value of stock options exercised during the year ended September 30, 2025 and 2024 were $10.6 million and $9.2 million, respectively.
2018 Employee Stock Purchase Plan
On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP). A total of 275,225 shares of the Company’s common stock were originally reserved for issuance under the 2018 ESPP. The number of shares reserved for issuance under the 2018 ESPP will be increased automatically on the first day of each fiscal year, following the fiscal year in which the 2018 ESPP becomes effective, by a number equal to the least of 249,470 shares, 1 % of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The number of shares reserved for issuance as of September 30, 2026 is as follows:
| (in thousands) | Shares available | |||||||
As of September 30, 2025 | ||||||||
| Additional shares authorized | ||||||||
| Shares issued during the period | ( | |||||||
As of September 30, 2026 | ||||||||
Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15 % of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods are beginning in February and August of each year, except the initial offering period which commenced with the initial public offering in October 2018 and ended on August 20, 2019. The fair value of ESPP purchase rights is estimated on the first day of each offering period using the Black-Scholes option-pricing model. The inputs are the Company’s historical stock price volatility, an expected term equal to the length of the purchase periods, a risk-free interest rate based on U.S. Treasury yields for matching maturities, and an expected dividend yield of zero.
98
Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85 % of the fair market value of the Company’s common stock on the first trading day of the offering period, which for the initial offering period is the price at which shares of the Company’s common stock were first sold to the public, or 85 % of the fair market value of the Company’s common stock on the last trading day of the offering period. During the years ended September 30, 2026, 2025 and 2024, the Company recorded $2.1 million, $2.4 million and $1.6 million expense related to the 2018 ESPP, respectively.
401(k) Savings Plan
During 2018, the Company adopted a 401(k) savings plan for the benefit of its employees. In January 2022, the Company modified its plan to include an employer matching contribution. The Company is required to make matching contributions to the 401(k) plan equal to 50 % of the first 6 % of wages deferred by each participating employee. For the year ended September 30, 2026 and 2025, the Company incurred expenses for employer matching contributions of $3.5 million and $3.0 million, respectively.
15. Net Loss Per Share
The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands, except per share data) | 2026 | 2025 | 2024 | |||||||||||||||||
| Numerator: | ||||||||||||||||||||
| Net loss attributable to common stockholders | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Denominator: | ||||||||||||||||||||
| Weighted-average shares used in computing net loss per share, basic and diluted | ||||||||||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | ( | $ | ( | $ | ( | ||||||||||||||
The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Shares subject to options (including performance options) to purchase common stock | ||||||||||||||||||||
| Unvested restricted stock units and performance stock units | ||||||||||||||||||||
| Shares subject to employee stock purchase plan | ||||||||||||||||||||
| Total | ||||||||||||||||||||
99
16. Segment Information
The Company operates in one operating segment, which also represents one reportable segment with the Company’s Chief Executive Officer as the chief operating decision maker (CODM). The CODM reviews the Company’s operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. Specifically, the CODM evaluates the Company’s financial performance and decides how to allocate resources based on consolidated net (loss) income, which enables the CODM to assess both the overall level of resources available and optimize distribution of resources across functions, product lines, regions and research and development programs in line with the Company's long-term corporate-wide strategic goals. The CODM also reviews disaggregated revenue by product line, geographic regions, and industry (see Note 3, Revenue).
The following table presents entity-wide significant expense categories and net loss details provided to the CODM:
| Year ended September 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Revenue | $ | $ | $ | |||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||
Cost of revenue[1] | $ | $ | $ | |||||||||||||||||
Research and development expenses[1] | ||||||||||||||||||||
Selling, general and administrative expenses[1] | ||||||||||||||||||||
| Depreciation and amortization | ||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||
| Litigation settlement costs, net of recoveries | ||||||||||||||||||||
| Impairment of long-lived assets | ||||||||||||||||||||
| Total costs and expenses | $ | $ | $ | |||||||||||||||||
| Loss from operations | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Gain on sale of business | $ | $ | $ | |||||||||||||||||
| Interest income | ||||||||||||||||||||
| Other income (expense), net | ( | ( | ||||||||||||||||||
| Income (loss) before income taxes | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Income tax expense | ( | ( | ( | |||||||||||||||||
| Net loss | $ | ( | $ | ( | $ | ( | ||||||||||||||
[1] Excludes depreciation and amortization and stock-based compensation expense
* * * * *
100
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026, which is the end of the period covered by this Annual Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were, in design and operation, effective at the reasonable assurance level as of September 30, 2026.
Management’s Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Internal control over financial reporting consists of policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) are designed and operated to provide reasonable assurance regarding the reliability of our financial reporting and our process for the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
Our management evaluated the effectiveness of our internal control over financial reporting using the criteria set forth in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the "COSO Framework"). Based on our management’s evaluation, our management concluded that our internal control over financial reporting was effective as of September 30, 2026.
The effectiveness of our internal control over financial reporting as of September 30, 2026 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report included in this section of this Form 10-K.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, as specified above. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met.
101
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Twist Bioscience Corporation
Opinion on Internal Control Over Financial Reporting
We have audited Twist Bioscience Corporation’s internal control over financial reporting as of September 30, 2026, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Twist Bioscience Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of September 30, 2026, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of September 30, 2026 and 2025, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended September 30, 2026, and the related notes and our report dated November 16, 2026 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
San Mateo, California
November 16, 2026
102
Item 9B. Other Information
Rule 10b5-1 Trading Plans
On August 5, 2026 , Adam Laponis , the Company’s Chief Financial Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). Mr. Laponis’ 10b5-1 Plan provides for the potential sale of up to 25,000 shares of the Company’s common stock and the potential gift of up to 1,500 shares of the Company’s common stock, and will expire on the earlier of November 19, 2027 or the date when all transactions under Mr. Laponis’ 10b5-1 Plan are completed.
On August 19, 2026 , Robert Chess , a member of the Company’s board of directors , adopted a 10b5-1 Plan. Mr. Chess’ 10b5-1 Plan provides for the potential sale of up to 25,588 shares of the Company’s common stock and will expire on the earlier of November 17, 2027 or the date when all shares under Mr. Chess’ 10b5-1 Plan are sold.
Other than as described above, during the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
103
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Information responsive to this item is incorporated by reference from our definitive proxy statement to be filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-K in connection with the 2027 Annual Meeting of Stockholders (the "Definitive Proxy Statement").
Item 11. Executive Compensation
Information responsive to this item is incorporated by reference from our Definitive Proxy Statement.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Information responsive to this item is incorporated by reference from our Definitive Proxy Statement.
Item 13. Certain Relationships and Related Transactions, and Director Independence
Information responsive to this item is incorporated by reference from our Definitive Proxy Statement.
Item 14. Principal Accounting Fees and Services
Information responsive to this item is incorporated by reference from our Definitive Proxy Statement.
104
PART IV
Item 15. Exhibits, Financial Statement Schedules
Documents filed as part of this report are as follows:
(a)Consolidated Financial Statements
Our Consolidated Financial Statements are included in the “Index to Consolidated Financial Statements” under Part II, Item 8 and filed as part of this Form 10-K.
(b)Consolidated Financial Statement Schedules
All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto.
(c)Exhibits
Set forth below is a list of exhibits that are being filed or incorporated by reference into this Form 10-K:
| Exhibit Number | Description | Filed / Furnished / Incorporated by Reference from Form | Incorporated by Reference from Exhibit Number | Date Filed | ||||||||||||||||||||||
| 3.1 | 10-K | 3.1 | 11/17/2025 | |||||||||||||||||||||||
| 3.2 | 8-K | 3.1 | 11/18/2022 | |||||||||||||||||||||||
| 4.1 | S-1/A | 4.1 | 10/17/2018 | |||||||||||||||||||||||
| 4.2 | Filed herewith | |||||||||||||||||||||||||
| +10.1 | S-1 | 10.1 | 10/3/2018 | |||||||||||||||||||||||
| +10.2 | 8-K | 10.2 | 2/11/2025 | |||||||||||||||||||||||
| +10.3 | S-1/A | 10.3 | 10/17/2018 | |||||||||||||||||||||||
| +10.4 | S-1 | 10.4 | 10/3/2018 | |||||||||||||||||||||||
| +10.5 | S-1/A | 10.8 | 10/17/2018 | |||||||||||||||||||||||
| +10.6 | S-8 | 99.2 | 2/12/2025 | |||||||||||||||||||||||
105
| Exhibit Number | Description | Filed / Furnished / Incorporated by Reference from Form | Incorporated by Reference from Exhibit Number | Date Filed | ||||||||||||||||||||||
| 10.7 | S-1 | 10.11 | 10/3/2018 | |||||||||||||||||||||||
| 10.7.1 | 10-Q | 10.2 | 5/1/2019 | |||||||||||||||||||||||
| 10.7.2 | 10-K | 10.7.2 | 11/17/2025 | |||||||||||||||||||||||
| 10.7.3 | Filed herewith | |||||||||||||||||||||||||
| 10.8* | 8-K | 10.1 | 12/22/2020 | |||||||||||||||||||||||
| 10.8.1* | 8-K | 10.1 | 4/16/2021 | |||||||||||||||||||||||
| 10.9* | Filed herewith | |||||||||||||||||||||||||
| +10.10 | 10-Q | 10.1 | 2/7/2023 | |||||||||||||||||||||||
| +10.11 | 10-Q | 10.1 | 2/2/2024 | |||||||||||||||||||||||
| +10.12 | 10-K | 10.14 | 11/18/2024 | |||||||||||||||||||||||
| +10.13 | 10-K | 10.16 | 11/18/2024 | |||||||||||||||||||||||
106
| Exhibit Number | Description | Filed / Furnished / Incorporated by Reference from Form | Incorporated by Reference from Exhibit Number | Date Filed | ||||||||||||||||||||||
| +10.14 | 10-K | 10.18 | 11/18/2024 | |||||||||||||||||||||||
| +10.15 | 10-K | 10.19 | 11/18/2024 | |||||||||||||||||||||||
| 10.16* | 10-Q | 10.1 | 8/4/2025 | |||||||||||||||||||||||
| 10.17* | 10-Q | 10.2 | 8/4/2025 | |||||||||||||||||||||||
| 10.18* | 10-Q | 10.3 | 8/4/2025 | |||||||||||||||||||||||
| 10.19 | S-3ASR | 1.2 | 6/18/2026 | |||||||||||||||||||||||
| 19.1 | Filed herewith | |||||||||||||||||||||||||
| 21.1 | Filed herewith | |||||||||||||||||||||||||
| 23.1 | Filed herewith | |||||||||||||||||||||||||
| 31.1 | Filed herewith | |||||||||||||||||||||||||
| 31.2 | Filed herewith | |||||||||||||||||||||||||
| 32.1 | Furnished herewith | |||||||||||||||||||||||||
107
| Exhibit Number | Description | Filed / Furnished / Incorporated by Reference from Form | Incorporated by Reference from Exhibit Number | Date Filed | ||||||||||||||||||||||
| 32.2 | Furnished herewith | |||||||||||||||||||||||||
| 97.1 | 10-K | 97.1 | 11/18/2024 | |||||||||||||||||||||||
| 101.INS | XBRL Instance Document | Filed herewith | ||||||||||||||||||||||||
| 101.SCH | XBRL Taxonomy Extension Schema Document | Filed herewith | ||||||||||||||||||||||||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith | ||||||||||||||||||||||||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith | ||||||||||||||||||||||||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | Filed herewith | ||||||||||||||||||||||||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith | ||||||||||||||||||||||||
| 104 | Cover page from the Company’s Annual Report on Form 10-K for the year ended September 30, 2026, formatted in Inline XBRL | |||||||||||||||||||||||||
| + | Indicates a management contract or compensatory plan. | ||||
| * | Certain information in this exhibit and exhibits or schedules thereto has been omitted pursuant to Regulation S-K Item 601(a)(5) and/or Item 601(b)(10)(iv) because it is both (i) not material and (ii) the type that Twist Bioscience Corporation customarily and actually treats as private and confidential. An unredacted copy of the exhibit or schedule will be furnished on a supplemental basis to the SEC upon request; provided that Twist Bioscience Corporation may request confidential treatment for any exhibit or schedule so furnished. | ||||
Item 16. Form of 10-K Summary
Not applicable
108
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| November 16, 2026 | Twist Bioscience Corporation | |||||||
| By: | /s/ Emily M. Leproust | |||||||
| Emily M. Leproust | ||||||||
| Chief Executive Officer | ||||||||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
| Signature | Title | Date | ||||||||||||
| /s/ Emily M. Leproust | Chief Executive Officer and | November 16, 2026 | ||||||||||||
| Emily M. Leproust | Chair of the Board of Directors (principal executive officer) | |||||||||||||
| /s/ Adam Laponis | Chief Financial Officer (principal financial | November 16, 2026 | ||||||||||||
| Adam Laponis | officer) | |||||||||||||
| /s/ Robert F. Werner | Chief Accounting Officer (principal | November 16, 2026 | ||||||||||||
| Robert F. Werner | accounting officer) | |||||||||||||
| /s/ Nelson C. Chan | Director | November 16, 2026 | ||||||||||||
| Nelson C. Chan | ||||||||||||||
| /s/ Robert Chess | Director | November 16, 2026 | ||||||||||||
| Robert Chess | ||||||||||||||
| /s/ Keith Crandell | Director | November 16, 2026 | ||||||||||||
| Keith Crandell | ||||||||||||||
| /s/ Jan Johannessen | Director | November 16, 2026 | ||||||||||||
| Jan Johannessen | ||||||||||||||
| /s/ Robert Ragusa | Director | November 16, 2026 | ||||||||||||
| Robert Ragusa | ||||||||||||||
| /s/ Trynka Shineman Blake | Director | November 16, 2026 | ||||||||||||
| Trynka Shineman Blake | ||||||||||||||
| /s/ Melissa Starovasnik | Director | November 16, 2026 | ||||||||||||
| Melissa Starovasnik | ||||||||||||||
109
Exhibit 4.2
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Twist Bioscience Corporation (“Twist,” “we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock. The following is a description of the material terms of our Amended and Restated Certificate of Incorporation dated as of November 2, 2018, as amended by the Certificate of Amendment filed with the Secretary of State of the State of Delaware on February 10, 2025 (the “Amended and Restated Certificate of Incorporation”) and our Bylaws as amended and restated effective November 17, 2022 (the “Amended and Restated Bylaws”) and of specified provisions of the Delaware General Corporation Law (the “DGCL”). The following description is intended as a summary only and is qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and the DGCL. We encourage you to read our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and the applicable provisions of the DGCL for more information.
General
Our Amended and Restated Certificate of Incorporation authorizes us to issue up to 200,000,000 shares of common and 10,000,000 shares of preferred stock, par value $0.00001 per share. As of September 30, 2026, 67,813,364 shares of common stock were issued and outstanding and no shares of preferred stock were issued and outstanding.
Common stock
The holders of Twist’s common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. Cumulative voting for the election of directors is not provided for in the Amended and Restated Certificate of Incorporation, which means the holders of a majority of Twist’s shares of common stock can elect all of the directors then standing for election. Subject to preferences that may be applicable to any outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available for that purpose. In the event of liquidation, dissolution or winding up of the Company, the holders of Twist’s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to the prior distribution rights of any outstanding preferred stock. The common stock has no preemptive or conversion rights or other subscription rights. All of the outstanding shares of common stock are fully paid and non-assessable.
Anti-takeover effects of Delaware law and Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
The Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws contain certain provisions that could have the effect of delaying, deterring or preventing another party from acquiring control of Twist. These provisions and certain provisions of Delaware law, which are summarized below, may discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of Twist to negotiate first with Twist’s board of directors. Twist believes that the benefits of increased protection of Twist’s potential ability to negotiate more favorable terms with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire Twist.
Undesignated preferred stock
As discussed above, Twist’s board of directors has the ability to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of Twist. These and
other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of Twist.
Limits on ability of stockholders to act by written consent or call a special meeting
The Amended and Restated Certificate of Incorporation provides that Twist’s stockholders may not act by written consent, which may lengthen the amount of time required to take stockholder actions. As a result, a holder controlling a majority of Twist’s capital stock would not be able to amend Twist’s bylaws or remove directors without holding a meeting of Twist’s stockholders called in accordance with Twist’s bylaws.
In addition, the Amended and Restated Certificate of Incorporation provides that special meetings of the stockholders may be called only by (i) the majority of Twist’s board of directors, (ii) the chairperson of the board of directors, (iii) the chief executive officer or (iv) the president (in the absence of a chief executive officer). Stockholders may not call a special meeting, which may delay the ability of Twist’s stockholders to force consideration of a proposal or for holders controlling a majority of Twist’s capital stock to take any action, including the removal of directors.
Requirements for advance notification of stockholder nominations and proposals
The Amended and Restated Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of Twist’s board of directors or a committee of
Twist’s board of directors. These provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of Twist.
Board classification
Twist’s board of directors is divided into three classes, one class of which is elected each year by Twist’s stockholders. The directors in each class serve three-year terms. For more information on the classified board, see Part III. Item 10 “Directors, executive officers and corporate governance—Board Composition” in Twist’s most recent Annual Report on Form 10-K filed with the SEC. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of Twist as it is more difficult and time-consuming for stockholders to replace a majority of the directors on a classified board.
No cumulative voting
The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws do not provide for cumulative voting in the election of directors. Cumulative voting allows a stockholder to vote a portion or all of its shares for one or more candidates for seats on the board of directors. Without cumulative voting, a minority stockholder may not be able to gain as many seats on Twist’s board of directors as the stockholder would be able to gain if cumulative voting were permitted. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on Twist’s board of directors to influence the decision of Twist’s board regarding a takeover.
Amendment of charter and bylaws provisions
The amendment of the above provisions of the Amended and Restated Certificate of Incorporation will require approval by holders of at least two thirds of Twist’s outstanding capital stock entitled to vote generally in the election of directors. The amendment of certain provisions of Twist’s bylaws will also require approval by the holders of at least two thirds of Twist’s outstanding capital stock entitled to vote generally in the election of directors.
Delaware anti-takeover statute
Twist is subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless:
•prior to the date of the transaction, Twist’s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
•upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, calculated as provided under Section 203; or
•at or subsequent to the date of the transaction, the business combination is approved by Twist’s board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.
Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock. Twist expects that the existence of this provision will have an anti-takeover effect with respect to transactions Twist’s board of directors does not approve in advance. Twist anticipates that Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.
The provisions of Delaware law and the provisions of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws, could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they might also inhibit temporary fluctuations in the market price of Twist’s common stock that often result from actual or rumored hostile takeover attempts. These provisions might also have the effect of preventing changes in Twist’s management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests.
Exhibit 10.7.3
THIRD AMENDMENT TO LEASE
THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of September 18, 2026 (the “Effective Date”), by and between 681 GATEWAY, LLC, a Delaware limited liability company (“Landlord”), and TWIST BIOSCIENCE CORPORATION, a Delaware corporation (“Tenant”).
RECITALS
A.Landlord, as the successor-in-title to ARE-San Francisco No. 32, LLC, a Delaware limited liability company, and Tenant are now parties to that certain Lease Agreement dated as of March 21, 2018 (the “Original Lease”), as amended by that certain (i) First Amendment to Lease dated as of March 21, 2019 (the “First Amendment”), and (ii) Second Amendment to Lease dated as of November 13, 2025 (the “Second Amendment”, and together with the Original Lease and First Amendment, collectively, the “Lease”). Pursuant to the Original Lease and First Amendment, Tenant leases from Landlord certain premises containing approximately 60,971 rentable square feet, consisting of (i) the entire first floor of the Building containing approximately 28,472 rentable square feet, and (ii) the entire second floor of the Building containing approximately 32,499 rentable square feet (collectively, the “Original Premises”) in a building located at 681 Gateway Boulevard, South San Francisco, California (the “Building”), which Original Premises are more particularly described in the Lease. Pursuant to the Second Amendment, Tenant agreed to lease from Landlord certain additional premises in the Building consisting of the entire third floor of the Building containing approximately 33,000 rentable square feet (the “3rd Floor Expansion Premises”). The commencement date and lease term for the 3rd Floor Expansion Premises has yet to occur as of the Effective Date. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.
B.The Term of the Lease for the Original Premises is currently scheduled to expire on June 30, 2036 (the “Scheduled Second Amendment Expiration Date”).
C.Landlord and Tenant desire to amend the Lease to, among other things, (i) modify certain terms of the Lease and Second Amendment pertaining to the 3rd Floor Expansion Premises, (ii) further expand the size of the Premises leased by Tenant under the Lease by adding the entire fourth (4th) floor of the Building, containing approximately 33,000 rentable square feet, as shown on Exhibit A attached hereto (the “4th Floor Expansion Premises”), and (iii) extend the Term of the Lease for one (1) additional year through June 30, 2037 (the “Third Amendment Expiration Date”).
NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:
1.Expansion Premises.
a.3rd Floor Expansion Premises. With respect to the pending addition of the 3rd Floor Expansion Premises under the Second Amendment, notwithstanding anything in the Second Amendment to the contrary, effective as of the Effective Date, certain terms pertaining to such expansion shall be modified as follows:
(i)the “Expansion Premises Commencement Date” under Section 2 of the Second Amendment shall be revised to be the date that is the later to occur of (1) January 1, 2027, and (2) the date that Landlord delivers the 3rd Floor Expansion Premises to Tenant with the 3rd Floor Demolition Work Substantially Completed (as such terms are defined below). The Expansion Premises Commencement Date is currently anticipated to occur on January 1, 2027 (the “Anticipated Expansion Premises Commencement Date”).
(ii)the “Expansion Premises Rent Commencement Date” under Section 2 of the Second Amendment shall be revised to be August 1, 2027; provided, that: (A) such date shall be extended on a day for day basis for each day that Landlord fails to deliver the 3rd Floor Expansion Premises to Tenant with the 3rd Floor Demolition Work Substantially Completed beyond the Anticipated Expansion Premises Commencement Date, except where any such delays are caused by any Tenant Delays (as defined below); and (B) such date shall be accelerated to be the date that Tenant commences business operations in the 3rd Floor Expansion Premises, if applicable.
b.4th Floor Expansion Premises. In addition to the Original Premises and the 3rd Floor Expansion Premises, commencing on the 4th Floor Expansion Premises Commencement Date (as defined in Section 2 below), Landlord shall lease to Tenant and Tenant shall lease from Landlord the 4th Floor Expansion Premises.
2.Delivery of 4th Floor Expansion Premises. The “4th Floor Expansion Premises Commencement Date” shall be the date that is the later to occur of (1) January 1, 2027, and (2) the date that Landlord delivers the 4th Floor Expansion Premises to Tenant with the 4th Floor Demolition Work Substantially Completed (as such terms are defined below). The 4th Floor Expansion Premises Commencement Date is currently anticipated to occur on January 1, 2027 (the “Anticipated 4th Floor Expansion Premises Commencement Date”). Landlord shall deliver the 4th Floor Expansion Premises to Tenant on the 4th Floor Expansion Premises Commencement Date for Tenant’s construction of the Tenant Improvements pertaining to the 4th Floor under the Second Amendment Work Letter attached to the Second Amendment (as modified under Section 8(b) below, with all references herein to the Second Amendment Work Letter meaning the same, as so modified). If Landlord fails to timely deliver the 4th Floor Expansion Premises, Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, and the Lease with respect to the 4th Floor Expansion Premises shall not be void or voidable. As used herein, the term “Tenant Improvements” shall have the meaning set forth for such term in the Second Amendment Work Letter.
The “4th Floor Expansion Premises Rent Commencement Date” shall be August 1, 2027; provided, that: (A) such date shall be extended on a day for day basis for each day that Landlord fails to deliver the 4th Floor Expansion Premises to Tenant with the 4th Floor Demolition Work Substantially Completed beyond the Anticipated 4th Floor Expansion Premises Commencement Date, except where any such delays are caused by any Tenant Delays (as defined below); and (B) such date shall be accelerated to be the date that Tenant commences business operations in the 4th Floor Expansion Premises, if applicable. The period commencing on the 4th Floor Expansion Premises Commencement Date and continuing through the day immediately preceding the 4th Floor Expansion Premises Rent Commencement Date may be referred to herein as the “4th Floor Expansion Premises TI Construction Abatement Period.” In addition: (A) Base Rent payable with respect to the Original Premises and 3rd Floor Expansion Premises will also be abated during the Original Premises Base Rent Abatement Period and the Expansion Premises Base Rent Abatement Period (as such terms are defined in Section 5 of the Second Amendment), respectively, as expressly provided for in Section 5 of the Second Amendment, and as amended by Sections 5(a) and (b) below, respectively); and (B) Base Rent payable with respect to the 4th Floor Expansion Premises will also be abated during the 4th Floor Expansion Premises Base Rent Abatement Period (as defined in Section 5 below), as expressly provided for in Section 5 below.
Upon the request of Landlord, Tenant shall execute and deliver a written acknowledgment of the 4th Floor Expansion Premises Commencement Date and the 4th Floor Expansion Premises Rent Commencement Date in the form of the “Acknowledgement of 4th Floor Expansion Premises Commencement Date” attached hereto as Exhibit C; provided, however, Landlord or Tenant’s failure to execute and deliver such acknowledgment shall not affect either party’s rights hereunder (for purposes of clarification, the Acknowledgement of Expansion Premises Commencement Date under the Second Amendment and the Acknowledgement of 4th Floor Expansion Premises Commencement Date hereunder may be combined into one singular acknowledgement by the parties, if applicable).
Except as otherwise expressly set forth in this Third Amendment (including Landlord’s obligations with respect to the Substantial Completion of the 4th Floor Demolition Work [as such terms are defined in Section 8(a)(i) below] and the 4th Floor Expansion Premises Warranty Items [as defined hereinbelow]): (i) Tenant shall accept the 4th Floor Expansion Premises in their condition as of the 4th Floor Expansion Premises Commencement Date; (ii) Landlord shall have no obligation for any defects in the 4th Floor Expansion Premises; and (iii) Tenant’s taking possession of the 4th Floor Expansion Premises shall be conclusive evidence that Tenant accepts the 4th Floor Expansion Premises and that the 4th Floor Expansion Premises were in good condition at the time possession was taken.
For the period of 180 consecutive days after the 4th Floor Expansion Premises Commencement Date, Landlord shall, at its sole cost and expense (which shall not constitute an Operating Expense), be responsible for any repairs that are required to be made to the Building Systems serving the 4th Floor Expansion Premises exclusively (such repairs, collectively, the “4th Floor Expansion Premises Warranty Items”), unless Tenant or any Tenant Party was responsible for the cause of such repair, in which case Tenant shall pay the cost.
Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of all or any portion of the 4th Floor Expansion Premises, and/or the suitability of the 4th Floor Expansion Premises for the conduct of Tenant’s business, and Tenant waives any implied warranty that the 4th Floor Expansion Premises are suitable for the Permitted Use.
3.Premises. Notwithstanding anything in Section 3 of the Second Amendment to the contrary:
a.Effective as of the Effective Date, Section 3(a) of the Second Amendment shall be deleted and in lieu thereof:
(i)Following the Expansion Premises Commencement Date, the terms “Premises” and “Rentable Area of Premises” on page 1 of the Lease shall be amended to reflect that (A) the “Premises” shall be revised to include the 3rd Floor Expansion Premises; and (B) the “Rentable Area of the Premises” shall be increased by 33,000 rentable square feet of the Expansion Premises (i.e., the 3rd Floor Expansion Premises);
(ii)Following the 4th Floor Expansion Premises Commencement Date, the terms “Premises” and “Rentable Area of Premises” on page 1 of the Lease shall be amended to reflect that (A) the “Premises” shall be revised to include the 4th Floor Expansion Premises; and (B) the “Rentable Area of the Premises” shall be increased by 33,000 rentable square feet of the 4th Floor Expansion Premises.
(iii)As a result of the foregoing, following the Expansion Premises Commencement Date and the 4th Floor Expansion Premises Commencement Date, the terms “Premises” and “Rentable Area of Premises” on page 1 of the Lease shall be deleted in their entirety and replaced with the following:
“Premises: That portion of the Building, containing approximately 126,971 rentable square feet, consisting of (i) the entire first floor of the Building containing approximately 28,472 rentable square feet, (ii) the entire second floor of the Building containing approximately 32,499 rentable square feet, (iii) the entire third floor of the Building containing approximately 33,000 rentable square feet, and (iv) the entire 4th floor of the Building containing approximately 33,000 rentable square feet, all as reasonably determined by Landlord, as shown on Exhibit A”
“Rentable Area of Premises: 126,971 sq. ft.”
b.As of the Expansion Premises Commencement Date and the 4th Floor Expansion Premises Commencement Date, as the case may be, Exhibit A attached to the Lease shall be amended to include the 3rd Floor Expansion Premises and 4th Floor Expansion
Premises, as the case may be, as described on Exhibit A attached to this Third Amendment.
4.Intentionally Omitted.
5.Base Rent.
a.Original Premises. Tenant shall continue to pay Base Rent with respect to the Original Premises as provided for under Section 5(a) of the Second Amendment through the Scheduled Second Amendment Expiration Date, subject to abatement during the Original Premises Base Rent Abatement Period as defined and set forth therein; provided, however, notwithstanding anything therein to the contrary, the Original Premises Base Rent Abatement Period shall be extended by one (1) additional calendar month, such that the same shall be a sixteen (16) month period ending on October 31, 2027 (as opposed to the 15-month period described in Section 5(a) of the Second Amendment that ends on September 30, 2027). Commencing on the 1-Year Extension Term Commencement Date (as defined below), Tenant shall continue to pay Base Rent with respect to the Original Premises as further increased on each Second Amendment Adjustment Date by multiplying the Base Rent payable with respect to the Original Premises immediately before such Second Amendment Adjustment Date by 3% and adding the resulting amount to the Base Rent payable with respect to the Original Premises immediately before such Second Amendment Adjustment Date.
b.3rd Floor Expansion Premises. Commencing on the Expansion Premises Rent Commencement Date, Tenant shall pay Base Rent with respect to the 3rd Floor Expansion Premises as provided for under Section 5(b) of the Second Amendment through the Scheduled Second Amendment Expiration Date, subject to abatement during the Expansion Premises Base Rent Abatement Period as defined and set forth therein; provided, however, (i) notwithstanding anything therein to the contrary, the Expansion Premises Base Rent Abatement Period shall be extended for one (1) additional calendar month, such that the same shall be a thirteen (13) month period (as opposed to the existing 12-month period described in Section 5(b) of the Second Amendment), and (ii) commencing on the 1-Year Extension Term Commencement Date, Tenant shall continue to pay Base Rent with respect to the 3rd Floor Expansion Premises as further increased on each Second Amendment Adjustment Date by multiplying the Base Rent payable with respect to the 3rd Floor Expansion Premises immediately before each Second Amendment Adjustment Date by 3% and adding the resulting amount to the Base Rent payable with respect to the 3rd Floor Expansion Premises immediately before such Second Amendment Adjustment Date.
c.4th Floor Expansion Premises. Commencing on the 4th Floor Expansion Premises Rent Commencement Date, in addition to Tenant’s right to abatement of Base Rent with respect to the Original Premises and the 3rd Floor Expansion Premises (as set forth in the Second Amendment, and as amended pursuant to Sections 5(a) and 5(b) above, respectively), Tenant shall pay Base Rent with respect to the 4th Floor Expansion Premises in the amount of $5.35 per rentable square foot of the 4th Floor Expansion Premises per month. Base Rent payable with respect to the 4th Floor Expansion Premises shall be increased on each Second Amendment Adjustment Date (as defined in the Second Amendment) thereafter through the Third Amendment Expiration Date by multiplying the Base Rent payable with respect to the 4th Floor Expansion Premises immediately before each Second Amendment Adjustment Date by 3% and adding the resulting amount to the Base Rent payable with respect to the 4th Floor Expansion Premises immediately before such Second Amendment Adjustment Date.
Notwithstanding anything to the contrary contained in this Third Amendment, so long as Tenant is not in default under the Lease beyond any applicable notice and cure periods, Base Rent with respect to the 4th Floor Expansion Premises only shall be abated for a period of 18 months commencing on the 4th Floor Expansion Premises Rent Commencement Date and ending on the last day of the 18th month
thereafter (the “4th Floor Expansion Premises Base Rent Abatement Period”). For the avoidance of doubt, Tenant shall be required to pay Operating Expenses, Utilities and all other amounts payable under the Lease with respect to the 4th Floor Expansion Premises during the 4th Floor Expansion Premises Base Rent Abatement Period.
6.Operating Expenses. Notwithstanding anything in Section 6 of the Second Amendment:
a.Commencing on the Expansion Premises Commencement Date, “Tenant’s Share of Operating Expenses” on page 1 of the Lease shall be increased by 25.99%, which shall be the applicable Tenant’s Share of Operating Expenses pertaining to the 3rd Floor Expansion Premises.
b.Commencing on the 4th Floor Expansion Premises Commencement Date, “Tenant’s Share of Operating Expenses” on page 1 of the Lease shall be increased by 25.99% which shall be the applicable Tenant’s Share of Operating Expenses pertaining to the 4th Floor Expansion Premises.
c.As a result of the foregoing, following the Expansion Premises Commencement Date and the 4th Floor Expansion Premises Commencement Date, the term “Tenant’s Share of Operating Expenses” on page 1 of the Lease shall be deleted in its entirety and replaced with the following:
“Tenant’s Share of Operating Expenses: 100.00%”
d.Notwithstanding the foregoing, Tenant shall have no obligation to pay Tenant’s Share of Operating Expenses pertaining to the 3rd Floor Expansion Premises during the Expansion Premises TI Construction Abatement Period, and/or Tenant’s Share of Operating Expenses pertaining to the 4th Floor Expansion Premises during the 4th Floor Expansion Premises TI Construction Abatement Period. For the avoidance of doubt, Tenant shall be required to pay Operating Expenses with respect to (i) the Original Premises, during the Original Premises Base Rent Abatement Period, (ii) the 3rd Floor Expansion Premises, during the Expansion Premises Base Rent Abatement Period, and (iii) the 4th Floor Expansion Premises, during the 4th Floor Expansion Premises Base Rent Abatement Period, including, without limitation, applicable administration rent that Tenant would have been required to pay in the absence of there being an Original Premises Base Rent Abatement Period, Expansion Premises Base Rent Abatement Period and 4th Floor Expansion Premises Base Rent Abatement Period.
7.Term. Notwithstanding anything to the contrary contained in the Lease, the Term with respect to the Original Premises is hereby extended for a term of 1 year commencing on July 1, 2036 (the “1-Year Extension Term Commencement Date”) and expiring on the Third Amendment Expiration Date (i.e., June 30, 2037). For the avoidance of doubt: (i) the Term with respect to the Original Premises, which is currently scheduled to expire on the Second Amendment Expiration Date, is extended to expire on the Third Amendment Expiration Date (i.e., June 30, 2037); (ii) the Term of the 3rd Floor Expansion Premises shall be for a term that is coterminous with the Term of the Original Premises (as so extended), commencing on the Expansion Premises Commencement Date and expiring on the Third Amendment Expiration Date; and (iii) the Term of the 4th Floor Expansion Premises shall be for a term that is coterminous with the Term of the Original Premises (as so extended), commencing on the 4th Floor Expansion Premises Commencement Date and expiring on the Third Amendment Expiration Date.
8.Landlord’s Demolition Work; Tenant Improvements; Allowances.
a.Landlord’s Demolition Work.
(i)Work; Completion. Landlord shall, using Building standard materials, in a good and workmanlike manner and in accordance with Building standards and Legal Requirements, perform the following work (collectively, “Landlord's Demolition
Work”): (i) with respect to the 3rd Floor Expansion Premises, that certain respective demolition work pertaining thereto set forth on Exhibit B attached hereto (the “3rd Floor Demolition Work”); and (ii) with respect to the 4th Floor Expansion Premises, that certain respective demolition work pertaining thereto set forth on Exhibit B attached hereto (the “4th Floor Demolition Work”). All design, permitting and construction costs and expenses connection with Landlord's Demolition Work shall be paid by Landlord as a deduction from the Total TI Allowance, as further set forth in Section 8(b)(ii) below. Landlord shall retain Dome Construction to perform Landlord’s Demolition Work. For purposes of this Third Amendment: (A) the 3rd Floor Demolition Work shall be deemed “Substantially Completed” (and “Substantial Completion of” the 3rd Floor Demolition Work shall occur) upon the completion of the 3rd Floor Demolition Work substantially in accordance with the applicable provisions of this Section 8(a)(i) and of Exhibit B attached hereto, with the exception of any minor punch-list items; and (B) the 4th Floor Demolition Work shall be deemed “Substantially Completed” (and “Substantial Completion of” the 4th Floor Demolition Work shall occur) upon the completion of the 4th Floor Demolition Work substantially in accordance with the applicable provisions of this Section 8(a)(i) and of Exhibit B attached hereto, with the exception of any minor punch-list items. Landlord shall use commercially reasonable efforts to cause Substantial Completion of Landlord’s Demolition Work (i.e., both the 3rd Floor Demolition Work and the 4th Floor Demolition Work) to occur on or before January 1, 2027. If Landlord shall suffer any actual delays in causing the 3rd Floor Demolition Work and/or 4th Floor Demolition Work, as the case may be, to be Substantially Completed as a direct result of any acts or omissions of Tenant, or its agents, contractors or employees when, as to any omission, such party has a duty to act (collectively, “Tenant Delays”), then, notwithstanding anything to the contrary set forth in this Lease and regardless of the actual date the 3rd Floor Demolition Work and/or 4th Floor Demolition Work, as the case may be, is Substantially Completed, the Expansion Premises Commencement Date (with respect to the 3rd Floor Demolition Work) and/or the 4th Floor Expansion Premises Commencement Date (with respect to the 4th Floor Demolition Work), as the case may be, shall be deemed to be the date the same would have occurred if no such Tenant Delays, as set forth above, had occurred; provided, however, (1) no Tenant Delay as set forth in this Section 8(a)(i) above shall be deemed to have occurred unless and until Landlord has provided written notice to Tenant (the “Tenant Delay Notice”) specifying the action or inaction by Tenant which Landlord contends constitutes the Tenant Delay, and (2) if such action or inaction is not cured by Tenant within one (1) business day of receipt of such Tenant Delay Notice (the “Tenant Delay Grace Period”), then a Tenant Delay pursuant to this Section 8(a)(i) above, as set forth in such Tenant Delay Notice, shall be deemed to have occurred commencing as of the expiration of the Tenant Delay Grace Period; provided that Tenant shall only be permitted an aggregate of five (5) days of Tenant Delay Grace Period and, thereafter, a Tenant Delay pursuant to Section 8(a)(i) shall commence upon the delivery of the Tenant Delay Notice to Tenant.
(ii)Inconveniences. The parties hereby agree that Landlord's Demolition Work may be performed during Tenant's occupancy of certain portions of the Premises, and in connection therewith, Tenant hereby acknowledges and agrees: (A) to accept any and all inconveniences associated with the performance of Landlord's Demolition Work which may occur during such occupancy including, without limitation, dust, noise, etc; (B) that the performance of Landlord's Demolition Work shall in no way constitute a constructive eviction of the Tenant under the Lease nor entitle Tenant to any abatement of rent payable pursuant to the Lease, as hereby amended; and (C) Landlord shall not be liable to Tenant for, and Tenant shall not be entitled to any compensation or damages from Landlord for, loss of the use of all or any part of the Premises or of any
personal property or improvements therein resulting from the performance of Landlord's Demolition Work, or for any inconvenience or annoyance occasioned thereby or for any injury to or interference with Tenant's business, except for any injury to persons or damage to property (but not loss of or interference with business or other consequential damages) to the extent caused by Landlord's gross negligence or intentional misconduct and not insured or required to be insured by Tenant under the Lease, as hereby amended. Notwithstanding the foregoing, in the performance of Landlord’s Demolition Work, Landlord shall not unreasonably interfere with Tenant’s access to and/or use of the Original Premises for the permitted use thereof under the Lease, as hereby amended.
b.Tenant Improvements.
(i)General Understanding and Application of Second Amendment Work Letter. The parties hereby acknowledge and agree as follows, all as more particularly set forth in and pursuant to the terms and conditions of this Section 8(b): (i) the Second Amendment Work Letter attached to the Second Amendment currently contemplates and governs the design and construction of certain “Tenant Improvements” to the Original Premises and the 3rd Floor Expansion Premises (therein the “Expansion Premises”), while providing the “Total TI Allowance” thereunder; and (ii) the parties now desire to expand the application of the Second Amendment Work Letter to include the design and construction of certain improvements to the 4th Floor Expansion Premises, while supplementing the Total TI Allowance and revising certain terms and conditions with respect to the use thereof, as so supplemented; and (iii) as such, Tenant may design and construct certain initial improvements for the Original Premises, 3rd Floor Expansion Premises and/or 4th Floor Expansion Premises (concurrently, or on a phased basis, at Tenant’s election) otherwise pursuant to and in accordance with the terms and conditions of the Second Amendment Work Letter as generically modified to apply to the different spaces comprising the overall Premises, and as further specifically modified hereinbelow.
(ii)Expansion of “Tenant Improvements”. Effective as of the Effective Date, the term “Tenant Improvements” set forth in Section 2(a) of the Second Amendment Work Letter shall be expanded to mean and refer to improvements to the Original Premises, 3rd Floor Expansion Premises and the 4th Floor Expansion Premises, as further defined herein. All references in the Second Amendment Tenant Work Letter to the Original Premises and the Expansion Premises (i.e., 3rd Floor Expansion Premises) implying the same are the total scope of space covered by the Second Amendment Work Letter shall be revised to mean and refer to the Original Premises, 3rd Floor Expansion Premises and 4th Floor Expansion Premises, unless such reference would be illogical or inconsistent with the provisions of the Lease, as hereby amended (including, without limitation, as a circumvention of any express limits on or applications of allowances to certain scopes of the Premises).
(iii)Modification of “Total TI Allowance”. Effective as of the Effective Date, the “Total TI Allowance” set forth in Section 5(b) of the Second Amendment Work Letter shall be revised as follows:
A.For 1st, 2nd and 3rd Floors. As the “Base Allowance” thereunder, Tenant shall continue to be entitled to the total aggregate amount of $23,022,895.00 (i.e., $245.00 per rentable square foot of the Original Premises and the 3rd Floor Expansion Premises, but not expanded to include the square footage of the 4th Floor Expansion Premises in such calculation); provided, that, except as otherwise defined and set forth hereinbelow as the Cross-Funding Ability: (1) a maximum portion
thereof in the total aggregate amount of $14,000,000.00 shall only be used with respect to the TI Costs pertaining to the demolition, design and construction of Tenant Improvements for the 3rd Floor Expansion Premises, including the 3rd Floor Demolition Work (the “3rd Floor TI Allowance”); and (2) a maximum portion thereof in the total aggregate amount of $9,022,895 shall only be used with respect to the TI Costs pertaining to the design and construction of Tenant Improvements for the Original Premises (the “Original Premises TI Allowance”). Tenant may not cross-fund any amounts between the 3rd Floor TI Allowance for the 3rd Floor Expansion Premises and/or the Original Premises TI Allowance for the Original Premises (and/or with respect to either specific allowance allocation, to any TI Costs pertaining to the design and construction of Tenant Improvements for the 4th Floor Expansion Premises), except that, upon written notice delivered by Tenant to Landlord on or before June 30, 2027, Tenant may elect to cross-fund up to a total aggregate amount of $1,500,000.00 from the 3rd Floor TI Allowance (that is unused and/or not then designated for use) to the design and construction of Tenant Improvements for the 4th Floor Expansion Premises and/or the Original Premises, as the case may be (the “Cross-Funding Ability”). Notwithstanding anything in the Second Amendment Tenant Work Letter and/or this Third Amendment to the contrary, but subject to application to Moving Costs as defined and set forth in Section 8(b)(v) below: (1) Tenant shall have no right to any portion of the 3rd Floor TI Allowance that is not disbursed on or before September 30, 2027 (except for any amounts thereof where on or before such date Tenant has submitted to Landlord a complete draw request therefor under Section 5(e) of the Second Amendment Work Letter [a “Complete Draw Request”], in which event Landlord’s obligation to disburse such amounts pursuant to such Complete Draw Request properly requisitioned shall survive such outside date); and (2) Tenant shall have no right to any portion of the Original Premises TI Allowance (including any cross-funded amounts) that is not disbursed on or before December 31, 2028 (except for any amounts thereof where on or before such date Tenant has submitted to Landlord a Complete Draw Request therefor, in which event Landlord’s obligation to disburse such amounts pursuant to such Complete Draw Request properly requisitioned shall survive such outside date).
B.FF&E Allowance for 1st, 2nd and 3rd Floors. As the “FF&E Allowance” thereunder, Tenant shall continue to be entitled to the total aggregate amount of $1,409,565.00 (i.e., $15.00 per rentable square foot of the Original Premises and the 3rd Floor Expansion Premises, but not expanded to include the square footage of the 4th Floor Expansion Premises in such calculation); provided, that, Tenant shall have no right to cross-fund and amounts thereof and shall have no right to any portion of the FF&E Allowance that is not disbursed on or before December 31, 2028 (except for any amounts thereof where on or before such date Tenant has submitted to Landlord a Complete Draw Request therefor, in which event Landlord’s obligation to disburse such amounts pursuant to such Complete Draw Request properly requisitioned shall survive such outside date).
(iv)4th Floor Allowances. With respect to the design and construction of Tenant Improvements for the 4th Floor Expansion Premises, as a separate addition to the “Total TI Allowance” set forth in Section 5(b) of the Second Amendment Work Letter, as revised under Section 8(b)(ii) hereinabove: (A) in augmentation of the Base Allowance thereunder, Landlord shall provide an additional tenant improvement allowance (the “4th Floor Base Allowance”) in the maximum
amount of $9,900,000.00 to be used solely for TI Costs pertaining to the demolition, design and construction of Tenant Improvements for the 4th Floor Expansion Premises, including the 4th Floor Demolition Work; and (B) as a part of the FF&E Allowance thereunder, Landlord shall provide an additional tenant improvement allowance (the “4th Floor FF&E Allowance”) in the maximum amount of $495,000.00 to be used solely for the payment of Tenant’s FF&E pertaining to the 4th Floor Expansion Premises. Notwithstanding anything in the Second Amendment Tenant Work Letter and/or this Third Amendment to the contrary, Tenant shall have no right to any portion of the 4th Floor Base Allowance and/or 4th Floor FF&E Allowance that is not disbursed on or before December 31, 2027 (except for any amounts thereof where on or before such date Tenant has submitted to Landlord a Complete Draw Request therefor, in which event Landlord’s obligation to disburse such amounts pursuant to such Complete Draw Request properly requisitioned shall survive such outside date).
(v)Moving Costs for 3rd and 4th Floors. Notwithstanding anything in the Second Amendment Tenant Work Letter and/or this Third Amendment to the contrary, Tenant may elect, by written notice (the “Moving Costs Notice”) delivered to Landlord at any time prior to December 31, 2028 (the “Moving Costs Outside Date”), to receive the then unused balance of the Original Premises TI Allowance, that has not been used to pay for (and/or designated to pay for) the applicable TI Costs pertaining to the Original Premises, in an amount up to, but not exceeding $600,000.00, as a reimbursement of the costs actually incurred and paid for by Tenant, as evidenced by invoices and paid receipts therefor (collectively, the “Moving Costs”), for the costs of moving and/or relocating Tenant’s personal property to the 3rd Floor Expansion Premises and/or the 4th Floor Expansion Premises, as the case may be. The Moving Costs Notice shall expressly state the exact amounts of the then unused portion of the Original Premises TI Allowance (in an amount up to, but not exceeding, $600,000.00) which Tenant elects to receive as reimbursement of the Moving Costs as described hereinabove. If Tenant properly and timely delivers the Moving Costs Notice to Landlord, then Landlord shall disburse such reimbursement to Tenant on or before the date that is thirty (30) days after Landlord's receipt of the Moving Costs Notice, together with all invoices and paid receipts evidencing the Moving Costs and lien releases from the applicable contractors and vendors to the extent such applicable parties have mechanics’ lien rights under applicable laws for any such particular scope of work. If Tenant fails to deliver the Moving Costs Notice to Landlord on or prior to the Moving Costs Outside Date, then Tenant shall have no further rights with respect to the use of the Original Premises TI Allowance for Moving Costs hereunder.
C.Modification of Test Fit Allowance. As to the $18,794.20 “test fit” allowance payable to the TI Architect for preparation of test fit drawings for the Original Premises and the 3rd Floor Expansion Premises pursuant to the last sentence of Section 5(b) of the Second Amendment Tenant Work Letter, such amount is hereby increased to $25,394.20 (to extend the $.20 per rentable square foot allowance to include the 4th Floor Expansion Premises).
9.Deletion of Right to Expand. As of the Effective Date, Section 13 of the Second Amendment is hereby deleted in its entirety and is of no further force or effect.
10.Clarification Re: Right to Extend Term. For purposes of clarification, the Extension Right(s) as previously modified under Section 14 of the Second Amendment may only be exercised with respect to the entire Premises then leased by Tenant under the Lease, and not separately for any portions thereof.
11.Revisions to Tenant Right to Terminate. Tenant shall continue to have Tenant’s Termination Right as defined and set forth in Section 16 of the Second Amendment, provided, that, effective as of the Effective Date, to account for the addition of the 4th Floor Expansion Premises to the Premises that would be terminated thereunder, the “Early Termination Payment” therein shall be revised to mean and amount equal to the sum of (1) all unamortized costs of the Total TI Allowance, as amended and clarified under Section 8(b) above to mean and include the Original Premises TI Allowance, 3rd Floor TI Allowance, FF&E Allowance, 4th Floor Base Allowance and 4th Floor FF&E Allowance (with amortization calculated from the applicable Commencement Date pertaining to the applicable space for which the applicable allowance applies through the Term using a 10% annual interest rate), (2) all of the unamortized leasing commissions paid by Landlord in connection with the Second Amendment and this Third Amendment (with amortization calculated (A) with respect to the Second Amendment, from the Commencement Date through the Term, and (B) with respect to this Third Amendment, from the 4th Floor Expansion Premises Commencement Date through the Term, in each event using a 10% annual interest rate), and (3) the unamortized amount of all Base Rent and Operating Expense abatements with respect to the Original Premises, the 3rd Floor Expansion Premises and the 4th Floor Expansion Premises, provided for in the Second Amendment and this Third Amendment.
12.Parking. In addition to Section 18 of the Second Amendment with respect to the 3rd Floor Expansion Premises, for the avoidance of doubt, subject to the terms of Section 10 of the Original Lease, Tenant’s number of parking spaces as provided for in Section 10 of the Original Lease shall increase (based on 2.8 parking spaces per 1,000 rentable square feet of the Premises) proportionately with the increase in the rentable square feet of the Premises as of the 4th Expansion Premises Commencement Date.
13.Single Tenant Changes. As a result of Tenant’s expansion into the 3rd Floor Expansion Premises and 4th Floor Expansion Premises, Tenant shall lease and occupy the entire rentable area of the Building. In connection therewith, the parties hereby acknowledge and agree that, notwithstanding anything in the Lease to the contrary:
(i)Tenant Maintained Security. Tenant hereby acknowledges that Landlord shall have no obligation to provide, or otherwise pay for, any guard service or other security measures for the benefit of the Premises or the Project. Tenant hereby assumes all responsibility for the protection of Tenant and its agents, employees, contractors, invitees and guests, and the property thereof, from acts of third parties, including keeping doors locked and other means of entry to the Premises closed. Tenant may, at its own expense, (i) install its own security system for the Building in accordance with the terms and conditions of Article 12 of the Original Lease (“Tenant’s Security System”) and/or (ii) retain and maintain interior security lobby attendant(s) within the Building (provided that the same shall be unarmed, shall not have any roaming security activities outside of the Building and shall be licensed and insured); provided, however, that Tenant shall coordinate the installation and operation of any new components of Tenant’s Security System with Landlord to assure that Tenant’s Security System is compatible with Landlord’s security system (if applicable) and the Building systems and equipment. Tenant shall be solely responsible, at Tenant’s sole cost and expense, for the installation, monitoring and operation of Tenant’s Security System (and, at Landlord’s election, removal of the same).
(ii)Janitorial. Landlord will not provide janitorial services for the Premises. Tenant shall provide janitorial and cleaning services in the Premises in compliance with applicable laws and consistent with first class life sciences projects in South San Francisco, California. Landlord shall continue to provide janitorial services to the Common Areas outside of and serving the Building.
14.Brokers. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, “Broker”) in connection with the transaction reflected
in this Third Amendment and that no Broker brought about this transaction, other than Savills, Inc., representing Tenant, and CBRE, Inc., representing Landlord (collectively, the “Identified Brokers”). Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than the Identified Brokers., claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing transaction.
15.California Accessibility Disclosure. Section 40(o) of the Lease is hereby incorporated into this Third Amendment by reference.
16.OFAC. Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (“OFAC”) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the “OFAC Rules”), (b) not listed on, and shall not during the Term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.
17.Miscellaneous.
a.This Third Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Third Amendment may be amended only by an agreement in writing, signed by the parties hereto.
b.This Third Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.
c.Tenant acknowledges that Landlord’s business operations are proprietary to Landlord or its affiliates. Absent prior written consent from Landlord, Tenant shall hold confidential and will not disclose to third parties, and shall require Tenant Parties to hold confidential and not disclose to third parties, information regarding the systems, controls, equipment, programming, vendors, tenants, and specialized amenities of Landlord or its affiliates. Notwithstanding the foregoing, Tenant may disclose such information (w) to Tenant’s affiliates, provided that Tenant advises Tenant’s affiliates such information is confidential, (x) to third parties as reasonably required to facilitate Tenant’s business and operations within the Premises (which may include disclosure to successors of Tenant’s interest in the Lease, subtenants and licensees), provided that Tenant deliver written notice to all parties requiring them to treat such information as confidential and not disclose to other parties, (y) for compliance with a valid order of a court or other governmental body having jurisdiction, or any law, statute, or regulation, or as otherwise required by law, and (z) in connection with Tenant’s enforcement of its rights under the Lease. Tenant shall notify Landlord promptly if Tenant becomes aware of any third party contacting Tenant or any Tenant Parties requesting information regarding Landlord’s or its affiliates business operations. For avoidance of doubt, disclosure of any information contained in Landlord’s marketing materials for the Building or the Project, will not violate the disclosure limitations set forth in this paragraph.
d.This Third Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic
signatures shall be deemed original signatures for purposes of this Third Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.
Except as amended and/or modified by this Third Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Third Amendment. In the event of any conflict between the provisions of this Third Amendment and the provisions of the Lease, the provisions of this Third Amendment shall prevail. Whether or not specifically amended by this Third Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Third Amendment.
(Signatures on next page)
IN WITNESS WHEREOF, Landlord and Tenant have executed this Third Amendment as of the day and year first above written.
TENANT:
TWIST BIOSCIENCE CORPORATION, a Delaware corporation
By: /s/ Emily Leproust
Name: Emily Leproust
Its: CEO, Twist Bioscience
S I hereby certify that the signature, name, and title above are my signature, name and title
LANDLORD:
681 GATEWAY, LLC, a Delaware limited liability company
By: /s/ Scott R. Bohn
Name: Scott R. Bohn
Its: Chief Development Officer
EXHIBIT A
4th FLOOR EXPANSION PREMISES

EXHIBIT B
LANDLORD’S DEMOLITION WORK

EXHIBIT C
ACKNOWLEDGMENT OF 4th FLOOR EXPANSION PREMISES COMMENCEMENT DATE
This ACKNOWLEDGMENT OF 4th FLOOR EXPANSION PREMISES COMMENCEMENT DATE is made this __ day of __________, ____, between 681 GATEWAY, LLC, a Delaware limited liability company (“Landlord”), and TWIST BIOSCIENCE CORPORATION, a Delaware corporation (“Tenant”), and is attached to and made a part of that certain Lease Agreement dated as of March 21, 2018, as amended by that certain First Amendment to Lease dated as of March 21, 2019, as further amended by that certain Second Amendment to Lease dated as of November 13, 2025, as further amended by that certain Third Amendment to Lease dated as of ______, 2026 (as amended, the “Lease”), by and between Landlord and Tenant. Any initially capitalized terms used but not defined herein shall have the meanings given them in the Lease.
Landlord and Tenant hereby acknowledge and agree, for all purposes of the Lease, that the 4th Floor Expansion Premises Commencement Date is __________, ______, the 4th Floor Expansion Premises Rent Commencement Date is __________, ______, and the termination date of the Base Term of the Lease shall be 11:59 p.m. on June 30, 2037 [NOTE TO DRAFTER WHEN COMPLETING THIS FORM – WHEN PREPARING FOR 3rd FLOOR, CONFIRM EXPIRATION DATE WAS PREVIOUSLY UPDATED]. In case of a conflict between the terms of the Lease and the terms of this Acknowledgment of 4th Floor Expansion Premises Commencement Date, this Acknowledgment of 4th Floor Expansion Premises Commencement Date shall control for all purposes.
IN WITNESS WHEREOF, Landlord and Tenant have executed this ACKNOWLEDGMENT OF 4th FLOOR EXPANSION PREMISES COMMENCEMENT DATE to be effective on the date first above written.
[Signature page follows]
TENANT:
_____________________________________
a _____________________________________
By: _____________________________________
Name: _____________________________________
Its: _____________________________________
I hereby certify that the signature, name, and title above are my signature, name and title
LANDLORD:
_____________________________________
a _____________________________________
By: _____________________________________
Name: _____________________________________
Its: _____________________________________
Exhibit 10.9
Certain information in this document identified by brackets [***] has been omitted because it is both (i) not material and (ii) the type that Twist Bioscience Corporation customarily and actually treats as private or confidential.
FUJIFILM DIMATIX, INC.
END USER SUPPLY AGREEMENT
THIS END USER SUPPLY AGREEMENT and attached Schedules (collectively, the “Agreement”) is made and entered into as of this 5th day of November 2015 (the “Effective Date”) by and between FUJIFILM Dimatix, Inc., a corporation organized under the laws of the State of Delaware, with a place of business at 2230 Martin Avenue, Santa Clara, CA 95050 (“FUJIFILM”), and Twist Bioscience Corporation, a corporation organized under the laws of California, with a place of business at 455 Mission Bay Blvd. South, Suite 545, San Francisco, CA 94158 USA (“Customer”) (each, a “Party” and, collectively, the “Parties”).
WHEREAS, FUJIFILM has agreed to sell, and Customer has agreed to purchase, certain FUJIFILM Products (as defined herein) solely for internal use and not for resale to any Third Party (as defined herein); and
WHEREAS, the purchase and sale of FUJIFILM Products shall be accomplished in accordance with the terms and conditions of this Agreement.
NOW THEREFORE, the Parties hereby agree as follows:
1.Definitions
1.1“Affiliate” means any corporation, partnership, association, or other entity with respect to which a Party, directly or indirectly through a subsidiary, has not less than a majority beneficial ownership, but only if that corporation, partnership, association, or other entity expressly agrees in writing to be bound by this Agreement, and only while that ownership relationship exists.
1.2“Claim” has the meaning set forth in Schedule 1.
1.3“Confidential Information” has the meaning set forth in Schedule 3.
1.4“Discloser” has the meaning set forth in Schedule 3.
1.5“Dispute” has the meaning set forth in Section 7.1.
1.6“FUJIFILM Ink” means Ink manufactured on behalf of FUJIFILM.
1.7“FUJIFILM Products” means Hardware and FUJIFILM Ink supplied by FUJIFILM to Customer.
1.8“Functional Fluids” means fluids other than human-perceivable inks, such as conductive fluids for electronics, bio materials for analysis, etc.
1.9“Hardware” means Jetting Assemblies, Printheads, printing assemblies, Print Engines and other ink jet devices supplied by FUJIFILM to Customer.
1.10“Ink” means printing inks and other materials such as Functional Fluids which are jetted by Printheads.
1.11“Intellectual Property” or “Intellectual Property Rights” have the meaning set forth in Schedule 3.
1.12“Jetting Assemblies” means a device manufactured by or under license from FUJIFILM that jets fluids on demand. Such device may be comprised of, but is not limited to, the following elements: [***]
1.13“Person” means a partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other entity.
1.14“Print Engine” means a device comprised of: (i) components for moving and controlling the movement of Jetting Assemblies and/or Printheads and print media, paper path, and ink supply components; (ii) a Printhead; and (iii) a power supply and covers.
1.15“Printhead” means a device that has been or may in the future be developed by FUJIFILM with a higher level of integration or more functionality or capability than in a Jetting Assembly.
Such devices may include one or more Jetting Assemblies as well as functions or capabilities beyond those of current or future Jetting Assemblies, including but not limited to: [***]
1.16“Recipient” has the meaning set forth in Schedule 3.
1.17“Term” means the period beginning on the Effective Date and ending on the date on which this Agreement terminates under Section 6.
1.18“Third Party” means any Person except FUJIFILM, Customer and their respective Affiliates.
2.Product Supply
2.1All FUJIFILM Products will be supplied by FUJIFILM to Customer in accordance with the terms and conditions of this Agreement.
2.2Customer represents and warrants to FUJIFILM that it is purchasing the FUJIFILM Products only for its internal use, and specifically not for resale to any Third Parties.
Notwithstanding the foregoing, Customer may from time to time sell a FUJIFILM Product to a Third Party upon the prior written approval of FUJIFILM
2.3 Schedule 1 sets forth the basic terms and conditions governing the sale of FUJIFILM Products to Customer. In addition, the Parties mutually agree:
2.3.1 THE WARRANTIES EXPRESSLY STATED IN THIS AGREEMENT ARE EXCLUSIVE AND IN LIEU OF ALL OTHER WARRANTIES, EXPRESS AND IMPLIED, AND ALL FUJIFILM PRODUCTS AND ANY SERVICES PROVIDED BY FUJIFILM HEREUNDER OR OTHERWISE ARE PROVIDED “AS IS,” AND “AS AND WHERE AVAILABLE,” AND WITH ALL FAULTS.
2.3.2 WITHOUT LIMITING THE FOREGOING, FUJIFILM SPECIFICALLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, WARRANTIES OF TITLE AND AGAINST INFRINGEMENT, OR ARISING OUT OF A COURSE OF DEALING. DETERMINATION OF THE SUITABILITY OF THE FUJIFILM PRODUCTS FOR INTENDED USE IS THE SOLE RESPONSIBILITY OF CUSTOMER, AND FUJIFILM SHALL HAVE NO RESPONSIBILITY IN CONNECTION THEREWITH.
2.4 Schedule 2 sets forth the prices and any related special terms and conditions applicable to the purchase of FUJIFILM Products. Schedule 2 shall be automatically updated to include new or additional FUJIFILM Products by means of Customer delivering a purchase order to FUJIFILM and by FUJIFILM’s acknowledgment and acceptance of (including any changes to) said purchase order for such new or additional FUJIFILM Products at then-current prices charged by FUJIFILM. Except for updating Schedule 2 to add new or additional FUJIFILM Products, no purchase order or other document submitted by Customer shall modify any provision of this Agreement.
3.Limitation of Liability
NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS), WHETHER BASED IN CONTRACT, TORT OR ANY OTHER LEGAL THEORY, OR FOR THE COST OF SUBSTITUTE GOODS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE.
FUJIFILM’S MAXIMUM LIABILITY FOR ANY DAMAGES TO CUSTOMER, CUSTOMER AFFILIATES, AND ANY OTHER THIRD PARTIES ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL NOT EXCEED, IN THE AGGREGATE, THE AMOUNTS RECEIVED BY FUJIFILM FROM CUSTOMER FOR THE SPECIFIC FUJIFILM PRODUCTS TO WHICH SUCH CLAIM OR DAMAGE RELATES.
THE FOREGOING LIMITATIONS SHALL NOT APPLY IN THE EVENT OF A BREACH BY EITHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS AS SET FORTH IN SECTION 4 BELOW AND IN SCHEDULE 3. THE PARTIES HAVE RELIED UPON THE LIMITATIONS SET FORTH HEREIN IN DETERMINING WHETHER TO ENTER INTO THIS AGREEMENT. THE REMEDIES PROVIDED TO CUSTOMER AND AFFILIATES IN THIS AGREEMENT ARE EXCLUSIVE.
4. Confidential Information and Intellectual Property Rights
4.1 In connection with the supply of FUJIFILM Products and related activities contemplated hereunder including, but not limited to, the testing of Inks, and/or the integration of FUJIFILM Products into Customer products, the Parties may share their respective Confidential Information on a voluntary basis. In order to foster a constructive and solution-oriented environment, the Parties agree to define and handle Confidential Information disclosures and Intellectual Property Rights from and after the Effective Date in accordance with Schedule 3.
4.2 The Parties agree that any agreement between them in effect as of the Effective Date covering Confidential Information will remain in full force and effect, but shall only cover disclosures made prior to the Effective Date.
4.3 Customer will not use FUIFILM’s name, trademarks, logos or service marks or refer to FUIFILM or any of its affiliates directly or indirectly in any customer list, advertising, sales presentation, news release, release to any professional or trade publication or for any other purposes without FUIFILM’s prior written approval of such use and of the form and substance of the reference.
5. Non-Solicitation; Non-Hire
5.1 During the Term and for a period of one (1) year thereafter, Customer will not hire, solicit, or attempt to hire, any person who is an employee of FUJIFILM, or who has been an employee within the preceding six (6) months, assist in such hiring by any other person, or encourage any such employee to terminate his or her relationship with FUJIFILM. During the Term and for a period of one (1) year thereafter, FUJIFILM will not hire, solicit, or attempt to hire, any person who is an employee of Customer, or who has been an employee within the preceding six (6) months, assist in such hiring by any other person, or encourage any such employee to terminate his or her relationship with Customer.
6. Term and Termination
6.1 The Term of this Agreement commences on the Effective Date and shall expire ten (10) years after the Effective Date, unless earlier terminated pursuant to Section 6.2 below. Thereafter, the Term will be extended by one (1) year on each anniversary of the Effective Date unless either Party notifies the other Party ninety (90) days prior to the anniversary of the Effective Date that the Agreement will terminate on the last day of the then current renewal period.
6.2 This Agreement may be terminated prior to expiration of the Term if any of the following occur:
6.2.1 FUJIFILM and Customer may at any time agree in writing to terminate this Agreement.
6.2.2 If Customer fails without cause to pay FUJIFILM any amount due hereunder, then FUJIFILM shall have the right to terminate this Agreement if Customer does not cure such failure within thirty (30) days after receipt of a written notice from FUJIFILM stating the facts on which FUJIFILM based its determination that such a failure occurred.
6.2.3 If either Party breaches a material obligation of this Agreement and such breach is not cured within ninety (90) days after receipt of a written notice from the non-breaching Party, the non-breaching Party shall have the right to terminate this Agreement.
6.3 All financial obligations which had accrued but which were unpaid as of the effective date of termination shall survive termination. All financial obligations, which would have accrued after the effective date of termination shall terminate. All then outstanding purchase orders shall terminate without liability or consequence to either Party as of the effective date of termination.
7. Miscellaneous
7.1 In the event of a disagreement between the Parties in connection with the performance of this Agreement and such disagreement is not reconciled by the normal commercial personnel of the Parties (a “Dispute”), the Vice President of Marketing & Sales (or his/her designee) of FUJIFILM and his/her counterpart at Customer will negotiate in good faith to attempt to resolve such Dispute. If the Dispute is not resolved within thirty (30) days from the commencement of such discussions, then Chief Executive Officer (or his/her designee) of FUJIFILM and his/her counterpart at Customer will meet and attempt in good faith to reach resolution. Such senior executives shall have at least sixty (60) days from the expiration of the previous thirty (30) day period to resolve the Dispute. The Parties must complete the foregoing dispute resolution process before serving written notice on the other Party alleging a material breach of this Agreement. Notwithstanding the foregoing, either Party may seek injunctive relief in a court of competent jurisdiction without the necessity of posting a bond to protect its Intellectual Property or Confidential Information.
7.2 FUJIFILM and Customer are contractors independent of one another. Nothing in this Agreement is intended to or shall constitute either Party as an agent, legal representative, partner, joint venture, franchisee, employee, or servant of the other for any purpose. Neither Party shall make any contract, agreement, warranty, or representation on behalf of the other Party, or incur any debt or other obligation in the other Party’s name, or act in any manner which has the effect of making that Party the apparent agent of the other; and neither Party shall assume liability for, or be deemed liable as a result of, any such action by the other Party. Neither Party shall be liable by reason of any act or omission of the other Party in the conduct of its business or for any resulting claim or judgment.
7.3 Neither Party may assign this Agreement or any of their respective rights and obligations under this Agreement without the express written consent of the other Party before that assignment, except that either Party may without the other Party’s prior consent assign this Agreement to a successor in interest by way of a merger, or a successor in ownership of all or substantially all of its assets. Any assignment under this Section 7.3 will not relieve the assigning Party of its outstanding financial obligations, if any, incurred before the assignment. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.
7.4 A waiver of a default of any term of this Agreement shall not be construed as a waiver of any later default of that provision or as a waiver of the provision itself. A Party’s performance after the other Party’s default shall not be construed as a waiver of that default.
7.5 Each term of this Agreement is severable. If a court having jurisdiction determines that any term is invalid or unenforceable under applicable law, that determination shall not affect the other terms of this Agreement, which other terms shall continue to be enforced as if the invalid or unenforceable provisions were omitted.
7.6 The state and federal law of the State of California, United States of America, shall govern the interpretation and enforcement of this Agreement and any dispute arising out of or related to this Agreement, without giving effect to any conflict of laws principles that may cause the law of any other jurisdiction to apply.
7.7 Except as this Agreement otherwise provides, no amendment to this Agreement shall be binding unless agreed to in a writing executed by FUJIFILM and Customer, and no approval, consent, or waiver shall be enforceable unless signed by the granting Party. The preprinted terms of any order (including, without limitation, a purchase order), acknowledgment, or other form do not amend this Agreement. No document shall be deemed to amend this Agreement by implication.
7.8 This Agreement states the complete agreement between FUJIFILM and Customer concerning this subject, except as stated in Section 4.2, and supersedes all earlier oral and written communications between FUJIFILM and Customer concerning this subject.
7.9 All notices, consents, approvals, or other communications hereunder shall be in writing and shall be deemed given if delivered personally or sent by overnight courier service, or e-mail, promptly confirmed by overnight courier service, as set forth below, addressed to the parties at the following addresses (or at such other address for a party as shall be specified by like notice, provided that notice of a change of address shall be effective only upon receipt):
If to FUJIFILM:
| Chief Executive Officer | Legal Department | ||||
| FUJIFILM Dimatix, Inc. | FUJIFILM Holdings America Corporation | ||||
| 2230 Martin Avenue | 200 Summit Lake Drive | ||||
| Santa Clara, California 95050 | Valhalla, New, York 10595 | ||||
If to Customer:
| Chief Financial Officer | Director of Supply Chain | ||||
| Twist Bioscience | Twist Bioscience | ||||
| 500 Terry Francois | 500 Terry Francois | ||||
| 6th Floor | 6th Floor | ||||
| San Francisco, CA 94158 | San Francisco, CA 94158 | ||||
Any notice, consent, approval and other communication if delivered personally or sent by overnight courier service shall be deemed given when so delivered (or delivery refused), and, in the case of e-mail, upon receipt of transmission if before the receiving party’s normal business hours, or on the next business day if receipt of transmission was after the receiving party’s normal business hours, and in either event, if confirmed by courier as set forth above.
7.10 This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. The parties agree that signatures by electronic mail in “portable document format” (“.pdf” format), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by a combination of such means, shall be deemed a valid and binding execution of this Agreement.
| AGREED TO AND ACCEPTED BY: | |||||
| FUJIFILM DIMATIX, INC. | TWIST BIOSCIENCE CORPORATION | ||||
By:/s/ Martin Schoeppler | By:/s/ Emily Leproust | ||||
| Name: Martin Schoeppler | Name: Emily Leproust | ||||
| Title: CEO and President | Title: CEO | ||||
| Date: 11/16/2015 | Date: 11/11/15 | ||||
LIST OF SCHEDULES
Schedule 1 Terms and Conditions
Schedule 2 Prices for FUJIFILM Products
Schedule 3 Confidentiality and Intellectual Property Rights
SCHEDULE 1
TERMS AND CONDITIONS
FORECASTS AND PRODUCTION ESTIMATES: Customer will provide FUJIFILM with a [***] of FUJIFILM Product requirements; provided, however, that orders placed hereunder are non-cancelable and non-deferrable beginning thirty [***] prior to scheduled delivery date. Customer will provide FUJIFILM with [***] advance notice to add significant additional manufacturing capacity. FUJIFILM may not be able to meet orders as a result of changes in or requirements in excess of those set forth in [***]. Furthermore, the Parties agree to use their reasonable efforts, particularly during significant ramp periods, to coordinate, communicate and level out product delivery requirements so that Customer’s requirements and FUJIFILM’s capacity are matched as closely as possible. Production estimates are not guaranteed, but result from careful analysis of Customer’s submitted requirements and present reasonably expected output under normal conditions.
ORDERS: Customer will order FUJIFILM Products through the issuance of purchase orders at least [***] in advance of the requested delivery dates. All preprinted terms and conditions on purchase orders are superseded entirely by the terms and conditions of this Agreement. Each purchase order will (i) adequately identify the FUJIFILM Product ordered by use of FUJIFILM’s product code, (ii) set forth the requested quantity, and (iii) specify the requested delivery method and date. Purchase orders must be in writing and may be sent via e‑mail or facsimile to FUJIFILM’s Customer Service group. To confirm its acceptance of each purchase order, FUJIFILM will issue to Customer an acknowledgment of such purchase order via e-mail within three (3) business days of receipt. If Customer does not receive an acknowledgment of a purchase order within this timeframe, Customer should contact FUJIFILM immediately to follow up on the status of the order.
Upon receipt of any purchase order submitted in accordance with this Agreement, FUJIFILM will either (i) accept the order via email, including confirmation of the ship date; or (ii) notify Customer of FUJIFILM’s proposed ship date, if FUJIFILM is unable to ship the FUJIFILM Product in the amounts and/or at the time or times requested. Once accepted, this will become the commitment date. If FUJIFILM cannot fulfill Customer’s purchase orders due to a shortage of any FUJIFILM Product, FUJIFILM shall notify Customer immediately via email and use its reasonable efforts to satisfy Customer’s purchase requirements as closely as possible.
PRICES: Prices are exclusive of federal, state or excise or use taxes which will be separately shown on invoices. Prices are Ex Works (INCO Terms 2010), as such terms are commonly understood in the industry. Specification changes by Customer may affect prices. Customer must provide FUJIFILM with a certificate for exemption from state taxes where applicable.
PAYMENT AND SECURITY: Payment shall be made by Customer within [***] of invoice date. For the purpose of securing payment of amounts due FUJIFILM from the Customer hereunder, Customer hereby grants to FUJIFILM: (i) a continuing first purchase money security interest in the FUJIFILM Products to be shipped hereunder, and all accessions thereto and substitutions therefor; and (ii) a continuing purchase money security interest in all of the proceeds of the foregoing. If Customer fails to make payment to FUJIFILM of any invoice for any FUJIFILM Product shipped by FUJIFILM within [***] of the date of such invoice, or should Customer become insolvent or be a party to any bankruptcy or receivership proceeding prior to full payment of all amounts payable hereunder, FUJIFILM may, notwithstanding any other provisions herein set forth, exercise any and all of its rights as a secured creditor under applicable law, including without limitation: (a) refuse to make further shipments to Customer; (b) with or without demand or notice to Customer declare the entire amount unpaid immediately due and payable; and (c) sell any or all of said products as permitted under applicable law, applying the proceeds of the sale to the expenses of retaking, repairing and selling said products, reasonable attorney’s fees and the satisfaction of all indebtedness then due and unpaid. Any surplus shall be paid to Customer and any deficiency shall be paid to FUJIFILM by Customer. All past due amounts shall accrue a delinquency charge at the rate of one percent (1%) per month.
The foregoing notwithstanding, if FUJIFILM, in its sole discretion, determines any Customer to have insufficient credit worthiness, FUJIFILM reserves the right to (i) require payment of all or a portion of the
invoice amount in advance of commencing work on or shipping any order, or (ii) require full payment in less than [***] from the invoice date of any order. For orders shipped outside the United States, payment may be made by (i) a bank draft on a bank acceptable to FUJIFILM, or (ii) by a confirmed, irrevocable letter of credit naming FUJIFILM as beneficiary with order or other terms as arranged by FUJIFILM. Any charges related to such letter of credit or other payment arrangement shall be for Customer’s account.
Nothing herein shall require FUJIFILM to ship FUJIFILM Products to Customer if any of the requirements in this payment and security section of Schedule 1 are not fulfilled by Customer.
DELIVERY: Delivery to a public carrier at FUJIFILM’s manufacturing facility, consigned as Customer directs, shall constitute transfer of the shipment’s title, ownership, possession, and property to Customer at point of such delivery. Carrier will thereafter be deemed as acting for Customer and the shipment will be at Customer’s risk. FUJIFILM Products will be delivered to Customer in packaging reasonably acceptable to Customer, given shipment, warehousing and storage requirements. Customer will advise FUJIFILM in writing of any special packaging or labeling requirements at the time of placing an order. Customer will pay the cost of any special packaging.
WARRANTY: All FUJIFILM Products are warranted to be free of defects in materials and workmanship for a period of [***] from date of shipment by FUJIFILM.
[***] FUJIFILM Products repaired or replaced under warranty will carry coverage for the balance of warranty period of such product from when such product was returned to FUJIFILM.
During the warranty period, FUJIFILM will, at its option, repair, replace or credit the purchase price of FUJIFILM Products which prove to be defective in materials or workmanship. Customer must return FUJIFILM products to the facility designated by FUJIFILM. Customer shall obtain a return materials authorization number and shipping instructions from FUJIFILM, follow the proper cleaning/flushing procedures in accordance with the respective product manual, and return the product shipping charges prepaid. Shipping charges for all agreed warranty returns will be paid by FUJIFILM and Customer shall pay for shipping for all rejected warranty returns. Warranty excludes all costs of customs clearance and any other related charges. All replaced products shall become the property of FUJIFILM.
The foregoing warranty shall not apply to defects that result from:
(1) improper installation, use, storage, care or maintenance by Customer or its customers;
(2) modification or alteration, damage, neglect, or abuse of a FUJIFILM Product;
(3) operation of a FUJIFILM Product not in accordance with FUJIFILM product manual recommendations, including power and environmental specifications; or
(4) externally induced contamination (including but not limited to premature drying or curing of inks in the nozzles);
DISCONTINUANCE: FUJIFILM may, at its option, discontinue any FUJIFILM Product supplied under this Agreement (“End of Life Product”); provided, however, that: (i) FUJIFILM shall give Customer [***] month’s prior written notice of any planned discontinuance; provided, however, that during such [***] month period, in addition to purchase orders issued and accepted by FUJIFILM pursuant to this Agreement, Customer shall, in its sole discretion, have the right to make a one-time buy of the End-of-Life Product and spare parts thereof. Customer shall have the right to schedule shipment of such one-time buy over a period of [***] months from the effective date of discontinuance of the End-of-Life Product.
CHANGE CONTROL: Any FUJIFILM Product supplied under this Agreement shall be included in the scope of FUJ1FILM’s released change control procedure, which addresses when and how customers are notified about changes to the product.
CUSTOMER INDEMNIFICATION: Customer shall indemnify, defend and hold FUJIFILM and its Affiliates harmless against any expense, judgment or loss for alleged infringement or violation of any patents, copyrights, mask works, trade secrets, trademarks, or proprietary or other information which result from FUJIFILM’s compliance with Customer’s designs, specifications or instructions.
GENERAL INDEMNIFICATION: FUJIFILM shall indemnify, defend and hold Customer harmless against any expense, judgment or loss arising out of gross negligence or intentionally tortious acts or omissions of FUJIFILM or its agents. Customer shall indemnify, defend and hold FUJIFILM harmless against any expense, judgment or loss arising out of, or related to (i) any gross negligence or intentionally tortious acts or omissions of Customer or its agents, (ii) Customer’s use of any FUJIFILM Product, and/or (iii) any claim by a Third Party arising out of, or relating to, the FUJIFILM Products.
CANCELLATION OR RETURNS: If FUJIFILM agrees to the cancellation by Customer of an order within thirty (30) days of scheduled delivery, all future work thereon will be stopped by FUJIFILM as soon as reasonably possible and a cancellation charge will be rendered in the amount of the costs incurred to the date of stoppage plus ten percent (10%), less allowances FUJIFILM may be able to make for standard components and salvage. Cancellation of any completed FUJIFILM Products shall not be effective and the order will be shipped and billed to Customer at the order prices.
SCHEDULE 2
PRICES FOR FUJIFILM PRODUCTS
The following prices include standard packaging.
A. PRINTHEADS and JETTING ASSEMBLIES
| Part Number | Description | Annual Forecast | Unit Price | Lead Time | ||||||||||
| [***] | [***] | [***] | [***] | [***] | ||||||||||
B. PRICE INCREASES
Beginning eighteen (18) months after the Effective Date, and/or from time to time thereafter, FUJIFILM may, by written notice delivered one hundred eighty (180) days in advance to Customer, increase prices for FUJIFILM Products listed on this Schedule 2. Price increases will not apply to orders that are non-cancelable and non-deferrable (pursuant to Schedule 1) as of the date of written notice of such increase. Any written notice (including via email) by FUJIFILM of a price increase in accordance with the foregoing shall be deemed an amendment to this Agreement and this Schedule 2 with effect as of the effective date of the applicable price increase.
SCHEDULE 3
CONFIDENTIALITY AND INTELLECTUAL PROPERTY RIGHTS
Confidentiality:
“Confidential Information” means all data, information and materials that a Party (“Discloser”) deems to be confidential and proprietary to it or its subsidiaries or affiliates and which Discloser discloses to the other Party (“Recipient”) during the Term: (i) in documents or other tangible materials clearly marked “CONFIDENTIAL;” or (ii) orally, or in any other intangible form, when first disclosed to the Recipient if, at that time, the Discloser advises the Recipient that the data, information and materials are confidential. Notwithstanding the foregoing, information that is disclosed without the marking or identification set forth in (i) and (ii) above, but which should be reasonably understood by Recipient to be proprietary or confidential to Discloser because of the circumstances of disclosure, or due to the nature of the information itself, shall be deemed Confidential Information of Discloser and treated as confidential in accordance with the terms set forth in the Agreement and this Schedule 3.
“Confidential Information” does not include any data, information and materials which the Recipient can show:
(a) the Recipient knew at the time of disclosure;
(b) the public knows or which is or becomes readily ascertainable by the public, and through no wrongful act of the Recipient;
(c) the Recipient receives from a Third Party without breaching an obligation owed to the Discloser, if the Third Party does not restrict the Recipient from disclosing that information;
(d) is independently developed by or for the Recipient without use of or reference to the Confidential Information of the Discloser;
(e) the Discloser discloses to a Third Party without similar restrictions on disclosure; or
(f) is required to be disclosed by law, provided, however, that in the event Recipient is ordered to disclose the Confidential Information pursuant to a judicial or governmental request, requirement or order, Recipient shall promptly, and in any event prior to complying therewith, notify the Discloser and allow Discloser a reasonable opportunity to seek a protective order or other appropriate remedy. Upon Discloser’s written request and at Discloser’s expense, take reasonable steps to assist Discloser in contesting such request, requirement or order or otherwise protecting Discloser’s rights.
During the Term and for five (5) years after the after the date of disclosure of Confidential Information, the Recipient shall (i) use reasonable efforts to prevent the disclosure of any Confidential Information to any Third Party, but in no event shall use less than reasonable care; (ii) not use the Confidential Information for any purpose other than the purpose for which such Confidential Information was disclosed under this Agreement; (iii) not disclose the Confidential Information to any Third Party, except that Recipient may disclose Confidential Information to those of its employees and affiliates directly concerned with this Agreement and on a need-to-know basis only, provided that Recipient informs each recipient of the confidential nature of the Confidential Information and each recipient agrees to be bound in writing by confidentiality obligations at least as restrictive as those contained herein; and (iv) not cause or permit the reverse engineering, reverse assembly or reverse compilation of any Confidential Information. All materials containing Confidential Information delivered by or on behalf of the Discloser under this Agreement are and shall remain the property of the Discloser. At the Discloser’s written request, or upon termination of the Recipient’s right to possess the Confidential Information, the Recipient shall promptly return to the Discloser, or destroy and certify the destruction of, all those materials and any copies. The Recipient agrees that it will not utilize or include any Confidential Information in any patent or patent or copyright filing.
Except for compliance with the terms and conditions of this Agreement including, but not limited to, confidentiality obligations and respect for Intellectual Property Rights, neither Party is (i) restricted from independently developing new products, improving existing products, or marketing any new, improved, or existing products that may be similar to Discloser’s products or services, as long as such development is performed (a) without use of or reliance on, and does not embed any of the Discloser’s Confidential Information; or (ii) committed to disclose any particular information or to develop, make, use, buy, sell, or otherwise dispose of any existing or future product, or to favor or recommend any product or service of the other Party.
The Parties may have executed a non-disclosure agreement prior to the Effective Date of this Agreement, which shall govern confidential information disclosed prior to the Effective Date. The provisions of this Agreement shall govern any confidential information disclosed on or after the Effective Date.
Intellectual Property Rights:
Each Party will retain its existing Intellectual Property Rights as of the Effective Date and nothing in this Agreement will amend that understanding. For the purposes of this Agreement, Intellectual Property and Intellectual Property Rights are defined as inventions and/or works and any and all rights under U.S. and/or foreign patents, trade secrets, know-how, copyrights, trademarks, and other industrial or intangible property rights of a similar nature; all rights pursuant to grants and/or registrations worldwide in connection with the foregoing and all other rights with respect thereto; all rights under applications for any such grant or registration, all rights of priority under international conventions to make such applications and the right to control their prosecution, and all rights under amendments, continuations, divisions, and continuations-in-part of such applications; and all rights under corrections, reissues, patents of addition, extensions, and renewals of any such grant, registration, and/or right. Furthermore, each Party will own all materials, documentation, software, know-how, inventions, processes, procedures, data, information and materials developed by a Party pursuant to this Agreement (“Work Product”) developed solely by its employees, agents, representatives and consultants, and all Intellectual Property Rights therein. Notwithstanding anything to the contrary, Fujifilm Products and any improvement, modification, or alteration thereto (collectively, “Improvements”) shall remain the property and Confidential Information of Fujifilm and in the case that an invention by employees, agents, representatives or consultants of Customer, either solely or jointly with employees, agents, representatives or consultants of Fujifilm, is made with respect to Fujifilm Products, Customer agrees, and hereby does, assign any all right title and interest in such inventions and Improvements to Fujifilm.
AMENDMENT No. 1 to End User Supply Agreement
This Amendment No. 1 (“Amendment”) to End User Supply Agreement is dated as of December 3, 2024 (“Effective Date”) between FUJIFILM Dimatix, Inc. (“Fujifilm”) and Twist BioScience Corporation (“Customer”).
WHEREAS, Fujifilm and Customer are Parties to an End User Supply Agreement dated as of November 5, 2015 (“Agreement”); capitalized terms used but not defined herein shall have the meanings assigned to them in the Agreement (as defined below).
WHEREAS, Fujifilm and Customer desire to amend the Agreement by among other things, extending the term of the Agreement an additional five (5) years from ten (10) years to fifteen (15) years, all as set forth herein.
NOW, THEREFORE, the Parties hereto agree as follows:
1The number and parenthetical “ten (10)” appearing in the first sentence of Section 6.1 is hereby deleted in its entirety and replaced with the number and parenthetical “fifteen (15)”.
2Schedules 1 and 2 of the Agreement are hereby deleted in their entirety and replaced with Schedules 1 and 2 attached hereto and hereby made a part of the Agreement.
3This Amendment shall be effective as of the Effective Date.
4Except as expressly provided herein, the Agreement remains unchanged in all respects.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date.
| FUJIFILM DIMATIX, INC. | TWIST BIOSCIENCE CORPORATION | ||||
By: /s/ Steven Billow | By: /s/ Emily Leproust | ||||
Name: Steven Billow | Name: Emily Leproust | ||||
Title: President & CEO | Title: CEO | ||||
SCHEDULE 1
TERMS AND CONDITIONS
FORECASTS AND PRODUCTION ESTIMATES: Customer will provide FUJIFILM with a [***] of FUJIFILM Product requirements; provided, however, that orders placed hereunder are non-cancelable and non-deferrable beginning [***] prior to scheduled delivery date. Customer will provide FUJIFILM with [***] advance notice to add significant additional manufacturing capacity. FUJIFILM may not be able to meet orders as a result of changes in or requirements in excess of those set forth in [***]. Furthermore, the Parties agree to use their reasonable efforts, particularly during significant ramp periods, to coordinate, communicate and level out product delivery requirements so that Customer’s requirements and FUJIFILM’s capacity are matched as closely as possible. Production estimates are not guaranteed, but result from careful analysis of Customer’s submitted requirements and present reasonably expected output under normal conditions.
ORDERS: Customer will order FUJIFILM Products through the issuance of purchase orders at least [***] in advance of the requested delivery dates. All preprinted terms and conditions on purchase orders are superseded entirely by the terms and conditions of this Agreement. Each purchase order will (i) adequately identify the FUJIFILM Product ordered by use of FUJIFILM’s product code, (ii) set forth the requested quantity, and (iii) specify the requested delivery method and date. Purchase orders must be in writing and may be sent via e-mail or facsimile to FUJIFILM’s Customer Service group. To confirm its acceptance of each purchase order, FUJIFILM will issue to Customer an acknowledgment of such purchase order via e-mail within three (3) business days of receipt. If Customer does not receive an acknowledgment of a purchase order within this timeframe, Customer should contact FUJIFILM immediately to follow up on the status of the order.
Upon receipt of any purchase order submitted in accordance with this Agreement, FUJIFILM will either: (i) accept the order via email, including confirmation of the ship date; or (ii) notify Customer of FUJIFILM’s proposed ship date, if FUJIFILM is unable to ship the FUJIFILM Product in the amounts and/or at the time or times requested. Once accepted, this will become the commitment date. If FUJIFILM cannot fulfill Customer’s purchase orders due to a shortage of any FUJIFILM Product, FUJIFILM shall notify Customer immediately via email and use its reasonable efforts to satisfy Customer’s purchase requirements as closely as possible.
PRICES: Prices are exclusive of federal, state or excise or use taxes which will be separately shown on invoices. Prices are Ex Works (INCO Terms 2010), as such terms are commonly understood in the industry. Specification changes by Customer may affect prices. Customer must provide FUJIFILM with a certificate for exemption from state taxes where applicable.
PAYMENT AND SECURITY: Payment shall be made by Customer within [***] of invoice date. For the purpose of securing payment of amounts due FUJIFILM from the Customer hereunder, Customer hereby grants to FUJIFILM: (i) a continuing first purchase money security interest in the FUJIFILM Products to be shipped hereunder, and all accessions thereto and substitutions therefor; and (ii) a continuing purchase money security interest in all of the proceeds of the foregoing. If Customer fails to make payment to FUJIFILM of any invoice for any FUJIFILM Product shipped by FUJIFILM within [***] of the date of such invoice, or should Customer become insolvent or be a party to any bankruptcy or receivership proceeding prior to full payment of all amounts payable hereunder, FUJIFILM may, notwithstanding any other provisions herein set forth, exercise any and all of its rights as a secured creditor under applicable law, including without limitation: (a) refuse to make further shipments to Customer; (b) with or without demand or notice to Customer declare the entire amount unpaid immediately due and payable; and (c) sell any or all of said products as permitted under applicable law, applying the proceeds of the sale to the expenses of retaking, repairing and selling said products, reasonable attorney’s fees and the satisfaction of all indebtedness then due and unpaid. Any surplus shall be paid to Customer and any deficiency shall be paid to FUJIFILM by Customer. All past due amounts shall accrue a delinquency charge at the rate of one percent (1%) per month.
The foregoing notwithstanding, if FUJIFILM, in its sole discretion, determines any Customer to have insufficient credit worthiness, FUJIFILM reserves the right to (i) require payment of all or a portion of the invoice amount in advance of commencing work on or shipping any order, or (ii) require full payment in less than [***] from the invoice date of any order. For orders shipped outside the United States, payment may be made by (i) a bank draft on a bank acceptable to FUJIFILM, or (ii) by a confirmed, irrevocable letter of credit naming FUJIFILM as beneficiary with order or other terms as arranged by FUJIFILM. Any charges related to such letter of credit or other payment arrangement shall be for Customer’s account.
Nothing herein shall require FUJIFILM to ship FUJIFILM Products to Customer if any of the requirements in this payment and security section of Schedule 1 are not fulfilled by Customer.
DELIVERY: Delivery to a public carrier at FUJIFILM’s manufacturing facility, consigned as Customer directs, shall constitute transfer of the shipment’s title, ownership, possession, and property to Customer at point of such delivery. Carrier will thereafter be deemed as acting for Customer and the shipment will be at Customer’s risk. FUJIFILM Products will be delivered to Customer in packaging reasonably acceptable to Customer, given shipment, warehousing and storage requirements. Customer will advise FUJIFILM in writing of any special packaging or labeling requirements at the time of placing an order. Customer will pay the cost of any special packaging.
WARRANTY: All FUJIFILM Products are warranted to be free of defects in materials and workmanship for a period of [***] from date of shipment by FUJIFILM.
[***] FUJIFILM Products repaired or replaced under warranty will carry coverage for the balance of warranty period of such product from when such product was returned to FUJIFILM.
During the warranty period, FUJIFILM will, at its option, repair, replace or credit the purchase price of FUJIFILM Products which prove to be defective in materials or workmanship. Customer must return FUJIFILM products to the facility designated by FUJIFILM. Customer shall obtain a return materials authorization number and shipping instructions from FUJIFILM, follow the proper cleaning/flushing procedures in accordance with the respective product manual, and return the product shipping charges prepaid. Shipping charges for all agreed warranty returns will be paid by FUJIFILM and Customer shall pay for shipping for all rejected warranty returns. Warranty excludes all costs of customs clearance and any other related charges. All replaced products shall become the property of FUJIFILM.
The foregoing warranty shall not apply to defects that result from:
1)improper installation, use, storage, care or maintenance by Customer or its customers;
2)modification or alteration, damage, neglect, or abuse of a FUJIFILM Product;
3)operation of a FUJIFILM Product not in accordance with FUJIFILM product manual recommendations, including power and environmental specifications;
4)externally induced contamination (including but not limited to premature drying or curing of inks in the nozzles); or
5)missing or malfunctioning nozzles as Customer expressly acknowledges that FUJIFILM does not test the FUJIFILM Products with fluid at Customer’s request,
DISCONTINUANCE: FUJIFILM may, at its option, discontinue any FUJIFILM Product supplied under this Agreement (“End of Life Product”); provided, however, that: (i) FUJIFILM shall give Customer [***] month’s prior written notice of any planned discontinuance; provided, however, that during such [***] month period, in addition to purchase orders issued and accepted by FUJIFILM pursuant to this Agreement, Customer shall, in its sole discretion, have the right to make a one-time buy of the End-of-Life Product and spare parts thereof. Customer shall have the right to schedule shipment of such one-time buy over a period of [***] months from the effective date of discontinuance of the End-of-Life Product.
CHANGE CONTROL: Any FUJIFILM Product supplied under this Agreement shall be included in the scope of FUJIFILM’s released change control procedure, which addresses when and how customers are notified about changes to the product.
CUSTOMER INDEMNIFICATION. Customer shall indemnify, defend and hold FUJIFILM and its Affiliates harmless against any expense, judgment or loss for alleged infringement or violation of any patents, copyrights, mask works, trade secrets, trademarks, or proprietary or other information which result from FUJIFILM’s compliance with Customer’s designs, specifications or instructions.
GENERAL INDEMNIFICATION: FUJIFILM shall indemnify, defend and hold Customer harmless against any expense, judgment or loss arising out of gross negligence or intentionally tortious acts or omissions of FUJIFILM or its agents. Customer shall indemnify, defend and hold FUJIFILM harmless against any expense, judgment or loss arising out of, or related to (i) any gross negligence or intentionally tortious acts or omissions of Customer or its agents, (ii) Customer’s use of any FUJIFILM Product, and/or (iii) claim by a Third Party arising out of, or relating to, the FUJIFILM Products.
CANCELLATION OR RETURNS: If FUJIFILM agrees to the cancellation by Customer of an order within thirty (30) days of scheduled delivery, all future work thereon will be stopped by FUJIFILM as soon as reasonably possible and a cancellation charge will be rendered in the amount of the costs incurred to the date of stoppage plus en percent (10%), less allowances FUJIFILM may be able to make for standard components and salvage. Cancellation of any completed FUJIFILM Products shall not be effective and the order will be shipped and billed to Customer at the order prices.
BUSINESS CONTINUITY PLAN: FUJIFILM will maintain a business continuity plan for its operations in New Hampshire.
CUSTOMER DISCONTINUANCE: Customer shall in good faith endeavor to provide FUJIFILM with written notice of a planned discontinuance of Customer Products that use any of the above FUJIFILM Products as soon as Customer has knowledge of the date of any such discontinuance but in any event not less than [***] prior to the date of any such discontinuance. Within [***] of the giving by Customer of any such notice, the parties will meet to develop a plan for FUJIFILM to reduce inventories of FUJIFILM Product.
SCHEDULE 2
PRICES FOR FUJIFILM PRODUCTS
The following prices include standard packaging.
A. PRINTHEADS and JETTING ASSEMBLIES
| Part Number | Description | Unit Price | ||||||
| [***] | [***] | [***] | ||||||
[***]
B. PRICE INCREASES
From time to time, FUJIFILM may, by written notice delivered at least ninety (90) days in advance to Customer, increase prices for FUJIFILM Products listed on this Schedule 2. [***]. Price increases will not apply to orders that are non-cancelable and non-deferrable (pursuant to Schedule 1) as of the date of written notice of such increase. Any written notice (including via email) by FUJIFILM of a price increase in accordance with the foregoing shall be deemed an amendment to this Agreement and this Schedule 2 with effect as of the effective date of the applicable price increase.
Exhibit 19.1
TWIST BIOSCIENCE CORPORATION
INSIDER TRADING COMPLIANCE PROGRAM
(Amended as of November 10, 2026)
This Insider Trading Compliance Program (this “Program”) consists of four sections:
Section I provides an overview; Section II sets forth the policies of Twist Bioscience Corporation (together with its subsidiaries, the “Company”) prohibiting insider trading; Section III explains insider trading; and Section IV consists of various procedures which have been put in place by the Company to prevent insider trading. This Program shall be overseen and managed by the Company’s Corporate Secretary (the “Insider Trading Program Manager”). The Corporate Secretary may delegate authority to administer the Program. In all cases where the Company’s Corporate Secretary or his/her designee is unavailable, the Company’s Chief Executive Officer may fill such role.
I.SUMMARY
Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of the Company as well as that of all persons affiliated with it. “Insider trading” occurs when any person purchases or sells a security while in possession of inside information relating to the security. As explained in Section III below, “inside information” is information which is considered to be both “material” and “non-public.” Insider trading is a crime and the penalties for violating the law include imprisonment, disgorgement of profits, civil fines of up to three (3) times the profit gained or loss avoided, and criminal fines of up to $5 million for individuals and $25 million for entities. Insider trading is also prohibited by this Program and could result in serious sanctions, including dismissal.
This Program applies to all officers, directors and employees of the Company and extends to all activities within and outside an individual’s duties at the Company. In the discretion of the Insider Trading Program Manager, this Program may also apply to consultants and contractors to the Company. Every officer, director and employee must review this Program. Questions regarding this Program should be directed to the Insider Trading Program Manager.
For purposes of this Program, the Company’s securities include common shares, stock awards covering common shares and any other securities the Company may issue from time to time, such as preferred shares, notes, warrants and convertible debentures. The Company’s securities also include derivative securities relating to the Company’s shares, even if not issued by the Company, such as exchange-traded options.
II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING
1. Prohibition against Insider Trading and Other Transactions
The Company will not transact in its own securities, except in compliance with applicable securities laws.
No officer, director or employee shall purchase or sell, or otherwise transact in, any type of security of the Company while in possession of material, non-public information relating to the Company. In addition, no officer, director or employee shall engage in transactions in securities of other publicly traded companies with which the Company has a business relationship while aware of material, non-public information about those companies learned in connection with such person’s role at, or relationship with, the Company.
Additionally, except for certain transactions under Company plans and transactions not involving a purchase or sale discussed below under Sections II. 2 and 3, no officer, director or employee shall purchase or sell any security of the Company during the period beginning at 9:30 a.m. ET on the date that is two (2) weeks before the end of any fiscal quarter of the Company (December 31, March 31, June 30 and September 30) and ending at 4:00 p.m. ET on the second (2nd) full trading day after the public release of earnings data for such fiscal quarter whether or not the Company or any of its officers, directors or employees is in possession of material, non-public information (the “Black-Out Period”). In the event that you leave the Company for any reason, this Program will continue to apply to you until any material nonpublic information known to you has become public or is no longer material.
From time to time, at the discretion of the Insider Trading Program Manager or the Board of Directors, the Company may:
(a)make temporary changes to the Black-Out Periods, including without limitation, extensions of any Black-Out Periods; and
(b)determine that designated persons should suspend trading because of developments known to the Company and not yet disclosed to the public. During such event-specific trading suspension, no designated person may engage in any transaction involving the purchase or sale of the Company’s securities nor disclose to others the fact of such suspension of trading.
Even outside of the Black-Out Period trading prohibition, any person possessing material nonpublic information concerning the Company should not engage in any transactions in the Company’s securities until such information has been known publicly for at least two (2) full trading days (as defined below), whether or not the Company has recommended a suspension of trading to that person. If an individual is aware of material non-public information when his or her employment terminates, the individual may not trade in the Company’s securities until that information has become public or is no longer material. Trading in the Company’s securities outside of the Black-Out Period should not be considered a “safe harbor,” and all persons should use sound judgment at all times to make sure that their trades are not effected while they are in possession of material non-public information about the Company.
For the purposes of this Program, a “trading day” shall mean a day on which The Nasdaq Stock Market LLC (“Nasdaq”) is open for trading during its core trading session from 9:30a.m. to 4:00 p.m. ET, and a “full trading day” shall mean the entire period from 9:30 a.m. to 4:00 p.m. ET on a trading day. Any trading during pre-market, after-hours, overnight or other extended-hours sessions shall not constitute a trading day or full trading day, and shall not shorten any waiting period under this Program.
No officer, director or employee shall directly or indirectly tip material, non-public information to anyone while in possession of such information. In addition, material, non-public information should not be communicated to anyone outside the Company under any circumstances (absent prior written approval by the Insider Trading Program Manager and execution of an appropriate confidentiality agreement), or to anyone within the Company other than on a need-to-know basis.
For the avoidance of doubt, this prohibition includes disclosing material, non-public information to expert network firms, research consulting firms, or similar organizations. No officer, director or employee shall participate in any paid or unpaid consultation, survey, interview or discussion arranged by any expert network firm, research consulting firm, investor advisory service or similar organization where the subject matter relates to the Company's business, products, operations, customers, markets, technology, financial condition or prospects, without advance written authorization. This prohibition applies regardless of whether the individual receives compensation, and regardless of whether the solicitation is received through work or personal channels, including LinkedIn, personal email or text messages. Any such solicitations should be reported promptly to the Insider Trading Program Manager and Corporate Affairs.
The Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Program engage in certain types of transactions. It therefore is the Company’s policy that any persons covered by this Program may not engage in any of the following transactions:
•Short Sales. Short sales of Company securities (i.e., the sale of a security that the seller does not own) may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have the potential to signal to the market that the seller lacks confidence in the Company’s prospects. In addition, short sales may reduce a seller’s incentive to seek to improve the Company’s performance. For these reasons, short sales of Company securities are prohibited. In addition, Section 16(c) of the Exchange Act prohibits officers and directors from engaging in short sales. (Short sales arising from certain types of hedging transactions are governed by the paragraph below captioned “Hedging Transactions.”)
•Hedging Transactions. Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit a director, officer or employee to continue to own Company securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the director, officer or employee may no longer have the same objectives as the Company’s other shareholders. Therefore, directors, officers and employees are prohibited from engaging in any such transactions.
•Margin Accounts and Pledged Securities. Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer’s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in Company securities, directors, officers and other employees are prohibited from holding Company securities in a margin account or otherwise pledging Company securities as collateral for a loan.
•Prediction Markets and Event Contracts. Use third-party platforms or prediction markets (including, without limitation, platforms such as Kalshi or Polymarket) to bet or wager, or establish a position in an event contract, on the performance of, or the occurrence or non-occurrence of events relating to, (i) the Company, or (ii) any other company which has a relationship with the Company (such as customers, suppliers, vendors or other business partners) based on confidential information that you obtained by virtue of your position at the Company. For the avoidance of doubt, this extends to prediction market contracts that do not involve the Company’s securities directly but that relate to events, transactions, product launches, regulatory actions, financial results, or other corporate activities about which the individual possesses material non-public information.
2. Transactions under Company Plans
This Program does not apply in the case of the following transactions, except as specifically noted:
•Stock Option Exercises. This Program does not apply to the grant and exercise of an employee stock option covering shares of the Company’s common stock (“Stock”), or to the withholding of shares of Stock subject to such option to satisfy tax withholding requirements. This Program does apply, however, to any sale of Stock as part of a same-day broker-assisted cashless exercise of an option, or any other market sale.
•Restricted Stock and Restricted Stock Unit Awards. This Program does not apply to the grant and vesting of restricted Stock and restricted stock units covering shares of Stock, or the withholding
of shares of Stock to satisfy tax withholding requirements upon the vesting of any restricted stock or restricted stock units. This Program does apply, however, to any broker-assisted sale, or any other market sale.
•Employee Stock Purchase Plan. This Program does not apply to purchases of shares of Stock pursuant to an employee stock purchase plan resulting from your periodic or lump sum contribution of money to the plan pursuant to the election you made at the time of your enrollment in the plan, to the extent the Company offers such a plan. This Program does apply, however, to your sales of Company securities purchased pursuant to such plan.
•Other Similar Transactions. Any other purchase of Company securities from the Company or sales of Company securities to the Company are not subject to this Program.
3. Sell to Cover Transactions
This Program does not apply to sell to cover transactions, to the extent approved and implemented by the Company, where shares are withheld by the Company upon vesting of equity awards and sold in order to satisfy tax withholding requirements. However, this exception does not apply to any other market sale for the purposes of paying required tax withholdings.
4. Transactions Not Involving a Purchase or Sale
Bona fide gifts of securities, including transfers to controlled entities (as defined below) for estate planning purposes, are subject to this Program including preclearance if applicable. Transactions in mutual funds that are invested in Company securities are not transactions subject to this Program.
III. EXPLANATION OF INSIDER TRADING
As noted above, “insider trading” refers to the purchase or sale of a security while in possession of “material,” “non-public” information relating to the security. “Securities” include not only stocks, bonds, notes and debentures, but also stock awards, warrants and similar instruments. “Purchase” and “sale” are defined broadly under the federal securities laws. “Purchase” includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. “Sale” includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions including conventional cash-for-stock transactions, conversions, the grant, and vesting and, if applicable, exercise of stock awards and acquisitions and exercises of warrants or puts, calls or other options related to a security. It is generally understood that insider trading includes the following:
•Trading by insiders while in possession of material, non-public information;
•Trading by persons other than insiders while in possession of material, non-public information where the information either was given in breach of an insider’s fiduciary duty to keep it confidential or was misappropriated; or
•Communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.
1. What Facts are Material?
The materiality of a fact depends upon the circumstances. A fact is considered “material” if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security or where the fact is likely to have a significant effect on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company’s business or to any type of security, debt or equity.
Although it is not possible to list all types of material information, the following are a few examples of information that is particularly sensitive and should be treated as material:
| changes in earnings and sales forecasts; | major marketing changes; | ||||
| increases or decreases in dividend payments; | unusual gains or losses in major operations; | ||||
| share splits or securities offerings; | public or private sales by the Company of a significant amount of securities; | ||||
| significant contracts and technology licenses; | purchase or sale of a significant asset; | ||||
| changes in management; | significant labor dispute; | ||||
| changes in auditors; | significant financial liquidity problems; | ||||
| the introduction of important products or services; | establishment of a repurchase program for the Company’s securities. | ||||
| potentially significant litigation development; | |||||
In addition, material information does not have to be related to a company’s business. For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.
A good general rule of thumb: when in doubt, do not trade.
2. What is Non-public?
Information is “non-public” if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as Dow Jones, Reuters Economic Services, The Wall Street Journal, Business Wire, Associated Press, or PR Newswire. The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination.
In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information, for example, you should generally allow at least two (2) full trading days (each consisting of the core trading session from 9:30 am to 4:00 pm ET) for the investing public to absorb and evaluate the information before you trade in the Company’s securities. Trading during pre-market, after-hours or overnight sessions does not count toward this period.
3. Who is an Insider?
“Insiders” include officers, directors and employees of a company and anyone else who has material inside information about a company. Insiders have independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company’s securities. All officers, directors and employees of the Company should consider themselves insiders with respect to material, non-public information about the Company’s business, activities and securities. Officers, directors and employees may not trade the Company’s securities while in possession of material, non-public information relating to the Company nor tip (or communicate except on a need-to-know basis) such information to others.
It should be noted that trading by members of an officer’s, director’s or employee’s household can be the responsibility of such officer, director or employee under certain circumstances and could give rise to legal and Company-imposed sanctions. In addition, this Program also applies to all trusts, family partnerships and other types of entities formed for your benefit or for the benefit of a member of your family and over which you have the ability to influence or direct investment decisions concerning securities (collectively referred to as “controlled entities”), and transactions by controlled entities should be treated for the purposes of this policy and applicable securities laws as if they were for your own account.
4. Trading by Persons Other than Insiders
Insiders may be liable for communicating or tipping material, non-public information to a third party (a “tippee”), and insider trading violations are not limited to trading or tipping by insiders. Persons other than insiders also can be liable for insider trading, including tippees who trade on material, non- public information tipped to them or individuals who trade on material, non-public information which has been misappropriated.
Tippees inherit an insider’s duties and are liable for trading on material, non-public information illegally tipped to them by an insider. Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words, a tippee’s liability for insider trading is no different from that of an insider. Tippees can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at social, business or other gatherings.
5. Penalties for Engaging in Insider Trading
Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers. The Securities and Exchange Commission (the “SEC”) and the U.S. Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority. Enforcement remedies available to the government or private plaintiffs under the federal securities laws, which may change from time to time, include:
•SEC administrative sanctions;
•Securities industry self-regulatory organization sanctions;
•Civil injunctions;
•Damage awards to private plaintiffs;
•Disgorgement of all profits;
•Civil fines for the violator of up to three (3) times the amount of profit gained or loss avoided;
•Civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or other controlled person) of up to the greater of $1 million or three (3) times the amount of profit gained or loss avoided by the violator;
•Criminal fines for individual violators of up to $5 million ($25 million for an entity); and
•Jail sentences of up to twenty (20) years.
In addition, insider trading could result in serious sanctions by the Company, including dismissal. Insider trading violations are not limited to violations of the federal securities laws: other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer Influenced and Corrupt Organizations Act, also may be violated upon the occurrence of insider trading.
6. Examples of Insider Trading
Examples of insider trading cases include actions brought against: corporate officers, directors and employees who traded a company’s securities after learning of significant confidential corporate developments; friends, business associates, family members and other tippees of such officers, directors and employees who traded the securities after receiving such information; government employees who learned of such information in the course of their employment; and other persons who misappropriated, and took advantage of, confidential information from their employers.
The following are illustrations of insider trading violations. These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity.
Trading by Insider
An employee of X Corporation learns that earnings to be reported by X Corporation will increase dramatically. Prior to the public announcement of such earnings, the employee purchases X Corporation’s
stock. The employee, an insider, is liable for all profits as well as penalties of up to three (3) times the amount of all profits. The employee also is subject to, among other things, criminal prosecution, including up to $5 million in additional fines and twenty (20) years in jail. Depending upon the circumstances, X Corporation and the individual to whom the employee reports could also be liable as controlling persons.
Trading by Tippee
An employee of X Corporation tells a friend that X Corporation is about to publicly announce that it has concluded an agreement for a major acquisition. This tip causes the friend to purchase X Corporation’s stock in advance of the announcement. The employee is jointly liable with his friend for all of the friend’s profits and each is liable for all penalties of up to three (3) times the amount of the friend’s profits. In addition, the employee and his friend are subject to, among other things, criminal prosecution, as described above.
7. Insider Reporting Requirements, Short-Swing Profits and Short Sales
A. Reporting Obligations Under Section 16(a)--SEC Forms 3, 4 and 5
Section 16(a) of the Securities Exchange Act of 1934, as amended (the “1934 Act”), generally requires all officers (as defined in SEC Rule 16a-1(f))[1] (“officers”), directors and 10% stockholders, within ten (10) days after the insider becomes an officer, director or 10% stockholder, to file with the SEC an “Initial Statement of Beneficial Ownership of Securities” on SEC Form 3 (“Form 3”) listing the amount of Stock, stock awards and warrants which the insider beneficially owns. Following the initial filing on Form 3, every change in the beneficial ownership of the Company’s Stock, stock awards and warrants must be reported on SEC Form 4 (“Form 4”) within two (2) business days after the date on which such change occurs or in certain cases on SEC Form 5 (“Form 5”) within forty-five (45) days after fiscal year end (September 30). Form 4s must be filed even if, as a result of balancing transactions, there has been no net change in holdings.
Special rules apply in certain situations. If an officer or director purchases or sells any Stock within six (6) months after his or her termination from such position, the transaction must be reported on Form 4 if he or she made any non-exempt opposite way purchase or sale within the preceding six (6) months and prior to termination.
B. Recovery of Profits Under Section 16(b)
For the purpose of preventing the unfair use of information which may have been obtained by an insider, any profits realized by any officer, director or 10% stockholder from any “purchase” and “sale” of Stock during a six (6) month period, so called “short-swing profits,” may be recovered by the Company. When such a purchase and sale occurs, good faith is no defense. The insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information.
The liability of an insider under Section 16(b) of the 1934 Act is to the Company itself. The Company, however, cannot waive its right to short-swing profits, and any Company stockholder can bring suit in the name of the Company. In this connection it must be remembered that reports of ownership filed with the SEC on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations. In addition, liabilities under Section 16(b) may require separate disclosure in the Company’s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders. No suit may be brought more than two (2) years after the date the profit was realized. However, if the insider fails to file a report of the transaction under Section 16(a), as required, the two (2) year limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed. Failure to report transactions and late filing of reports require separate disclosure in the Company’s proxy statements.
Officers and directors must consult the attached “Short-Swing Profit Rule Section 16(b) Checklist” attached hereto as Attachment A in addition to consulting with the Insider Trading Program Manager prior to engaging in any transactions involving the Company’s securities, including without limitation, the Company’s Stock, stock awards or warrants.
C, Short Sales Prohibited Under Section 16(c)
Section 16(c) of the 1934 Act prohibits insiders from making short sales of the Company’s Stock, i.e., sales of shares which the insider does not own at the time of sale or sales of Stock against which the insider does not deliver the shares within twenty (20) days after the sale. Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c). Insiders violating Section 16(c) face criminal liability.
The Insider Trading Program Manager must be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16.
8. Prohibition of Records Falsifications and False Statements
Section 13(b)(2) of the 1934 Act requires companies subject to the 1934 Act to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls. The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading or incomplete statement to any accountant in connection with any audit or filing with the SEC. These provisions reflect the SEC’s intent to discourage officers, directors and other persons with access to the Company’s books and records from taking action that might result in the communication of materially misleading financial information to the investing public.
IV. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING
The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading. Every officer, director and employee is required to follow these procedures.
1. Identifying Material, Non-public Information
Prior to directly or indirectly trading any security of the Company, every officer, every director and the employees listed on Schedule 1 (as amended from time to time by the Insider Trading Program Manager) is required to contact the Insider Trading Program Manager (as part of the pre-clearance procedure discussed below in Section D) and make an initial determination whether the Company and/or such officer, director or employee listed on Schedule 1 (as amended from time to time) is in possession of material, non-public information relating to such security. In making such assessment, the explanations of “material” and “non-public” information set forth above should be of assistance. If after consulting with the Insider Trading Program Manager it is determined that the Company and/or such officer, director or employee is in possession of material, non-public information, there may be no trading of such security.
2. Information Relating to the Company
A.Access to Information
Access to material, non-public information about the Company, including the Company’s business, earnings or prospects, should be limited to officers, directors and employees of the Company on a need-to-know basis. In addition, such information should not be communicated to anyone outside the Company under any circumstances (absent prior written approval by the Insider Trading Program Manager and execution of an appropriate confidentiality agreement) or to anyone within the Company on an other than need-to-know basis.
In communicating material, non-public information to employees of the Company, all officers, directors and employees must take care to emphasize the need for confidential treatment of such information and adherence to the Company’s policies with regard to confidential information.
B. Inquiries From Third Parties
Inquiries from third parties, such as industry analysts, members of the media, expert network firms, research consulting firms, investor advisory services, or any other outside party seeking information about the Company should be directed to the Insider Trading Program Manager and Corporate Affairs. Officers, directors and employees should not engage with, respond to, or participate in any such inquiry without prior authorization from the Insider Trading Program Manager.
3. Limitations on Access to the Company Information
The following procedures are designed to maintain confidentiality with respect to the Company’s business operations and activities.
A. All officers, directors and employees should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among other things:
•Maintaining the confidentiality of Company related transactions;
•Conducting their business and social activities so as not to risk inadvertent disclosure of confidential information. Review of confidential documents in public places should be restricted or conducted in such a manner as to prevent access by unauthorized persons;
•Restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents);
•Promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings;
•Disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate;
•Restricting access to areas likely to contain confidential documents or material, nonpublic information; and
•Avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.
B. Personnel involved with material, non-public information, to the extent feasible, should conduct their business and activities in areas separate from other Company activities.
4. Pre-Clearance of Trades by Officers, Directors and Certain Employees
To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale of the Company securities, all transactions in Company securities (including without limitation, acquisitions and dispositions of the Company’s Stock, the sale of the Company’s Stock issued upon exercise of stock options and the settlement of an restricted stock units or performance share awards) (including same-day broker assisted sales) by all officers, all directors and the employees listed on Schedule 1 (as amended from time to time by the Insider Trading Program Manager) must be precleared by the Insider Trading Program Manager (or the Chief Executive Officer in the event the preclearance request pertains to a transaction involving Company securities owned by the Insider Trading Program Manager). Additionally, except for the exercise of options for cash (but not the sale of such shares), the granting of stock awards, and the receipt or purchase of shares in settlement of any restricted stock unit agreement, performance share agreement or stock appreciation rights agreement (but not the sale of any such shares, including the payment of any associated taxes through the surrender or sale of shares received from such stock award (or the right to receive such shares)), neither the Company nor any of its officers, directors or employees
may transact in any securities of the Company during the Black-Out Period, including gifts as described in Section II.4. above. Also, please consult the “Insider Trading Reminders” attached hereto as Attachment B.
5. Avoidance of Certain Aggressive or Speculative Trading
Officers, directors and employees and their respective family members (including spouses, minor children or any other family members living in the same household), should ordinarily not directly or indirectly participate in transactions in the Company’s securities involving trading activities which by their aggressive or speculative nature may give rise to an appearance of impropriety. Such activities would include the purchase of put or call options, or the writing of such options.
V. RULE 10B5-1 TRADING PLANS
1.Overview
SEC Rule 10b5-1 (“Rule 10b5-1”) will protect directors, officers and employees from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade the Company’s Stock (a “Trading Plan”) entered into in good faith and in accordance with the terms of Rule 10b5-1 of the 1934 Act and all applicable state laws and shall be exempt from the trading restrictions set forth in this Program. The initiation of, and any amendment (but not a revocation or termination) of, any such Trading Plan will be deemed to be a transaction in the Company’s securities and such initiation or amendment is subject to all limitations and prohibitions of transactions involving the Company’s securities. To meet the exemption described above, each such Trading Plan, and any amendment, revocation or termination thereof, must (1) comply with the requirements of Rule 10b5-1, including without limitation, the ongoing requirement that the person who enters into the Trading Plan must act in good faith with respect to such Trading Plan (and in the case of directors and officers, the certification that the director or officer, as the case may be, at the time of the adoption of the Trading Plan, is not aware of material, nonpublic information about the Company or its securities and is adopting the Trading Plan in good faith and not as part of a plan or scheme to evade the prohibitions of 1934 Act Section 10(b) and SEC Rule 10b-5), (2) comply with any Rule 10b5-1 guidelines or requirements adopted from time to time by the Company, and (3) be pre-approved by the Insider Trading Program Manager. Where a Trading Plan pertains to trades involving Company securities owned by the Insider Trading Program Manager, all references to “Insider Trading Program Manager” in this Section V shall be replaced with “Chief Executive Officer”.
Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) the Company’s Stock without the restrictions of windows and black-out periods even when there is undisclosed material information. A Trading Plan might also help reduce negative publicity that may result when key executives sell the Company’s Stock. Rule 10b5-1 only provides an “affirmative defense” in the event there is an insider-trading lawsuit. It does not prevent someone from bringing a lawsuit.
A director, officer and employee may enter into a Trading Plan only when he or she is not in possession of material, nonpublic information, and only during a trading window period outside of the Black-Out Period. In addition, a required initial Cooling-off Period (as defined below) must be observed before executing the first trade under such Trading Plan. Except for one later-commencing Trading Plan under which trading is not authorized to begin until after all trades under the earlier commencing Trading Plan are completed or expired without execution (subject to the proviso contained in Rule 10b5-1(c)(1)(ii)(D)(2)) or as otherwise permitted under Rule 10b5-1(c)(1)(ii)(D), a director, officer or employee who enters into a Trading Plan may not have another outstanding Trading Plan (and may not subsequently enter into any additional Trading Plans) for purchases or sales of any class of securities of the Company on the open market (i.e., Trading Plans cannot “overlap”). Additionally, a director, officer or employee may not enter into a Trading Plan designed to effect the open-market purchase or sale of the total amount of securities as a single transaction (i.e., a “single-trade plan”) more than once during any consecutive 12-month period. Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of
each trade to permit the Company’s filing coordinator to assist in the preparation and filing of a required Form 4. No director, officer or employee who enters into a Trading Plan may purchase or sell the Company’s Stock outside such Trading Plan as long as that Trading Plan is in place. For purposes of this Policy, the term “Cooling-off Period” means either, in the case of directors and officers, the later of (1) ninety (90) days following the establishment of a Trading Plan or (2) two business days following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the fiscal quarter in which the Trading Plan was adopted (subject to a maximum of one hundred twenty (120) days after the establishment of the Trading Plan); or, in the case of all other employees, ninety (90) days following the establishment of a Trading Plan.
From time to time, for legal or other reasons, the Insider Trading Program Manager may direct that purchases and sales pursuant to any Trading Plan be suspended or discontinued. Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Section V and result in a loss of the exemption set forth herein.
Officers, directors and employees may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company’s Stock. Trading Plans are to be implemented only during open window periods and when the individual is not aware of any material non-public information. Trades pursuant to a Trading Plan may occur at any time. Please review the following description of how a Trading Plan works.
Pursuant to Rule 10b5-1, assuming the individual continues to act in good faith with respect to the Trading Plan, an individual’s purchase or sale of securities will not be “on the basis of” material non-public information if:
•First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).
•Second, the Trading Plan must:
•specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold; or
•include a written formula or computer program for determining the amount, price and date of the transactions.
•Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.
2. Termination/Amendments to Trading Plans
Termination of a Trading Plan should occur only in unusual circumstances, and effectiveness of any revocation of a Trading Plan will be subject to the prior review and written approval of the Insider Trading Program Manager. Termination is effected upon written notice to the broker. However, if the individual terminates the Trading Plan, then the individual must agree not to trade under a successor Trading Plan for the applicable Cooling-off Period after termination of the predecessor Trading Plan.
Under certain circumstances, a Trading Plan must be terminated. This includes circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. Accordingly, Trading Plans should provide that a Trading Plan terminates upon announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. Either the Insider Trading Program Manager or administrator of the Company’s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of termination.
Amendments to Trading Plans will not be allowed.
3. Discretionary Plans Prohibited
Discretionary Trading Plans, where the discretion or control over trading is transferred to a broker or other third party, are not permitted. Trading Plans that meet the requirements described above, including Trading Plans under which a broker executes transactions in accordance with the amount, price and date, or written formula or computer program, specified in the Trading Plan, remain permitted.
4. Reporting (if required)
SEC Form 144 (“Form 144”) will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings. A footnote at the bottom of the Form 144 should indicate that the trades “are in accordance with a Trading Plan that complies with Rule 10b5-1.” For Section 16 reporting persons, Form 4s should be filed before the end of the second (2nd) business day following the date that the broker, dealer or plan administrator informs the individual that a transaction was executed. Similarly, the appropriate box should be checked at the top of the first page of the Form 4 to indicate the trades are made pursuant to a Trading Plan.
5. Stock Awards
Cash exercise of options currently can be executed at any time. Same day broker-assisted sales of exercised options and vested stock awards (such as restricted stock units) are subject to trading windows. However, the Company will permit same day broker-assisted sales under Trading Plans.
The Trading Plans do not exempt the individuals from complying with the Section 16 six (6) month short-swing profit rules or liability.
6. Quarterly Disclosures; Public Announcements
The Company shall disclose information regarding Rule 10b5-1 Plans adopted by directors and officers as required by Item 408(a) of Regulation S-K and may make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1. It will consider in each case whether a public announcement of a particular Trading Plan should be made. It may also make public announcements or respond to inquiries from the media as transactions are made under a Trading Plan.
7. Pledging the Company’s Stock to Secure Margin of Other Loans
The Company does not permit officers or directors to pledge the Company’s Stock as collateral to secure loans. Such pledges also cannot be carried out through a Trading Plan.
8. Put and Call Options and other Hedging Transactions
Put and call options and other hedging transactions will not be permitted under a Trading Plan. In fact, such transactions outside of a Trading Plan may destroy the protection afforded by a Trading Plan.
VI. EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE
After reading this Program statement all officers, directors and employees should execute and return to the individual noted therein the applicable Certification of Compliance form attached hereto as Attachment C or Attachment D.
* * * * *
Attachment A
SHORT-SWING PROFIT RULE SECTION 16(b) CHECKLIST
Note: ANY combination of a non-exempt PURCHASE AND non-exempt SALE or a non-exempt SALE AND non-exempt PURCHASE within six (6) months of each other results in a violation of Section 16(b), and the “profit” must be recovered by the Company. It makes no difference how long the shares being sold have been held--or that you are an insider for only one of the two matching transactions. The highest priced sale will be matched with the lowest priced purchase within the six (6) month period.
SALES
If a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household):
1.Have there been any purchases by the insider (or family members living in the same household) within the past six (6) months?
2.Are any purchases anticipated or required within the next six (6) months?
3.Has a Form 4 been prepared?
Note: If a sale is to be made by an affiliate of the Company and unregistered stock is to be sold, has a Form 144 been prepared and has the broker been reminded to sell pursuant to Rule 144?
PURCHASES
If a purchase for stock is to be made:
1.Have there been any sales by the insider (or family members living in the same household) within the past six (6) months?
2.Are any sales anticipated or required within the next six (6) months (such as tax-related or year-end transactions)?
3.Has a Form 4 been prepared?
BEFORE PROCEEDING WITH A PURCHASE OR SALE, CONSIDER WHETHER YOU ARE AWARE OF MATERIAL, NON-PUBLIC INFORMATION WHICH COULD AFFECT THE PRICE OF THE STOCK.
Attachment B
INSIDER TRADING REMINDERS
Before engaging in any transaction in the Company’s securities, please read the following:
Both the federal securities laws and the Company’s Program prohibit transactions in the Company’s securities at a time when you may be in possession of material information about the Company which has not been publicly disclosed. This also applies to members of your household as well as all others whose transactions may be attributable to you.
Material information, in short, is any information which could affect the price of the securities. Either positive or negative information may be material. Once a public announcement has been made, you should wait until the information has been made available to the public for at least two (2) full trading days (each consisting of the core trading session from 9:30 a.m. to 4:00 p.m. ET, excluding pre-market, after-hours and overnight trading) before engaging in any transaction.
Neither the Company nor any of its officers, directors or employees may trade in any securities of the Company during the period beginning at 9:30 a.m. ET on the date that is two (2) weeks before the end of any fiscal quarter of the Company and ending at 4:00 p.m. ET on the second (2nd) full trading day after the public release of earnings data for such quarter whether or not the Company or any of its officers, directors or employees is in possession of material, non-public information. Important: All transactions by officers, directors and employees listed on Schedule 1 must be precleared with the Insider Trading Program Manager (or the Chief Executive Officer in the event the preclearance request pertains to a transaction involving Company securities owned by the Insider Trading Program Manager).
For further information and guidance, please refer to our Insider Trading Compliance Program and do not hesitate to contact the Corporate Secretary.
ALL TRANSACTIONS IN TWIST BIOSCIENCE CORPORATION SECURITIES BY OFFICERS, DIRECTORS AND EMPLOYEES LISTED ON SCHEDULE 1 MUST BE PRECLEARED BY CONTACTING THE INSIDER TRADING PROGRAM MANAGER (OR CHIEF EXECUTIVE OFFICER IN THE EVENT THE PRECLEARANCE REQUEST PERTAINS TO A TRANSACTION INVOLVING COMPANY SECURITIES OWNED BY THE INSIDER TRADING PROGRAM MANAGER).
Attachment C
Non-employee Directors
CERTIFICATION OF COMPLIANCE
RETURN BY _________, _____
TO: Insider Trading Program Manager
FROM: ___________________________
RE: INSIDER TRADING COMPLIANCE PROGRAM OF Twist Bioscience Corporation
I have received, reviewed and understand the above-referenced Insider Trading Compliance Program and hereby undertake, as a condition to my present and continued affiliation with Twist Bioscience Corporation, to comply fully with the policies and procedures contained therein.
I hereby certify, to the best of my knowledge, that during the calendar year ending December 31, _____, I have not violated the policies and procedures set forth in the above-referenced Insider Trading Compliance Program. I agree that I will be subject to sanctions imposed by the Company, in its discretion, for violation of the above-referenced Insider Trading Compliance Program and will continue to comply with, and remain subject to, such policies and procedures as set forth therein. I acknowledge and agree that the Company may give stop-transfer and other instructions to the Company’s transfer agent against the transfer of the Company’s securities as necessary to ensure compliance with the above-referenced Insider Trading Compliance Program.
___________________________ ___________________
SIGNATURE DATE
___________________________
TITLE
Attachment D
Officers, Employee Directors & Employees
CERTIFICATION OF COMPLIANCE
RETURN BY _________, ____
TO: Insider Trading Program Manager
FROM: ___________________________
RE: INSIDER TRADING COMPLIANCE PROGRAM OF Twist Bioscience Corporation
I have received, reviewed and understand the above-referenced Insider Trading Compliance Program and hereby undertake, as a condition to my present and continued employment at Twist Bioscience Corporation, to comply fully with the policies and procedures contained therein.
I hereby certify, to the best of my knowledge, that during the calendar year ending December 31, ____, I have not violated the policies and procedures set forth in the above-referenced Insider Trading Compliance Program. I agree that I will be subject to sanctions imposed by the Company, in its discretion, for violation of the above-referenced Insider Trading Compliance Program and will continue to comply with, and remain subject to, such policies and procedures as set forth therein. I acknowledge and agree that the Company may give stop-transfer and other instructions to the Company’s transfer agent against the transfer of the Company’s securities as necessary to ensure compliance with the above-referenced Insider Trading Compliance Program.
___________________________ _____________________
SIGNATURE DATE
___________________________
TITLE
Exhibit 21.1
Twist Bioscience Corporation Subsidiaries
Twist Bioscience Corporation has the following subsidiaries:
1.Genome Compiler Corporation, a Delaware corporation, which itself owns Twist Bioscience Israel Ltd. (formerly “Genome Compiler Israel Ltd.”), an Israel limited liability company.
2.Twist Bio Computing, LLC, a Delaware limited liability company.
3.Twist Pharmaceutical Solutions, LLC, a Delaware limited liability company.
4.Twist Bioscience Singapore PTE. LTD., a Singapore company, which itself owns Twist Bioscience (China) Company Limited, a Chinese limited liability company.
5.iGenomX International Genomics, LLC, a Delaware limited liability company.
6.Twist Bioscience Netherlands B.V., a private limited company incorporated under Dutch law, which itself owns each of Twist Bioscience UK Ltd, a private limited company incorporated under the laws of England and Wales and Twist Bioscience Germany GmbH, a German limited liability company.
7.AbX Biologics, Inc., a Delaware corporation.
8.Twist Bioscience Japan K.K., a Japanese stock company.
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statements on Form S-3 (333-296897) of Twist Bioscience Corporation,
(2)Registration Statement on Form S-8 (333-228123) relating to the 2018 Equity Incentive Plan and 2013 Stock Plan of Twist Bioscience Corporation,
(3)Registration Statement on Form S-8 (333-228547) relating to the 2018 Employee Stock Purchase Plan of Twist Bioscience Corporation,
(4)Registration Statements on Form S-8 (Nos. 333-236373, 333-258639, 333-268573, 333-275690, and 333-283303) relating to the 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan of Twist Bioscience Corporation,
(5)Registration Statement on Form S-8 (333-274202) relating to the Inducement Equity Incentive Plan of Twist Bioscience Corporation, and
(6)Registration Statement on Form S-8 (333-284874) relating to the Amended and Restated 2018 Equity Incentive Plan and the Amended and Restated Inducement Equity Incentive Plan of Twist Bioscience Corporation;
of our reports dated November 16, 2026, with respect to the consolidated financial statements of Twist Bioscience Corporation and the effectiveness of internal control over financial reporting of Twist Bioscience Corporation included in this Annual Report (Form 10-K) of Twist Bioscience Corporation for the year ended September 30, 2026.
/s/ Ernst & Young LLP
San Mateo, California
November 16, 2026
Exhibit 31.1
Certification of Principal Executive Officer pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Emily M. Leproust, certify that:
1.I have reviewed this Annual Report on Form 10-K of Twist Bioscience Corporation for the year ended September 30, 2026;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| /s/ Emily M. Leproust | |||||
| Emily M. Leproust | |||||
| Chief Executive Officer | |||||
| (Principal Executive Officer) | |||||
Date: November 16, 2026
Exhibit 31.2
Certification of Principal Financial Officer pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Adam Laponis, certify that:
1.I have reviewed this Annual Report on Form 10-K of Twist Bioscience Corporation for the year ended September 30, 2026;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| /s/ Adam Laponis | |||||
| Adam Laponis | |||||
| Chief Financial Officer | |||||
Date: November 16, 2026
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002
In connection with the Annual Report of Twist Bioscience Corporation (the “Company”) on Form 10-K for the year ended September 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Emily M. Leproust, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 16, 2026
| /s/ Emily M. Leproust | |||||
| Emily M. Leproust | |||||
| Chief Executive Officer | |||||
| (Principal Executive Officer) | |||||
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002
In connection with the Annual Report of Twist Bioscience Corporation (the “Company”) on Form 10-K for the year ended September 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Adam Laponis, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 16, 2026
| /s/ Adam Laponis | |||||
| Adam Laponis | |||||
| Chief Financial Officer | |||||